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METHOD OF IDENTIFYING INHIBITORS
OF GLUTATHIONE S-TRANSFERASE (GST)
GENE EXPRESSION
This work was supported in part by grants CA55835 and
POI CA 55261 from National Cancer Institute, National
Institutes of Health, USA, and by a research grant award
from the Kleberg Foundation.
BACKGROUND OF THE INVENTION
A. Field of the Invention
The present invention involves the field of cancer diag-
nosis and treatment. More specifically, the present invention
relies on the identification and targeting of polymorphic
forms of glutathione S-transferases (GSTs) in tumorcells.
B. Related Art
The glutathione S-transferases, or GSTs are a family of
proteins whose best known function is the catalysis of the
neutrophilic attack of the sulfur atom of glutathione by
electrophilic groups of a variety of endogenous and exog-
enous compounds,including many mutagens, carcinogens,
alkylating anticancer agents and electrophilic products of
xenobiotic metabolism (Mannervik and Danielson, 1988;
Pickett and Lu, 1989; Hayes and Pulford, 1995; Comman-
deuret al., 1995). The currently known humansoluble GSTs
are classified into four groups, a, 4, m and 6 according to
their N-terminal amino acid sequence homology, enzymatic
substrate specificity, and antigenicity (Mannervik et al.,
1992).
GSTs are involved in many cellular functions, the best
characterized of which is their role as phase II enzymes in
which they catalyze the S-conjugation of glutathione (GSH)
with a wide variety of electrophilic compounds, including
many mutagens, carcinogens, anticancer agents and their
metabolites (Mannervik, 1985; Mannervik and Danielson,
1988; Pickett and Lu, 1989; Daniel, 1993; Boyland and
Chasseaud, 1969; Coles and Ketterer, 1980; Ketterer and
Sies, 1987; Sato, 1989; Morrow and Cowan, 1990; Waxman,
1990; Tsuchida and Sato, 1992; Commandeuretal., 1995).
Significant over-expression of the GST-m geneis associ-
ated with malignant transformation, tumor drug resistance,
and poor patient survival (Sato, 1989; Morrow and Cowan,
1990; Waxman, 1990; Tsuchida and Sato, 1992; Comman-
deur et al., 1995; Tidefelt et al., 1992; Muramatsu etal.,
1993; Gilbert et al., 1993; Tew, 1994), and in many human
tumors and pre-neoplastic lesions, the GST-w protein is
over-expressed, even though, in the corresponding normal
tissues the protein is either absent or expressed at very low
levels.
The GST-m gene has been mappedto arelatively small
region of chromosome 11q13 which contains a number of
cancer-associated genes and proto-oncogenes, including,
bell/prad1, int2 and hstfl, some of which have been
reported to be co-amplified with the GST-m gene in some
tumors (Lammie and Peters, 1991; Saint-Rufet al., 1991). In
human malignant gliomas, a positive correlation has been
demonstrated between the level of GST-z expression (by
immunocytochemistry) as well as both the histological grade
of the tumor and patient survival (Saint-Ruf et al., 1991;
Hara et al. 1990). An association between high GST-1
protein expression and 2-chloroethylnitrosourea resistance
in some humangliomacell lines also has been demonstrated
(Ali-Osmanet al., 1990).
The nucleotide sequences of the complete human GST-1
cDNAand GST-z gene reported to date from a variety of
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sources (Kanoet al., 1987; Moscow etal., 1988; Cowell et
al., 1988; Morrowet al., 1989) suggest that only one human
GST-a gene exists (Mannervik et al., 1992). Theisolation of
two different GST-a proteins (Ahmad et al., 1990) from
human placenta, however, strongly suggests that genetic
polymorphism may exist in the human GST-z genelocus.
Whetheror notthis putative polymorphic nature plays a role
in tumorigenesis remains unclear, and thus it is important to
explore both the structural and functional variation in this
gene locus.
SUMMARYOF THE INVENTION
It is, therefore, a goal of the present invention to exploit
the association of GST- with certain forms of malignancy.
Morespecifically, it is a goal of the present invention to
provide methods of diagnosis and treatment for cancers
based on the differential involvement of variant forms of
GST-a.It also is, therefore, a goal to provide compositions
that facilitate such diagnostic and therapeutic endeavors
including genes, polypeptides, oligonucleotides, peptide
fragments and antibodies.
In accordance with these objectives, there is provided a
method for inhibiting growth of a tumor cell comprising
reducing the activity level of at least one of hGSTP1*B
protein or hGSTP1*C protein in said tumorcell.
In preferred embodiments, the reduction in the activity of
hGSTP*B or of hGSTP*C protein is achieved by reducing
the expression of said hGSTP1*B or hGSTP1*C protein. In
certain embodiments,this reduction in expressionis effected
by contacting the tumor cell with an antisense nucleic acid
that hybridizes to an hGSTP1*B or hGSTP1*C nucleic acid
under intracellular conditions, but does not hybridize sub-
stantially to an hGSTP1*A nucleic acid under intracellular
conditions.
In other embodiments, the hGSTP1*B or hGSTP1*C
nucleic acid is an MRNA.In particular embodiments, the
antisense nucleic acid is an mRNAexpressed from a vector
construct comprising at least a portion of said hGSTP1*Bor
hGSTP1*C nucleic acid. In yet other embodiments, the
vector construct comprises at least a portion of the coding
region of said hGSTP1*B or hGSTP1*C nucleic acid. In
preferred embodiments, the coding region is derived from a
cDNA.In other embodiments the vector construct including
at least base +313 or +341 of SEQ ID NO:4.
In still further embodiments, the vector construct com-
prises at least a portion of transcribed but non-translated
region of said hGSTP1*B or hGSTP1*C nucleic acid. In
those embodiments where the vector construct comprises a
portion of transcribed but non-translated region of the
hGSTP1*B or hGSTP1*C nucleic acid, the region may be
an intron.
In other embodiments, the vector construct comprises at
least a portion of a translated region. In preferred embodi-
ments the portion of a translated region comprisesat least a
portion of exons 5 and 6 from said hGSTP1*Cnucleic acid.
The present invention also provides methods where the
antisense nucleic acid may be a DNAmolecule.In preferred
embodiments, the DNA molecule is a cDNA molecule. In
other aspects of the invention the DNAincludesat least base
+313 or +341 of SEQ ID NO:4.
The present invention further provides a method of reduc-
ing the expression of at least one of hGSTP1*B protein or
hGSTP1*C protein in the tumor cell, wherein reducing the
expression comprises contacting said tumor cell with a
ribozymethat cleaves an hGSTP1*B or hGSTP1*C nucleic
acid under intracellular conditions. In preferred
5,968,737
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embodiments, the ribozyme cleaves at least at about base
+313 or +341 of SEQ ID NO:4.
In other aspects the present invention, there is provided a
method of reducing the expression of hGSTP1*Bprotein or
hGSTP1*C protein in tumor cells, wherein reducing the
activity comprises contacting the tumor cells with an anti-
body that binds immunologically to an hGSTP1*B or
hGSTP1*C protein, but that does not bind substantially to an
hGSTP1*A protein. In one such embodiment the antibody
binds to an epitope that includes residue 104 or 113 of SEQ
ID NO:3.In certain embodiments in which the expression of
hGSTP1*B protein or hGSTP1 *C protein in a tumorcell is
reduced, the tumor cell is in a human subject.
Anotheraspect of the present invention provides a method
for increasing the growth inhibitory activity of an alkylating
agent in a tumor cell comprising reducing the activity level
of at least one of hGSTP1*B protein or hGSTP1*Cprotein
in said tumorcell.
In yet another embodiment, the present invention pro-
vides an isolated polypeptide having the sequence of
hGSTP1*B (SEQ ID NO:1). In still another embodiment the
present invention provides an isolated polypeptide having
the sequence of hGSTP1*C (SEQ ID NO:3). In preferred
embodiments the present invention provides an isolated
nucleic acid encoding hGSTP1*B (SEQ ID NO:1). An
isolated nucleic acid encoding hGSTP1*C (SEQ ID NO:3)
is provided in another aspect of the present invention
In those embodiments that provide an isolated nucleic
acid encoding hGSTP1*B, a preferred sequence is that of
SEQ ID NO:2. In those embodiments that provide an
isolated nucleic acid encoding hGSTP1*C, a preferred
sequence is that of SEQ ID NO:4.
The present invention provides an expression vector com-
prising a nucleic acid encoding at least a portion of
hGSTP1*B (SEQ ID NO:1). The present invention further
provides an expression vector comprising a nucleic acid
encoding at least a portion of hGSTP1*C (SEQ ID NO:3).
In certain embodiments where the expression vector com-
prises a nucleic acid encoding at least a portion of
hGSTP1*B (SEQ ID NO:1), the sequence may be that of
SEQ ID NO:2. In other embodiments where the expression
vector comprises a nucleic acid encodingat least a portion
of hGSTP1*C (SEQ ID NO:3), the sequence maybethat of
SEQ ID NO:4. In some embodiments, the nucleic acid is
positioned antisense to, and underthe control of, a promoter
active in eukaryoticcells.
The present invention further provides an antibody that
binds immunologically to at least one of an hGSTP1*B or
hGSTP1*C protein, but does not bind to an hGSTP1*A
protein. In preferred embodiments, the antibody binds to an
epitope that includesat least residue 104 or 113 of SEQ ID
NO:3.
Other embodiments of the present invention provide an
antisense nucleic acid that hybridizes to an hGSTP1*B or
hGSTP1*C nucleic acid under intracellular conditions, but
does not hybridize substantially to an hGSTP1*A nucleic
acid under intracellular conditions.
Also provided by the present invention is a ribozymethat
cleaves an hGSTP1*B or hGSTP1*C nucleic acid under
intracellular conditions, but does not substantially cleave an
hGSTP1*A nucleic acid under intracellular conditions.
The present invention further provides a method ofpre-
paring a molecule that binds to an hGSTP1*B or hGSTP1*C
protein but does not substantially bind to an hGSTP1*A
protein. The method may comprise determining a three-
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dimensional structure of an hGSTP1*B or hGSTP1*C pro-
tein and designing a molecule that binds to an hGSTP1*Bor
hGSTP1*C protein, but that does not bind substantially to an
hGSTP1*Aprotein. In some embodiment the method further
comprises testing the designed molecule for binding to said
hGSTP1*B or hGSTP1*C protein. In yet other embodiment
the method may comprise testing the designed molecule for
binding to said hGSTP1*Aprotein.
In another aspect, the present invention discloses methods
for the identification of a candidate inhibitor substance that
inhibits GST-z activity comprising the steps of: contacting
a cell expressing a GST-a protein with a candidate inhibitor
substance; and comparing the growth of said cell with the
growth of said cell in the absence of said candidate inhibitor
substance; wherein an increase in growth is indicative of
said substance being an inhibitor of GST-w activity. In
certain embodiments, the GST-x protein being expressed is
GSTP*B. In other embodiments the GST-2 protein being
expressed is GSTP*C.In yet other embodiments the GST-1
protein being expressed is not GSTP*A.
In some embodiments, the candidate inhibitor substance
is an antisense molecule to an hGSTP1*B or hGSTP1*C
nucleic acid under intracellular conditions. In other pre-
ferred embodiments the candidate substance is a ribozyme
that cleaves an hGSTP1*B or hGSTP1*C nucleic acid under
intracellular conditions. In certain other embodiments, the
candidate substance is a small molecule inhibitor. In those
embodiments where the candidate substance is a small
molecule inhibitor, the candidate substance may be a sub-
stituted isoxazole, heterocyclic aromatic compound; or a
sugar-linked aromatic compound.
The present invention further discloses a method for the
identification of a candidate inhibitor substance that inhibits
GST-a expression. In preferred embodiments, the method
comprises the steps of: contacting a cell expressing a GST-1t
protein with a candidate inhibitor substance and comparing
the expression of GST-z of said cell with the expression of
GST-z of said cell in the absence of said candidate inhibitor
substance; wherein a decrease in the expression of GST-z is
indicative of said substance being an inhibitor of GST-7
expression. In particular embodiments, the candidate sub-
stance for the inhibition of expression of GST-z proteinsis
an antisense molecule to an hGSTP1*B or hGSTP1*C
nucleic acid under intracellular conditions. In other embodi-
ments of the present invention, the candidate substance is a
ribozymethat cleaves an hGSTP1*B or hGSTP1*C nucleic
acid under intracellular conditions.
Other objects, features and advantages of the present
invention will become apparent from the following detailed
description. It should be understood, however, that the
detailed description and the specific examples, while indi-
cating preferred embodimentsof the invention, are given by
wayofillustration only, since various changes and modifi-
cations within the spirit and scope of the invention will
becomeapparentto those skilled in theart from this detailed
description.
BRIEF DESCRIPTION OF THE DRAWINGS
The file of this patent contains at least one drawing
executed in color. Copies of this patent with color
drawing(s) will be provided by the Patent and Trademark
Office upon request and paymentof the necessary fee.
The following drawings form part of the present specifi-
cation and are included to further demonstrate certain
aspects of the present invention. The invention maybebetter
understood by reference to one or more of these drawings in
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combination with the detailed description of specific
embodiments presented herein:
FIG.1. A simplified restriction map of SuperCos-GSTpi.
The solid box corresponds to the position of the isolated
GST-z gene.
FIGS. 2A and 2B. FIG. 2A: Subclones of SuperCos-
GSTpi for DNA sequencing of entire GST-7m gene.
PBS.GST-/A (exons 2 and 3, and intron 2), pBS.GST-2/B
(exons3 to 6 and introns 3 to 5), pBS.GST-a/C (exons6 and
7, intron 6, and 3'-untranslated region) and pBS.GST-1/D
(exons 2 to 7 and introns 2 to 6). FIG. 2B: DNA sequencing
strategy used to obtain the complete GST-m gene nucleotide
sequence. Arrows indicate the sequencing directions of the
primers. Sequencing was performed at least twice in both
directions.
FIG.3. Region of intron 5 of the GST-z gene showing one
palindromic and four direct repeats of RARE consensus
half-sites arranged in tandem between +1521 and +1644.
FIGS. 4A, 4B, 4C and 4D. Effect of all-trans RA on
GST-a gene expression in MGR-3cells. Cells were exposed
to 1 uM RAfor 6 hrs or 48 hrs, after which cells were
harvested for northern analysis for GST-a transcripts and
GST-a protein.
FIG. 5. pCMV-GSTpi eukaryotic expression vector con-
struct.
FIGS. 6A,6B, 6C, 6D, 6E, 6F, and 6G. Strategy used to
obtain the entire nucleotide sequences of the three GST-1
cDNAvariants. The arrows indicate both the directions and
the regions sequenced.
FIG. 6B. Nucleotide and predicted amino acid sequence
for GSTPI*A, GSTPI*B and GSTPI*C.
FIG. 7. Mae II and Xem I restriction endonuclease maps
of variant GST-1 cDNAs.
FIGS. 8A-C. Lineweaver-Burke plots for the catalysis of
the conjugation of GSH with CDNB by GSH-affinity chro-
matography purified recombinant GSTPla-la (FIG. 8A),
GSTP1b-1b (FIG. 8B) and GSTP1c-1c (FIG. 8C). Reaction
rates were determined with 2.5 mM GSHand 0.015 unit of
each enzyme.
FIGS. 9A and 9B. Super-imposed energy-minimized
3-dimensional architecture of the H-site region of the
GSTP1a(red), GSTP1b (cyan) and GSTP1c (yellow), show-
ing the deviations in the side chains relative to each other.
GSTP1b and GSTPic were created by substituting Val,o,
for Ile,5, (FIG. 9A), and both Ile,,, and Ala,,,; with Val
(FIG. 9B) in the X-ray crystallographic structure of the
human placental GSTP1a (Reindeeret al., 1992; Reinemer
et al., 1993), imported from the Brookhaven Protein Data-
bank.
FIGS. 10A-C.Intracellular stability of variant GST-1
mRNAs. Total RNA was isolated from cells treated with
actinomycin D to block de novo RNA synthesis. The cell
lines each expressed only one GST-a7 mRNAvariant. (FIG.
10A: GSTPI*A; FIG. 10B: GSTPI*B; FIG. 10C:
GSTPI*C);
FIGS. 11A-C. Thermal stability of variant GST-a pro-
teins. Recombinant GSTPla-la (FIG. 11A), GSTP1b-1b
(FIG. 11B) and GSTPic-1c (FIG. 11C) were incubated at
45° C., and every 15 mins, over one hour, residual GST
activity was determined with CDNBassubstrate.
FIGS. 12A and 12B. Kaplan-Meier curves showing the
relationship between low, moderate and high levels of
GST-a expression in malignant gliomasandpatient survival:
FIG. 12A) all glioma patients; FIG. 12B) glioblastoma
multiforme patients.
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FIGS. 13A and 13B. Kaplan-Meier curesfor the relation-
ship between the presence and absence of nuclear GST-x in
malignant gliomas and patient survival: FIG. 13A) all
glioma patients; FIG. 13B) glioblastoma multiforme
patients.
FIG. 14. Phosphorothioate antisense-ONandits effect on
GSTP1*C expression. ON is designed aroundthe initiation
site of GSTP1*C mRNA expressed in glioblastoma multi-
formecell line.
FIG. 15. Phosphorothioate antisense-ONandits effect on
GSTP1*C expression. ON is designed aroundthe initiation
site of GSTP1*C mRNA expressed in glioblastoma multi-
formecell line.
FIG. 16. Antisense-ON and its effect on GSTP1*C
expression. ONis designed around the A to G transition and
position 313. Treatment with 10 U/ml of RNAse H.
FIG. 17. Antisense-ON and its effect on GSTP1*C
expression. ON is designed aroundthe C to T transition and
position 341. Treatment with 10 U/ml of RNAse H or no
RNAse H.
FIG. 18. Molecular modeling of putative GSTP1*C
ligands in the H-bindingsite.
FIG. 19. Molecular modeling of putative GSTP1*C
ligands in the H-bindingsite.
DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS
A. The Present Invention
The human GST-a gene and its cDNA (Kanoet al., 1987;
Moscowet al., 1988) have been previously described, and
based on the identical nucleotide sequences observed in four
different reports, it has been generally accepted that only one
human GST-m gene exists (Mannervik et al., 1992).
However, as described herein, three different full-length
GST-at cDNAs (hGSTP1*A, hGSTP1*B, and hGSTP1*C
SEQ ID NO:3, SEQ ID NO:5 AND SEQ ID NO:7,
respectively) were isolated from Agt11 libraries prepared
from human malignant glioma cells. hGSTP1*A, wasiden-
tical to the GST-a gene described in previous reports (Kano
et al., 1987; Moscowet al., 1988); the other two cDNAs
were, however, new. Their respective encoded peptides,
GSTP1a, GSTP1b and GSTP1c,are closely related and arise
from two nucleotide transitions of A~G and C-T at
positions +313 and +341, respectively, of the cDNAs.
Intracellular stabilities of the variant mRNAs were deter-
mined and the proteins encoded by the GST-a cDNAs were
expressed in EF. coli, purified by GSH-affinity
chromatography, and used in enzyme kinetic analyses to
determine the functional consequences of the structural
differences. To further examine the structural consequences
of the amino acid alterations in the encoded GST-z peptides,
computer modeling was used to introduce the amino acid
changesinto the three-dimensionalstructure of the placental
GST-a proteins that had been previously isolated and
co-crystallized with S-hexylglutathione (Reindeer et al.,
1992). The expression of each of the gene variants in
primary specimens,cell lines of malignant gliomas, normal
brain, normal placenta and peripheral blood lymphocytes
was investigated and the concordance of the observed geno-
type and phenotype was determined by DNA-PCR and
RNA-PCRof representative specimens. Preliminary analy-
sis of the distribution frequency of the gene variants in tumor
and normal specimens were performed. The results are
summarized below.
The presence and expression of the variant GST-7 mRNA
in both normal and malignant specimens indicate allelo-
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polymorphism of the GST-a gene locus, rather than muta-
tions. One of the placental tissues examined here expressed
hGSTP1*B exclusively. In a prior report (Ahmad et al.,
1990), a GST-z protein isolated from human placenta was
shownto have the Ile,,,—Val,94 substitution caused by the
A->Gtransition at +313 in hGSTP1*B. However, since
neither the gene encoding this GST-x peptide nor the cDNA
corresponding to its mRNA had been previously described,
the results were inconclusive as to whether this protein was
a new GST-z gene, or emanated from a naturally-occurring
polymorphism of a known GST-x gene. Similarly, until now,
there has been noreport of the isolation of the full-length
hGSTP1*C cDNAorgene. A truncated cDNAencoding 176
amino acids (83.8%) of the N-terminus of hGSTP1*C has
previously been isolated from a human lung Agtl1 cDNA
library (Board et al., 1989). Comparison of the nucleotide
sequences of the human GST-2 cDNAs reported here with
that of the rat orthologue, GSTP (Sakaiet al., 1987) showed
codons 104 and 113 to be amongthosealtered in the GST-1
cDNAs ofthe two species, with changes from humanto rat
of Tle,,,—Gly,9, and Ala,,,—~Asn,,3. This suggested that
these positions are among the least conserved in the GST-1
gene from an evolutionary standpoint.
The nucleotide transitions giving rise to the GST-m vari-
ants also altered several restriction endonuclease recognition
sites in the variant cDNAs,thus allowing characterization of
the cDNAs byrestriction endonuclease mapping using the
restriction enzymes, Mae II and Xcm I. This technique of
determining GST-z subtype is simple, rapid and specific,
and is suitable for screening large numbers of specimens.
Alternatively, the GST-m phenotype/genotype can be deter-
mined by southern or northern hybridizations with oligo-
nucleotide probes specific for the different variants, as was
demonstrated in this study. However, because of cross-
hybridization, the specificity of the latter procedure is
limited, particularly, for differentiating hGSTP1*B from the
other two GST-z variants. Furthermore, it does not allow
conclusive detection of mixtures of GST-m genes or mRNAs
in a single specimen. This is best achieved by restriction
mapping and nucleotide sequencing.
Following transcriptional block with actinomycin D, the
present inventors observed only a modest difference in the
intracellular half-lives of the mRNAtranscripts between the
variant GST-a genes. hGSTP1*A transcripts were least
stable (t,,. of 9.4 hrs), while transcripts of hGSTP1*B were
most stable, with a half-life of 14.1 hrs. Overall, the
observed half-lives were longer than the 3.8 hrs to 8.6 hrs
(after ethacrynic acid treatment) previously reported for
GST-a transcripts in other cell types (She et al., 1995).
Using computer modeling, the inventors have created the
three-dimensional structures of the peptides encoded by the
genes, hGSTP1*B and hGSTP1*C, namely, GSTP1b and
GSTPic, from the previously determined X-ray crystallo-
graphic structure of GSTP1a (Reindeeret al., 1992; Reine-
mer et al., 1993). Energy minimizations of the resulting
structures showed significant deviations in atomic coordi-
nates and inter-side chain distances of five of the six key
H-site amino acid residues caused by the amino acid
changes. Of the affected residues, Tyr,5, was the most
altered, particularly, with respect to its distances to Val,,,
Val,; and Tyr,. The changes are much larger as one
progresses from GSTP1ato either GSTP1b or GSTP1c than
from GSTP1b to GSTPIc, indicating a greater impact on
active site structure and function by the +313 transition than
by the change at +341.
Predictions from the structural modeling data are sup-
ported by the enzyme kinetic differences the inventors
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observed between the three variant GST-2 enzymes. In
catalyzing the conjugation of GSH with CDNB,the Km for
CDNB of GSTP1a-1a was approximately 3-fold lower than
that of either GSTP1b-1b or GSTP1c-1c. The Vmax values
also differed similarly between the three enzymes. These
results are in agreement with those in a previous study
(Zimniaket al., 1994),at least for GSTP1b,in which a 4-fold
lower Km value for CDNB was observed for recombinant
GSTPla-1la relative to GSTP1b-1b, produced from a
GSTP1*c cDNA, created artificially by site-directed
mutagenesis. The data suggest that the observed enzyme
kinetic effects of the Val,,, substitution are, at least in part,
the result of steric effects caused by substituting Val,,, for
Tle,,4 in the GST-a active (H-) site.
The computer modeling study showed that the
Tle,942Val,54 substitution in GSTP1b-1b and GSTPic-1c
significantly affected 5 of the 6 amino acidslining the H-site,
and caused significant shifts in the side chains of the residues
sterically restricted the region of the H-site bordered by
Tytiog, Val,;, Val,. and, to a lesser extent Phe,, while
opening up the region bordered by Tyr, and Val,,. These
findings suggest that bulky substrates may fit better in the
space lined by these residues and Ie,,, while less bulky
ones may bindbetter in the larger space lined by Val,, and
might explain previousfindings that the Km of GSTP1a-1la
for CDNB was lower than that for GSTP1b-1b, while the
opposite was true for the bulkier bromosulphthalein
(Zimniak et al., 1994).
An additional basis for the functional differences
observed between the variant GST-z proteins could reside in
the fact that domain II of the GST-a peptide, in which the
H-site resides, contains five a-helices, two of which (aD
[AAgi-107] and @E [AAjoo.132]) contain the amino acid
substitutions of Ile,),—>Val,,, and Ala,,,—~Val,(Reindeer
et al., 1992; Reinemeret al., 1993). A right-handed super-
helix exists in this region, generated, in part, by an up-down
arrangement of aD and aE and across-over connection
between @E and a third helix, aF to form a superhelix
(Reindeeret al., 1992; Reinemeret al., 1993). In a previous
study, it has been shown that the thermodynamic propensi-
ties of Ile, Ala and Val to contribute to the a-helical structure
in a protein differ significantly (Blaber et al., 1993), as
indicated by the computed free energy (AAG) when the
protein folds to the native a-helix structure. Consequently,
the changes of Ile or Ala to Val could result in subtle
alterations in the a-helical or super-helical structure that can
affect H-site architecture, and ultimately, result in differ-
ences in substrate binding affinities and catalytic activities
between the GST-a enzymes.
This, indeed, was found in this study for all three proteins,
using the substrate CDNB, and for GSTPla-1la and
GSTP1b-1b with other substrates (Zimniak et al., 1994).
Interestingly, recombinant GSTP1a-1alostits activity at 45°
C.at twice the rate of GSTP1b-1b or GSTPic-1c. A similar
difference in thermostability between GSTP1a and GSTP1b
has been previously reported (Zimniak et al., 1994). The
inventors speculate that this might be due to differential
changes in H-site stability induced by the increased
temperature, and differences in the free energy of the a-helix
formed with the different amino acids at codons 104 and
113.
An important implication of the observed differences
between the variant GST-z proteins with respect to their Km
values for CDNBisthat the use of CDNBto determine GST
activity in cells or tissues containing different GST-z variant
proteins will yield results that underestimate the contribution
of GSTP1b-1b and GSTPic-1c, relative to GSTPla-la.
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However, the present inventors have shown that such a
quantitative determination can be made with an ELISA
assay using placental GST-a antibodies, which, as shown
herein, cross-react with all three GST-z proteins.
Theresults of the distribution frequencies of the different
GST-a gene variants among the specimens showed
hGSTP1*C to be present at a 4-fold higher frequency in
malignant gliomas than in normal tissues, primarily lym-
phocytes. Conversely, hGSTP1*A is more frequently
present in normal cells and tissues than in gliomas. Further
studies will clarify whether the higher frequency of
GSTP1*Cin tumorsrepresents a clonal selection or a loss of
heterozygosity associated with the malignant process. In
contrast to the other two GST-z genes, hGSTP1*B appears
to be a relatively rare allele, and homozygously, was not
present in any of the tumor specimensorcell lines studied.
It is also intriguing that none of the specimens examined was
heterozygous for hGSTP1*B and hGSTP1*C.It may be that
the functionally different GST-z proteins provide a mecha-
nism for fine-tuning/regulation of GST-z activity in cells and
tissues and, as such, because of the similar catalytic prop-
erties of GSTP1b-1b and GSTPic-1c, no biological advan-
tage exists in co-expressing these two GST-m’s in a single
cell or tissue. Future studies will determine whether the
different GST- peptides dimerize to equal degrees with
each other and yield GST-z proteins with different catalytic
activities for different substrates.
It is reasonable to expect that the differences in H-site
structure of the variant GST-z proteins will result in differ-
ences in the binding affinity for different mutagens, carcino-
gens and alkylating anticancer agents to this site, and
subsequently, in a differential ability of the enzymes to
catalyze the conjugation of these compounds to GSH. This
will have significant implications with respect to the risk of
individuals, having different GST-~ genotypes and/or
phenotypes, to develop cancer.It also should provide a basis
for rationally designing novel GST-a-targeted anticancer
therapies, as described in the examples.
Extending the above studies to the genomic level, an
isolated hGSTP1*C gene was localized within 2.1 kB Not
I/HinD Iand 11.5 kB HinD III fragments of a cosmid
vector clone designated SuperCos-GSTpi. The 3116 base
pairs included 161 bp upstream ofthe initiating methionine
ATG codon and 222 nucleotides downstream of the TGA
stop codon, and encodes 210 amino acids in seven exons.
Exon-intron organization was determined by identification
of the AG/GT splicing signals and by comparison of the
sequence with the sequence of the previously described
GST-a cDNAfrom this cell line (Ali-Osman et al., 1990).
The promoter region of the isolated gene was similarto that
previously described by Cowell et al. (1988) and Morrow et
al. (1989), and contained all the regulatory elements, TATA
box and both the AP1 and two SP1 sites, previously
reported. In addition, however, an anti-oxidant response
element (ARE) wasidentified in the AP1 site of the gene.
This ARE has subsequently been identified in the previously
described GST-z gene. The sequenceis identical to the ARE
core sequence (GTGACTCAGC) of the human NAD(P)
H:quinone oxidoreductase gene (Hayes and Pulford, 1995;
Xia et al., 1991), and has a high degree of homologyto the
ARE (GTGACAAAGCSEQ ID NO:32) in the rat GST Ya
gene (Hayes and Pulford, 1995; Li and Jaiswal, 1992).
The major differences between the “c” variant GST-1
gene described here and the gene previously reported are the
nucleotide transitions ofA—>G at +1404 and C-+Tat +2294,
which confirmed the isolated gene to be the hGSTP1*C
variant of the GST-z. The ATC (Ile)->GTC (Val) and GCC
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(Ala)GTC (Val) changes in codons 104 and 113,
respectively, caused by these transitions were both in the
electrophile binding (H-) site of the GST-z peptide.
Other structural differences between the isolated
hGSTP1*C and the GST-m gene previously described
included transitions in introns 5 and 6, which, although
altering restriction cleavage sites useful in structural char-
acterization of the gene, do not involve knownregulatory
motifs. A structural difference of potential functional
significance, however, was the guanine insertion at +51 in
the conserved IRE (CCCGCGTC)in intron 1. This IRE is
highly homologous to the IRE-A (CCCGCCTC) in the
human glyceraldehyde-3-phosphate dehydrogenase gene
(Nasrin et al., 1990), and to the IRE in the GST-m gene
isolated from both the HPB-ALL and MCF-7 cell lines
(Cowell et al., 1988, Morrowet al., 1989), and may account
for the activation of the GST-m gene by insulin (Ahmad et
al., 1990). It remains to be established whether the single
guanine insertion in the IRE of the hGSTP1*C gene
described here is a common feature of glioma cells and
whetherit significantly alters insulin-binding, and ultimately
insulin-responsiveness of the GST-z gene.
The identification, for the first time, of functional RAREs
in the GST-z geneis a particularly important finding of this
study. The identified sequences are highly homologous to
the RARE half site, 5'-A(G)GG(T)TC(G)A-3' present in
other RA-responsive genes, such as, those encoding RAR
types a2, B2 and y2 (Xia et al., 1996; Board et al., 1989;
Hoffmnan, 1990; Favreau and Pickett, 1990; Leroy et al.,
1991; Lehmannetal., 1992; Smith et al., 1991; Mangelsdorf
et al., 1991; Pikarsky et al., 1994), and the cellular retinoic
acid and retinol binding proteins (CRABPs and CRBPs)
(Mangelsdorfet al., 1991; Pikarsky et al., 1994; Boylan and
Gudas, 1991; Durand et al., 1992; , 1992; Yang-Yenet al.;
Schule et al., 1991). In the hGSTP1*C gene, the four repeats
of RARE consensus half sites and the one palindromic
halfsite are all located in intron 5, in contrast to the majority
of previously described RARES, which are cis-acting and
occur in the promoter regions of the genes regulated.It is,
however, not unusual for regulatory motifs to be present
within introns. Indeed, in a variety of genes, including
oncogenes, tumor suppressor genes, growth-factor and
growth factor receptor genes (Vasioset al., 1989; Stumpoet
al., 1988; Taub et al., 1987; Lozano and Levine, 1991; Jung
et al., 1993; Takimoto and Kuramoto, 1993; Chrysogelos,
1993; Chen et al., 1994), functional intronic regulatory
elements are located distant in primary structure from the
transcription start site of the regulated genes. In the GST-a
gene, the RARE motif is approximately 1,500 bp from the
transcription start site, a distance similar to that of the
tissue-specific regulatory element in the p53 gene (Taub et
al., 1987) and the two negative regulatory elements of the
PDGF-A chain gene (Lozano and Levine, 1991) from their
transcription startsites.
Two of the RAREs in hGSTP1*C are separated by five
nucleotides and two others by 13 nucleotides, which corre-
spond to the minimal nucleotide spacer required for RARE
functionality (Xia et al. 1996). These two RAREs are
therefore likely to be the functional RAREs in the
hGSTPI*C gene. Using a gel mobility shift assay, it was
showed that nuclear protein extracts from MGR-3 cells in
which RAR-f had been induced by prior treatment with
all-trans RA, contained a fraction that bound specifically to
the RAREs in the hGSTP1*C gene. Furthermore, following
all-trans RA treatment, expression of the GST-m gene was
increased significantly in MGR-3 cells. Since functionality
of RAREsrequires binding to RA-RAR complexes(Glasset
5,968,737
11
al., 1991), these data provide strong evidence that the
RAREsin the hGSTP1*C gene are functional, and suggest
that the RA-RAR-RAREbinding maycontribute, at least in
part, to the observed activation of the GST-z genebyalltrans
retinoic acid in the MGR-3 cell line. The results contrast
with those of a previous study in which a down-regulation
of the GST-m gene was observed in a GST-x-CAT fusion
gene construct following exposureto all-trans retinoic acid
(Xia et al., 1993). Recent evidence, using CAT plasmid
deletion constructs, also showed that the AP1 site in the
GST-x promoteris required for RA-mediated gene suppres-
sion (Xia et al., 1996).
Based on these observations, the data shown here, and the
known RA-mediated up- and down-regulation of RA
responsive genes (Lehmann et al., 1992), a model is pro-
posed in which activation and suppression of the GST-2
gene by RA occurs by two separate mechanisms. In this
model, the GST- gene is activated by the binding of the
RA-RAR complex to RAREsin the gene. Suppression of the
GST-a gene, on the other hand, occurs via competitive
inhibition of the binding of AP1-binding proteins, such as
jun and fos, to the AP1 DNAsite by the RA-RAR complex,
as has been previously suggested (Xia et al., 1996; Schule et
al., 1991). Such a model is consistent with a proposed
general mechanism for RA-mediated gene regulation by
ligand-activated RARs (Lehmannet al., 1992; Durandet al.,
1992; Fanjui et al. 1994). The latter mechanism of RA
induction of GST-z gene expression, may constitute part of
the molecular basis for the cancer preventive action of
long-term administration of retinoic acid (Lipman et al.,
1987). The activation of the GST-a gene by all-trans RA in
MGR-3cells observed in this study was a delayed process,
similarto the late transcriptional induction of the laminin B1
gene by RA (Vasios et al., 1991), and consistent with a
mechanism involving RAR-ligand binding to RARES.
These results and observationsare exploited, according to
the present invention, as described in detail in the following
sections.
B. Polypeptides and Peptides
The present invention, in one embodiment, encompasses
the new GST-a amino acid sequences discussed above. The
present invention also encompasses hybrid molecules con-
taining portions from one GST-z fused with portions of
another. Alternatively, a fusion of this sort could be gener-
ated with sequencesall three variants in a single polypeptide
molecule. Also encompassed are fragments of the disclosed
molecules, as well as insertion, deletion or replacement
mutants in which non-GST-m sequences are introduced,
GST-a sequences are removed, or GST-m sequences are
replaced with non-GST-a sequences, respectively.
GST-2’s, according to the present invention, may be
advantageously cleaved into fragments for use in further
structural or functional analysis, or in the generation of
reagents such as GST--related polypeptides and GST-1-
specific antibodies. This can be accomplished by treating
purified or unpurified GST-2’s with a peptidase such as
endoproteinase glu-C (Boehringer, Indianapolis, Ind.).
Treatment with CNBr is another method by which GST-1
fragments may be produced from natural GST-2. Recombi-
nant techniques also can be used to produce specific frag-
ments of GST-z.
More subtle modifications and changes may be made in
the structure of the encoded GST-z polypeptides of the
present invention andstill obtain a molecule that encodes a
protein or peptide with characteristics of the natural GST-2
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polypeptides, including the variants described above. The
following is a discussion based upon changing the amino
acids of a protein to create an equivalent, or even an
improved, second-generation molecule. The amino acid
changes may be achieved by changing the codons of the
DNAsequence, according to the following codon table,
Table A:
 
TABLE A
Amino Acid Names and
abbreviations Codons
Alanine Ala A GCA GCCGCG GCU
Cysteine cys c UGC UGU
Aspartic acid Asp D GAC GAU
Glutamic acid Glu E GAA GAG
Phenylalanine Phe F uuc uuu
Glycine Gly G GGA GGCGGG GGU
Histidine His H CAC CAU
Isoleucine Ile I AUA AUC AUU
Lysine Lys K AAA AAG
Leucine Leu L UUA UUGCUA CUCCUG CUU
Methionine Met M AUG
Asparagine Asn N AAC AAU
Proline Pro P CCA CCCCCG CCU
Glutamine Gln Q CAA CAG
Arginine Arg R AGA AGGCGA CGCCGG cCGU
Serine Ser Ss AGC AGUUCA UccUCG UCU
Threonine Thr T ACA ACCACG ACU
Valine Val Vv GUA GUCGUG GUU
Tryptophan Trp W UGG
Tyrosine Tyr Y UAC UAU
 
It is knownthat certain amino acids may be substituted for
other amino acids in a protein structure in order to modify
or improve its antigenicity or activity (see, e.g., Kyte &
Doolittle, 1982; Hopp, U.S. Pat. No. 4,554,101, incorpo-
rated herein by reference). For example, through the sub-
stitution of alternative amino acids, small conformational
changes may be conferred upon a polypeptide which result
in increased activity or stability. Alternatively, amino acid
substitutions in certain polypeptides may be utilized to
provide residues which may then be linked to other mol-
ecules to provide peptide-molecule conjugates which retain
enough antigenicity of the starting peptide to be useful for
other purposes. For example, a selected GST-m peptide
bound to a solid support might be constructed which would
have particular advantages in diagnostic embodiments.
The importance of the hydropathic index of amino acids
in conferring interactive biological function on a protein has
been discussed generally by Kyte & Doolittle (1982),
wherein it is found that certain amino acids may be substi-
tuted for other amino acids having a similar hydropathic
index or core andstill retain a similar biological activity. As
displayed in Table B below, amino acids are assigned a
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hydropathic index on the basis of their hydrophobicity and
charge characteristics. It is believed that the relative hydro-
pathic character of the amino acid determines the secondary
structure of the resultant protein, which in turn defines the
interaction of the protein with substrate molecules. Preferred
substitutions which result in an antigenically equivalent
peptide or protein will generally involve amino acids having
index scores within +2 units of one another, and more
preferably within 1 unit, and even more preferably, within
 
+0.5 units.
TABLE B
Amino Acid Hydropathic Index
Isoleucine 4.5
Valine 4.2
Leucine 3.8
Phenylalanine 2.8
Cysteine/cystine 2.5
Methionine 1.9
Alanine 1.8
Glycine -0.4
Threonine -0.7
Tryptophan -0.9
Serine -0.8
Tyrosine -13
Proline -1.6
Histidine -3.2
Glutamic Acid -3.5
Glutamine -3.5
Aspartic Acid -3.5
Asparagine -3.5
Lysine -3.9
Arginine -4.5
 
Thus, for example, isoleucine, which has a hydropathic
index of +4.5, will preferably be exchanged with an amino
acid such as valine (+4.2) or leucine (+3.8). Alternatively, at
the other end of the scale, lysine (-3.9) will preferably be
substituted for arginine (-4.5), and so on.
Substitution of like amino acids may also be made on the
basis of hydrophilicity, particularly where the biological
functional equivalent protein or peptide thereby created is
intended for use in immunological embodiments. U.S. Pat.
No. 4,554,101, incorporated herein by reference, states that
the greatest local average hydrophilicity of a protein, as
governed by the hydrophilicity of its adjacent amino acids,
correlates with its immunogenicity and antigenicity, i.e. with
an important biological property of the protein.
As detailed in U.S. Pat. No. 4,554,101, each amino acid
has also been assigned a hydrophilicity value. These values
are detailed below in Table C.
 
TABLE C
Amino Acid Hydrophilic Index
arginine +3.0
lysine +3.0
aspartate 43.0 +1
glutamate $3.0 +1
serine +0.3
asparagine +0.2
glutamine +0.2
glycine 0
threonine -0.4
alanine -0.5
histidine -0.5
proline -0.5 +1
cysteine -1.0
methionine -1.3
valine -1.5
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TABLE C-continued
 
Amino Acid Hydrophilic Index
leucine -18
isoleucine -18
tyrosine -2.3
phenylalanine -2.5
tryptophan -3.4
It is understood that one amino acid can be substituted for
another having a similar hydrophilicity value andstill obtain
a biologically equivalent, and in particular, an immunologi-
cally equivalent protein. In such changes,the substitution of
amino acids whose hydrophilicity values are within +2 is
preferred, those which are within +1 are particularly
preferred, and those within +0.5 are even more particularly
preferred.
Accordingly, these amino acid substitutions are generally
based on the relative similarity of R-group substituents, for
example, in terms of size, electrophilic character, charge,
and the like. In general, preferred substitutions which take
various of the foregoing characteristics into consideration
will be known to those of skill in the art and include, for
example, the following combinations: arginine and lysine;
glutamate and aspartate; serine and threonine; glutamine and
asparagine; and valine, leucine and isoleucine.
In addition, peptides derived from these polypeptides,
including peptides of at least about 6 consecutive amino
acids from these sequences, are contemplated. Alternatively,
such peptides may comprise about 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,
47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60
consecutive residues. For example, a peptide that comprises
6 consecutive amino acid residues may comprise residues 1
to 6, 2 to 7, 3 to 8 and so on of the GST-a protein. Such
peptides may be represented by the formula
x to (x+)=5' to 3’ the positions of the first and last consecutive
residues
where x is equal to any numberfrom 1to the full length of
the GST-a protein and n is equal to the length of the peptide
minus 1. Where the peptide is 10 residues long (n=10-1),the
formula represents every 10-mer possible for each antigen.
For example, where x is equal to 1 the peptide would
comprise residues 1 to (1+[10-1]), or 1 to 10. Where x is
equal to 2, the peptide would comprise residues 2 to (2+
[10-2]), or 2 to 11, and so on.
Syntheses of peptides are readily achieved using conven-
tional synthetic techniques such as the solid phase method
(e.g., through the use of a commercially available peptide
synthesizer such as an Applied Biosystems Model 430A
Peptide Synthesizer). Peptides synthesized in this manner
may then be aliquoted in predetermined amounts and stored
in conventional manners, such as in aqueous solutions or,
even more preferably, in a powder or lyophilized state
pending use.
In general, due to the relative stability of peptides, they
may bereadily stored in aqueoussolutions for fairly long
periods of time if desired, e.g., up to six months or more, in
virtually any aqueous solution without appreciable degra-
dation or loss of antigenic activity. However, where
extended aqueous storage is contemplated it will generally
be desirable to include agents including buffers such as Tris
or phosphate buffers to maintain a pH of 7.0 to 7.5.
Moreover, it may be desirable to include agents which will
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inhibit microbial growth, such as sodium azide or Merthi-
olate. For extended storage in an aqueousstate it will be
desirable to store the solutions at 4° C., or more preferably,
frozen. Of course, where the peptide(s) are stored in a
lyophilized or powdered state, they may bestored virtually
indefinitely, e.g., in metered aliquots that may be rehydrated
with a predetermined amountof water (preferably distilled,
deionized) or buffer prior to use.
Ofparticular interest are peptides that represent antigenic
epitopes that lie within the GST-w polypeptides of the
present invention. An “epitope” is a region of a molecule
that stimulates a response from a T-cell or B-cell, and hence,
elicits an immune response from these cells. An epitopic
core sequence, as used herein,is a relatively short stretch of
amino acids that is structurally “complementary” to, and
therefore will bind to, binding sites on antibodies or T-cell
receptors. It will be understood that, in the context of the
present disclosure, the term “complementary” refers to
amino acids or peptides that exhibit an attractive force
towards each other. Thus, certain epitopic core sequences of
the present invention may be operationally defined in terms
of their ability to compete with or perhaps displace the
binding of the corresponding GST-a antigen to the corre-
sponding GST-1-directed antisera.
The identification of epitopic core sequences is known to
those of skill in the art. For example U.S. Pat. No. 4,554,101
teaches identification and preparation of epitopes from
amino acid sequences on the basis of hydrophilicity, and by
Chou-Fasman analyses. Numerous computer programs are
available for use in predicting antigenic portionsof proteins,
examples of which include those programs based upon
Jameson-Wolf analyses (Jameson and Wolf, 1988; Wolf et
al., 1988), the program PepPlot® (Brutlag et al., 1990;
Weinbergeretal., 1985), and other new programsfor protein
tertiary structure prediction (Fetrow & Bryant, 1993) that
can be used in conjunction with computerized peptide
sequence analysis programs.
In general, the size of the polypeptide antigen is not
believed to be particularly crucial, so long as it is at least
large enough to carry the identified core sequence or
sequences. The smallest useful core sequence anticipated by
the present disclosure would be on the order of about 6
amino acids in length. Thus, this size will generally corre-
spond to the smallest peptide antigens prepared in accor-
dance with the invention. However, the size of the antigen
may be larger where desired, so long as it contains a basic
epitopic core sequence.
C. Polynucleotides and Oligonucleotides
In addition to polypeptides, the present invention also
encompasses nucleic acids encoding the GST-1’s discussed
above. Because of the degeneracy of the genetic code, many
other nucleic acids also may encode a given GST-a. For
example, four different three-base codons encode the amino
acids alanine, glycine, proline, threonine and valine, while
six different codons encode arginine, leucine and serine.
Only methionine and tryptophan are encoded by asingle
codon. Table A provides a list of amino acids and their
corresponding codonsfor use in such embodiments.In order
to generate any nucleic acid encoding GST-z, one need only
refer to the codon table provided herein. Substitution of the
natural codon with any codon encoding the same aminoacid
will result in a distinct nucleic acid that encodes GST-90 . As
a practical matter, this can be accomplished bysite-directed
mutagenesis of an existing GST-a gene or de novo chemical
synthesis of one or more nucleic acids.
The observations regarding site-directed mutagenesis and
chemical synthesis, presented above with respect to substi-
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tutional mutants GST-m peptides and polypeptides, apply
with equal force to the discussion of nucleic acids. More
specifically, substitutional mutants generated by site-
directed changes in the nucleic acid sequence that are
designed to alter one or more codonsof a given polypeptide
or epitope may provide a more convenient wayof generating
large numbers of mutants in a rapid fashion. The nucleic
acids of the present invention provide for a simple way to
generate fragments (e.g., truncations) of GST-2, GST-a-
GST-« fusion molecules (discussed above) and GST-a
fusions with other molecules. For example, utilization of
restriction enzymes, nucleases, linkers and ligases in the
GST-a gene permits one to manipulate the structure of these
genes, and the resulting gene products.
The nucleic acid sequence information provided by the
present disclosure also allows for the preparation of rela-
tively short DNA (or RNA) sequences that have the ability
to specifically hybridize to gene sequences of the selected
GST-a gene. In these aspects nucleic acid probes of an
appropriate length are prepared based on a consideration of
the coding sequence of the GST-a gene,or flanking regions
near the GST-m gene, such as regions downstream and
upstream in the GST-a gene in the chromosome.Theability
of such nucleic acid probes to specifically hybridize to
GST-a gene sequences lends them particular utility in a
variety of embodiments. For example, the probes can be
used in a variety of diagnostic assays for detecting of an
inteact GST-m gene in a given sample. In addition, these
oligonucleotides can be inserted, in frame, into expression
constructs for the purpose of screening the corresponding
peptides for reactivity with existing antibodies or for the
ability to generate diagnostic or therapeutic reagents.
To provide certain of the advantages in accordance with
the invention, the preferred nucleic acid sequence employed
for hybridization studies or assays includes sequencesthat
are complementary to at least a 10 to 20, or so, nucleotide
stretch of the sequence, although sequences of 30 to 60 or so
nucleotides are also envisionedto be useful. A size ofat least
9 nucleotides in length helps to ensure that the fragment will
be of sufficient length to form a duplex molecule that is both
stable and selective. Though molecules having complemen-
tary sequences overstretches greater than 10 bases in length
are generally preferred, in order to increase stability and
selectivity of the hybrid, and thereby improve the quality
and degree of the specific hybrid molecules obtained. Thus,
one will generally prefer to design nucleic acid molecules
having GST-a gene-complementary stretches of 15 to 20
nucleotides, or even longer, such as 30 to 60, where desired.
Such fragments may be readily prepared by, for example,
directly synthesizing the fragment by chemical means, by
application of nucleic acid reproduction technology, such as
the PCR technology of U.S. Pat. No. 4,603,102, or by
introducing selected sequences into recombinant vectors for
recombinant production.
The probesthat would be useful may be derived from any
portion of the GST-a variants. Therefore, probes are spe-
cifically contemplated that comprise nucleotides 1 to 9, or 2
to 10, or 3 to 11 and so forth up to a probe comprising the
last 9 nucleotides of the nucleotide sequence of each GST-z.
Thus, each probe would comprise at least about 9 linear
nucleotides of the nucleotide sequence, designated by the
formula “n to n+8,” where n is an integer from 1 to the
number of nucleotides in the sequence. Longer probes that
hybridize to the GST-a gene under low, medium, medium-
high and high stringency conditions are also contemplated,
including those that comprise the entire nucleotide sequence
of the GST-z variants. This hypothetical may be repeated for
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probes having lengths of about 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 and
greater bases.
A variety of hybridization techniques and systems are
known which can be used in connection with the hybrid-
ization aspects of the invention, including diagnostic assays
such as those described in Falkow et al., U.S. Pat. No.
4,358,535. Depending on the application envisioned, one
will desire to employ varying conditions of hybridization to
achieve varying degrees of selectivity of the probe toward
the target sequence. For applications requiring a high degree
of selectivity, one will typically desire to employrelatively
stringent conditions to form the hybrids, for example, one
will select relatively low salt and/or high temperature
conditions, such as provided by 0.02M-0.15M NaCl at
temperatures of 50° C. to 70° C. These conditions are
particularly selective, and tolerate little, if any, mismatch
between the probe and the template or target strand.
Ofcourse, for some applications, for example, where one
desires to prepare mutants employing a mutant primerstrand
hybridized to an underlying template, less stringent hybrid-
ization conditions are called for in order to allow formation
of the heteroduplex. In these circumstances, one would
desire to employ conditions such as 0.15M-0.9Msalt, at
temperatures ranging from 20° C. to 55° C. In any case,it
is generally appreciated that conditions can be rendered
more stringent by the addition of increasing amounts of
formamide, which serves to destabilize the hybrid duplex in
the same manner as increased temperature. Thus, hybrid-
ization conditions can be readily manipulated, and the
method of choice will generally depend on the desired
results.
In certain embodiments, one may desire to employ
nucleic acid probes to isolate variants from clone banks
containing mutated clones. In particular embodiments,
mutant clone colonies growing on solid media which contain
variants of the GST-a sequence could be identified on
duplicate filters using hybridization conditions and methods,
such as those used in colony blot assays, to obtain hybrid-
ization only between probes containing sequence variants
and nucleic acid sequence variants contained in specific
colonies. In this manner, small hybridization probes con-
taining short variant sequences of the GST-m gene may be
utilized to identify those clones growing on solid media
which contain sequence variants of the entire GST-a gene.
These clones can then be grown to obtain desired quantities
of the variant GST-a nucleic acid sequences or the corre-
sponding GST-x antigen.
In diagnostic embodiments, nucleic acid sequences of the
present invention are used in combination with an appro-
priate means, such as a label, for determining hybridization.
Awide variety of appropriate indicator means are known in
the art, including radioactive, enzymatic or other ligands,
such as avidin/biotin, which are capable of giving a detect-
able signal. In preferred diagnostic embodiments, one will
likely desire to employ an enzyme tag such as urease,
alkaline phosphatase or peroxidase, instead of radioactive or
other environmental undesirable reagents. In the case of
enzyme tags, colorimetric indicator substrates are known
which can be employed to provide a meansvisible to the
human eye or spectrophotometrically, to identify specific
hybridization with nucleic acid-containing samples.
In general, it is envisioned that the hybridization probes
described herein will be useful both as reagents in solution
hybridizations as well as in embodiments employing a solid
phase. In embodiments involving a solid phase, the test
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DNA (or RNA) from suspected clinical samples, such as
exudates, body fluids (e.g., amniotic fluid, middle ear
effusion, bronchoalveolar lavage fluid) or even tissues, is
adsorbed or otherwise affixed to a selected matrix or surface.
This fixed, single-stranded nucleic acid is then subjected to
specific hybridization with selected probes under desired
conditions. The selected conditions will depend on the
particular circumstances based on the particular criteria
required (depending,for example, on the G+C contents, type
of target nucleic acid, source of nucleic acid, size of hybrid-
ization probe, etc.). Following washing of the hybridized
surface so as to remove nonspecifically bound probe
molecules, specific hybridization is detected, or even
quantified, by means ofthe label.
The nucleic acid encoding the variant sequences may be
useful in conjunction with polymerase chain reaction (PCR)
methodology to detect changes in the genomic make-up of
cells, for example, of tumorcells. In general, by applying the
PCR technology as set out, e.g., in U.S. Pat. No. 4,60,102,
one mayutilize various portions of the GST-m gene sequence
as oligonucleotide probes for the PCR amplification of a
defined portion of a GST-m nucleic acid in a sample. The
amplified portion of the GST-2 sequence may then be
detected by hybridization with a hybridization probe con-
taining a complementary sequence. In this manner,
extremely small concentrations of nucleic acid may detected
in a sample utilizing GST-7 sequences.
Antisense Technology
In a specific application of a sequence that hybridizes to
GST-a, the present invention contemplates the use of anti-
sense constructs. The term “antisense”is intended to refer to
polynucleotide molecules complementary to a portion of a
RNA GST-z, or the DNA corresponding thereto. “Comple-
mentary” polynucleotides are those which are capable of
base-pairing according to the standard Watson-Crick
complementarity rules. That is, the larger purines will base
pair with the smaller pyrimidines to form combinations of
guanine paired with cytosine (G:C) and adenine paired with
either thymine (A:T) in the case of DNA,or adenine paired
with uracil (A:U) in the case of RNA. Inclusion of less
common bases such as inosine, 5-methylcytosine,
6-methyladenine, hypoxanthine and others in hybridizing
sequences does not interfere with pairing.
Targeting double-stranded (ds) DNA with polynucle-
otides leads to triple-helix formation; targeting RNA will
lead to double-helix formation. Antisense polynucleotides,
when introduced into a target cell, specifically bind to their
target polynucleotide and interfere with transcription, RNA
processing, transport, translation and/or stability. Antisense
RNAconstructs, or DNA encoding such antisense RNA’s,
may be employed to inhibit gene transcriptionor translation
or both within a host cell, either in vitro or in vivo, such as
within a host animal, including a human subject.
The intracellular concentration of monovalent cation is
approximately 160 mm (10 mm Na*; 150 mM K*). The
intracellular concentration of divalent cation is approxi-
mately 20 mM (18 mM Mg*; 2 mM Ca**).The intracellular
protein concentration, which would serve to decrease the
volume of hybridization and, therefore, increase the effec-
tive concentration of nucleic acid species, is 150 mg/ml.
Constructs can be tested in vitro under conditions that mimic
these in vivo conditions.
Antisense constructs may be designed to bind to the
promoter and other control regions, exons, introns or even
exon-intron boundaries of a gene. It is contemplated that the
mosteffective antisense constructs. for the present invention
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will include regions complementary to the mRNAstartsite.
One can readily test such constructs simply by testing the
constructs in vitro to determine whether levels of the target
protein are affected. Similarly, detrimental non-specific inhi-
bition of protein synthesis also can be measured by deter-
mining target cell viability in vitro.
As used herein, the terms “complementary” or “anti-
sense” mean polynucleotides that are substantially comple-
mentary over their entire length and have very few base
mismatches. For example, sequences of fifteen bases in
length may be termed complementary when they have a
complementary nucleotide at thirteen or fourteen nucle-
otides out of fifteen. Naturally, sequences which are “com-
pletely complementary” will be sequences which are
entirely complementary throughout their entire length and
have no base mismatches.
Other sequences with lower degrees of homologyalso are
contemplated. For example, an antisense construct which
has limited regions of high homology, but also contains a
non-homologous region (e.g., a ribozyme) could be
designed. These molecules, though having less than 50%
homology, would bind to target sequences under appropriate
conditions.
The polynucleotides according to the present invention
may encode an GST-z gene or a portion of thereof that is
sufficientto effect antisense inhibition of protein expression.
The polynucleotides may be derived from genomic DNA,
i.e., cloned directly from the genomeof a particular organ-
ism. In other embodiments, however, the polynucleotides
may be complementary DNA (cDNA). cDNA is DNA
prepared using messenger RNA (mRNA)as template. Thus,
a cDNAdoes not contain any interrupted coding sequences
and usually contains almost exclusively the coding region(s)
for the corresponding protein. In other embodiments, the
antisense polynucleotide may be produced synthetically.
It may be advantageous to combine portions of the
genomic DNA with cDNAor synthetic sequences to gener-
ate specific constructs. For example, where an intron is
desired in the ultimate construct, a genomic clone will need
to be used. The cDNA or a synthesized polynucleotide may
provide more convenientrestriction sites for the remaining
portion of the construct and, therefore, would be used for the
rest of the sequence.
As stated above, although the antisense sequences may be
full length genomic or cDNA copies, or large fragments
thereof, they also may be shorter fragments, or
“oligonucleotides,” defined herein as polynucleotides of 50
or less bases. Although shorter oligomers (8-20) are easier
to make and increase in vivo accessibility, numerous other
factors are involved in determining the specificity of base-
pairing. For example, both binding affinity and sequence
specificity of an oligonucleotide to its complementary target
increase with increasing length. It is contemplated that
oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19, 20, 25, 30, 35, 40, 45 or 50 base pairs will be used. While
all or part of the gene sequence may be employed in the
context of antisense construction,statistically, any sequence
of 17 bases long should occur only once in the human
genome and, therefore, suffice to specify a unique target
sequence.
In certain embodiments, one may wish to employ anti-
sense constructs which include other elements, for example,
those which include C-5 propyne pyrimidines. Oligonucle-
otides which contain C-5 propyne analogues of uridine and
cytidine have been shown to bind RNA with high affinity
and to be potent antisense inhibitors of gene expression
(Wagneret al., 1993).
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Ribozymes
As an alternative to targeted antisense delivery, targeted
ribozymes may be used. The term “ribozyme”is refers to an
RNA-based enzyme capable of targeting and cleaving par-
ticular base sequences in both DNA and RNA. Ribozymes
can either be targeted directly to cells, in the form of RNA
oligonucleotides incorporating ribozyme sequences, or
introduced into the cell as an expression vector encoding the
desired nbozymal RNA. Ribozymes may be used and
applied in much the same way as described for antisense
polynucleotide. Ribozyme sequences also may be modified
in much the same wayas described for antisense polynucle-
otide. For example, one could incorporate non-Watson-
Crick bases, or make mixed RNA/DNAoligonucleotides, or
modify the phosphodiester backbone, or modify the
2'-hydroxy in the ribose sugar group of the RNA.
Alternatively, the antisense oligo- and polynucleotides
according to the present invention may be provided as RNA
via transcription from expression constructs that carry
nucleic acids encoding the oligo- or polynucleotides. A
general discussion of expression constructs and vectors is
provided below.
Screening for Antisense and Ribozyme Inhibitors of
GST-p Expression
Therationale of the antisense oligonucleotide or ribozyme
therapeutic agents in this invention is that they can be used
to down-regulate the expression of specific variants of the
human GST-z gene by hybridizing with the mRNAtran-
scripts of these genes and thereby preventing their transla-
tion into protein. By so doing the defense against therapy
that the GST-a protein offers the tumorcell is blocked and
the tumor becomes more sensitive to subsequent therapy.
Additionally, by suppressing the expression of the GST-2
gene in the tumorcell, the contribution of the GST-z protein
to the rapid growth and progression of the tumor is dimin-
ished. In the rational design the antisense molecules to
hybridize with relatively small regions (15 bases) of the
GST-a mRNA. Such small region targeting has a distinct
advantage over full-length antisense polynucleotide strate-
gies because it allows for higher selectivity in the targeting
of different regions of the gene, and enables us to specifi-
cally and differentially down-regulate expression of the
different GST-a gene variants.
In certain embodiments the present invention provides
Accordingly, in screening assays to identify antisense mol-
ecules which alter the expression of GST-m gene in for
example cancer cells, are provided by the present invention.
In these embodiments, the present invention is directed to a
method for determining the ability of a candidate antisense
or ribozyme molecule to decrease the GST-m expression of
cancer cells, the method including generally the steps of:
(a) obtaining a cell with GST-a expression;
(b) admixing a candidate molecule with the cell; and
(c) determining the ability of the candidate substance to
inhibit the GST-x content of the cell.
To identify a candidate substance as being capable of
decreasing GST-a expression, one would measure or deter-
mine the basal GST-a status of, for example a cancercell
prior to any additions or manipulation. One would then add
the candidate molecule to the cell and redetermine the
GST-a activity in the presence of the candidate molecule. A
candidate antisense or ribozyme which decreases the GST-1t
expression or contentof a cell relative to the composition in
its absence is indicative of a candidate substance being an
inhibitor of GST-a expression.
Asignificant decrease in GST-a expression, is represented
by a decrease in GST-a protein levels of at least about
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30%-40%, and most preferably, by decreases of at least
about 50%, with higher values of course being possible.
Assays that measure GST-a content in cells are well known
in the art and may be conductedin vitro or in vivo, and have
been described elsewhere in the specification.
Alternatively, it may be desirable simply to measure
inhibition of growth of cancer cells, for example, by mea-
suring growth according to the MTTassay. A significant
inhibition in growth is represented by decreases of at least
about 30%—40% as compared to uninhibited, and most
preferably, of at least about 50%, with more significant
decreases also being possible. Growth assays as measured
by the MTT assay are well knownin the art. Assays may be
conducted as described by Mosmannet al., 1983; Rubinstein
et al., 1990 (incorporated herein by reference). Therefore, if
a candidate molecule exhibited inhibition of growth of
cancercells in this type of study, it would likely be a suitable
compound for use in the present invention.
Quantitative in vitro testing of the antisense or ribozyme
molecules is not a requirement of the invention as it is
generally envisioned that the agents will often be selected on
the basis of their known properties or by structural and/or
functional comparison to those agents already demonstrated
to be effective. Therefore, the effective amounts will often be
those amounts proposed to be safe for administration to
animals in another context.
D. Expression Vectors
In order to express a GST-2 polypeptide or antisense
construct, it is necessary to provide an GST-z nucleic acid
in an expression cassette. The expression cassette contains a
GST-a nucleic acid undertranscriptional control of a pro-
moter. A “promoter” refers to a DNA sequence recognized
by the synthetic machinery of the cell, or introduced syn-
thetic machinery, required to initiate the specific transcrip-
tion of a gene. The phrase “under transcriptional control”
means that the promoter is in the correct location and
orientation in relation to the nucleic acid to control RNA
polymerase initiation and expression of the gene. Those
promoters most commonly used in prokaryotic recombinant
DNAconstruction include the B-lactamase (penicillinase)
and lactose promoter systems (Changetal., 1978; Itakuraet
al., 1977; Goeddel et al., 1979) and a tryptophan (trp)
promoter system (Goeddelet al., 1980; EPO Appl. Publ. No.
0036776). While these are the most commonly used, other
microbial promoters have been discovered and utilized, and
details concerning their nucleotide sequences have been
published, enabling a skilled worker to ligate them func-
tionally with plasmid vectors (EPO Appl. Publ. No.
0036776).
The appropriate expression cassette can be inserted into a
commercially available expression vector by standard sub-
cloning techniques. Throughout this application, the terms
“expression construct” or “expression vector” are meant to
include any type of genetic construct containing a nucleic
acid encoding an antisense product in whichpartorall of the
nucleic acid sequence is capable of being transcribed. For
example, the E. coli vectors pUC or pBluescript™ may be
used according to the present invention to produce recom-
binant GST-7z polypeptide in vitro. The manipulation of
these vectors is well known in the art. In general, plasmid
vectors containing replicon and control sequences which are
derived from species compatible with the host cell are used
in connection with these hosts. The vector ordinarily carries
a replication site, as well as marking sequences which are
capable of providing phenotypic selection in transformed
cells. For example, F. coli is typically transformed using
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pBR322, a plasmid derived from an F.coli species (Bolivar
et al., 1977). pBR322 contains genes for ampicillin and
tetracycline resistance and thus provides easy means for
identifying transformed cells. The pBR plasmid, or other
microbial plasmid or phage must also contain, or be modi-
fied to contain, promoters which can be used by the micro-
bial organism for expression of its own proteins.
In addition, phage vectors containing replicon and control
sequences that are compatible with the host microorganism
can be used as a transforming vector in connection with
these hosts. For example, the phage lambda GEM™-11 may
be utilized in making recombinant phage vector which can
be used to transform host cells, such as E. coli LE392.
In one embodiment, the protein is expressed as a fusion
protein with B-gal, allowing rapid affinity purification of the
protein. Examples of such fusion protein expression systems
are the glutathione S-transferase system (Pharmacia,
Piscataway, N.J.), the maltose binding protein system (NEB,
Beverley, Mass.), the FLAG system (IBI, New Haven,
Conn.), and the 6xHis system (Qiagen, Chatsworth, Calif.).
Someof these fusion systems produce recombinant protein
bearing only a small number of additional amino acids,
which are unlikely to affect the functional capacity of the
recombinant protein. For example, both the FLAG system
and the 6xHis system add only short sequences, both of
which are known to be poorly antigenic and which do not
adversely affect folding of the protein to its native confor-
mation. Other fusion systems produce proteins where it is
desirable to excise the fusion partner from the desired
protein. In another embodiment, the fusion partner is linked
to the recombinantprotein by a peptide sequence containing
a specific recognition sequence for a protease. Examples of
suitable sequencesare those recognized by the Tobacco Etch
Virus protease (Life Technologies, Gaithersburg, Md.) or
Factor Xa (New England Biolabs, Beverley, Mass.).
E. coli is a preferred prokaryotic host. For example, E.
coli strain RR1is particularly useful. Other microbial strains
which may be used include F. coli strains such as E. coli
LE392, EF. coli B, and E. coli X 1776 (ATCC No. 31537).
The aforementionedstrains, as well as E. coli W3 110 (F-,
lambda-, prototrophic, ATCC No. 273325), bacilli such as
Bacillus subtilis, or other enterobacteriaceae such as Salmo-
nella typhimurium or Serratia marcescens, and various
Pseudomonasspecies may be used. These examplesare, of
course, intended to be illustrative rather than limiting.
Recombinantbacterial cells, for example F. coli, are grown
in any of a numberof suitable media, for example LB, and
the expression of the recombinant polypeptide induced by
adding IPTG to the media or switching incubation to a
higher temperature. After culturing the bacteria for a further
period of between 2 and 24 hours,the cells are collected by
centrifugation and washed to remove residual media. The
bacterial cells are then lysed, for example, by disruption in
a cell homogenizer and centrifuged to separate the dense
inclusion bodies and cell membranes from the soluble cell
components. This centrifugation can be performed under
conditions whereby the dense inclusion bodies are selec-
tively enriched by incorporation of sugars such as sucrose
into the buffer and centrifugation at a selective speed.
If the recombinant protein is expressed in the inclusion
bodies, as is the case in many instances, these can be washed
in any of several solutions to remove some of the contami-
nating host proteins, then solubilized in solutions containing
high concentrations of urea (e.g. 8M) or chaotropic agents
such as guanidine hydrochloride in the presence of reducing
agents such as B-mercaptoethanol or DTT (dithiothreitol).
Under some circumstances, it may be advantageous to
incubate the polypeptide for several hours under conditions
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suitable for the protein to undergo a refolding process into
a conformation which more closely resembles that of the
native protein. Such conditions generally include low pro-
tein concentrations less than 500 yg/ml, low levels of
reducing agent, concentrations of urea less than 2M and
often the presence of reagents such as a mixture of reduced
and oxidized glutathione which facilitate the interchange of
disulphide bonds within the protein molecule.
The refolding process can be monitored, for example, by
SDS-PAGE or with antibodies which are specific for the
native molecule (which can be obtained from animals vac-
cinated with the native molecule isolated from parasites).
Following refolding, the protein can then be purified further
and separated from the refolding mixture by chromatogra-
phy on any of several supports including ion exchange
resins, gel permeation resins or on a variety of affinity
columns.
In preferred another embodiment, the expression system
used is one driven by the baculovirus polyhedron promoter.
The gene encoding the protein can be manipulated by
standard techniques in order to facilitate cloning into the
baculovirus vector. A preferred baculovirus vector is the
pBlueBacvector (Invitrogen, Sorrento, Calif.). The vector
carrying the a4 gene is transfected into Spodoptera fru-
giperda (Sf9) cells by standard protocols, and the cells are
cultured and processed to produce the recombinantprotein.
There are a variety of other eukaryotic vectors that
provide a suitable vehicle in which recombinant GST-z can
be produced. In various embodiments of the invention, the
expression construct may comprise a virus or engineered
construct derived from a viral genome. Theability of certain
viruses to enter cells via receptor-mediated endocytosis and
to integrate into host cell genome and express viral genes
stably and efficiently have made them attractive candidates
for the transfer of foreign genes into mammalian cells
(Ridgeway, 1988; Nicolas and Rubenstein, 1988; Baichwal
and Sugden, 1986; Temin, 1986). The first viruses used as
vectors were DNA viruses including the papovaviruses
(simian virus 40, bovine papilloma virus, and polyoma)
(Ridgeway, 1988; Baichwal and Sugden, 1986) and aden-
oviruses (Ridgeway, 1988; Baichwal and Sugden, 1986) and
adeno-associated viruses. Retroviruses also are attractive
gene transfer vehicles (Nicolas and Rubenstein, 1988;
Temin, 1986) as are vaccina virus (Ridgeway, 1988) adeno-
associated virus (Ridgeway, 1988) and HSV (Gloriosoetal.,
1995). Such vectors may be used to (i) transform cell lines
in vitro for the purpose of expressing proteins of interest or
(ii) to transform cells in vitro or in vivo to provide thera-
peutic polypeptides in a gene therapy scenario.
With respect to eukaryotic vectors, the term promoter will
be used here to refer to a group of transcriptional control
modules that are clustered around theinitiation site for RNA
polymerase II. Much of the thinking about how promoters
are organized derives from analyses of several viral
promoters, including those for the HSV thymidine kinase
(tk) and SV40 early transcription units. These studies, aug-
mented by more recent work, have shown that promoters are
composed of discrete functional modules, each consisting of
approximately 7-20 bp of DNA,and containing one or more
recognition sites for transcriptional activator or repressor
proteins.
At least one module in each promoter functions to posi-
tion the start site for RNA synthesis. The best known
example of this is the TATA box, but in some promoters
lacking a TATA box, such as the promoter for the mamma-
lian terminal deoxynucleotidyl transferase gene and the
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promoter for the SV40 late genes, a discrete element over-
lying the start site itself helps to fix the place of initiation.
Additional promoter elements regulate the frequency of
transcriptional initiation. Typically, these are located in the
region 30-110 bp upstream of the start site, although a
number of promoters have recently been shown to contain
functional elements downstream ofthestart site as well. The
spacing between promoter elements frequently is flexible, so
that promoter function is preserved when elements are
inverted or movedrelative to one another.In the tk promoter,
the spacing between promoter elements can be increased to
50 bp apart before activity begins to decline. Depending on
the promoter, it appears that individual elements can func-
tion either co-operatively or independently to activate tran-
scription.
The particular promoter that is employed to control the
expression of a nucleic acid is not believed tobecritical, so
long as it is capable of expressing the nucleic acid in the
targeted cell. Thus, where a human cell is targeted, it is
preferable to position the nucleic acid coding region adja-
cent to and under the control of a promoter that is capable
of being expressed in a human cell. Generally speaking,
such a promoter might include either a human or viral
promoter. Preferred promoters include those derived from
HSV, including the «4 promoter. Another preferred embodi-
mentis the tetracycline controlled promoter.
In various other embodiments, the human cytomegalovi-
rus (CMV) immediate early gene promoter, the SV40 early
promoter and the Rous sarcoma virus long terminal repeat
can be used to obtain high-level expression of transgenes.
The use of other viral or mammalian cellular or bacterial
phage promoters which are well-knownin the art to achieve
expression of a transgene is contemplated as well, provided
that the levels of expression are sufficient for a given
purpose. Tables 2 and 3 list several elements/promoters
which may be employed, in the context of the present
invention, to regulate the expression of a transgene. This list
is not intended to be exhaustiveof all the possible elements
involved in the promotion of transgene expression but,
merely, to be exemplary thereof.
Enhancers were originally detected as genetic elements
that increased transcription from a promoter located at a
distant position on the same molecule of DNA. This ability
to act over a large distance had little precedent in classic
studies of prokaryotic transcriptional regulation. Subsequent
work showedthat regions of DNAwith enhanceractivity are
organized much like promoters. Thatis, they are composed
of many individual elements, each of which binds to one or
more transcriptional proteins.
The basic distinction between enhancers and promoters is
operational. An enhancer region as a whole mustbe able to
stimulate transcription at a distance; this need notbetrue of
a promoter region or its component elements. On the other
hand, a promoter must have one or more elementsthat direct
initiation of RNA synthesis at a particular site and in a
particular orientation, whereas enhancers lack these speci-
ficities. Promoters and enhancers are often overlapping and
contiguous, often seeming to have a very similar modular
organization.
Additionally any promoter/enhancer combination (as per
the Eukaryotic Promoter Data Base EPDB) could also be
used to drive expression of a transgene. Use of a T3, T7 or
SP6 cytoplasmic expression system is another possible
embodiment. Eukaryotic cells can support cytoplasmic tran-
scription from certain bacterial promoters if the appropriate
bacterial polymerase is provided, either as part of the
delivery complex or as an additional genetic expression
construct.
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Host cells include eukaryotic microbes, such as yeast
cultures may also be used. Saccharomyces cerevisiae, or
common baker’s yeast is the most commonly used among
eukaryotic microorganisms, although a number of other
strains are commonly available. For expression in
Saccharomyces, the plasmid YRp7, for example, is com-
monly used (Stinchcombet al., 1979; Kingsmanet al., 1979;
Tschemperet al., 1980). This plasmid already contains the
trp1 gene which provides a selection marker for a mutant
strain of yeast lacking the ability to grow in tryptophan,for
example ATCC No. 44076 or PEP4-1 (Jones, 1977). The
presence of the trp1 lesion as a characteristic of the yeast
host cell genome then provides an effective environmentfor
detecting transformation by growth in the absence of tryp-
tophan.
Suitable promoting sequencesin yeast vectors include the
promoters for 3-phosphoglycerate kinase (Hitzemanet al.,
1980) or other glycolytic enzymes (Hess et al. 1968;
Holland et al., 1978), such as enolase, glyceraldehyde-3-
phosphate dehydrogenase, hexokinase, pyruvate
decarboxylase, phosphofructokinase, glucose-6-phosphate
isomerase, 3-phosphoglycerate mutase, pyruvate kinase,tri-
osephosphate isomerase, phosphoglucose isomerase, and
glucokinase. In constructing suitable expression plasmids,
the termination sequences associated with these genes are
also ligated into the expression vector 3' of the sequence
desired to be expressed to provide polyadenylation of the
mRNAand termination. Other promoters, which have the
additional advantage of transcription controlled by growth
conditions are the promoter region for alcohol dehydroge-
nase 2, isocytochrome C, acid phosphatase, degradative
enzymes associated with nitrogen metabolism, and the
aforementioned glyceraldehyde-3-phosphate
dehydrogenase, and enzymes responsible for maltose and
galactose utilization. Any plasmid vector containing a yeast-
compatible promoter, origin of replication and termination
sequences is suitable.
In addition to eukaryotic microorganisms, cultures of
cells derived from multicellular organisms mayalso be used
as hosts. In principle, any such cell culture is workable,
whether from vertebrate or invertebrate culture. However,
interest has been greatest in vertebrate cells, and propagation
of vertebrate cells in culture (tissue culture) has become a
routine procedure in recent years (Tissue Culture, 1973).
Examples of such useful host cell lines are VERO and HeLa
cells, Chinese hamster ovary (CHO)cell lines, and W138,
BHK, COS-7, 293 and MDCKcell lines. Expression vectors
for such cells ordinarily include (if necessary) an origin of
replication, a promoter located in front of the gene to be
expressed, along with any necessary ribosomebindingsites,
RNAsplice sites, polyadenylation site, and transcriptional
terminator sequences.
E. Non-Viral Delivery Systems
In addition to the use of the viral expression vectors
described above, expression vectors containing genes
encoding GST-a’s of the present invention may be delivered
to cells using a variety of other methods. These include
calcium phosphate precipitation (Graham and Van Der Eb,
1973; Chen and Okayama, 1987; Rippeet al., 1990) DEAE-
dextran (Gopal, 1985), electroporation (Tur-Kaspaet al.,
1986;Potteret al., 1984), direct microinjection (Harland and
Weintraub, 1985), DNA-loaded liposomes (Nicolau and
Sene, 1982; Fraley et al., 1979) and lipofectamine-DNA
complexes, cell sonication (Fechheimer et al., 1987), gene
bombardmentusing high velocity microprojectiles (Yang et
al., 1990), polycations (Boussif et al., 1995) and receptor-
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mediated transfection (Wu and Wu, 1987; Wu and Wu,
1988). Some of these techniques may be successfully
adapted for in vivo or ex vivo use.
In one embodiment of the invention, expression vector
(viral or non-viral) may simply consist of naked recombi-
nant vector. Transfer of the construct may be performed by
any of the methods mentioned above which physically or
chemically permeabilize the cell membrane. For example,
Dubenskyet al. (1984) successfully injected polyomavirus
DNAin the form of CaPO,precipitates into liver and spleen
of adult and newborn mice demonstrating active viral rep-
lication and acute infection. Benvenisty and Neshif (1986)
also demonstrated that direct intraperitoneal injection of
CaPO, precipitated plasmids results in expression of the
transfected genes. It is envisioned that DNA encoding an
GSTx construct may also be transferred in a similar manner
in vivo.
Another embodiment of the invention for transferring a
naked DNAexpression vectorinto cells may involveparticle
bombardment. This method depends on the ability to accel-
erate DNA coated microprojectiles to a high velocity allow-
ing them to pierce cell membranes and enter cells without
killing them (Klein etal., 1987). Several devices for accel-
erating small particles have been developed. One such
device relies on a high voltage discharge to generate an
electrical current, which in turn provides the motive force
(Yanget al., 1990). The microprojectiles used have consisted
of biologically inert substances such as tungsten or gold
beads.
Selected organs including the liver, skin, and muscle
tissue of rats and mice have been bombarded in vivo (Yang
et al., 1990; Zelenin et al., 1991). This may require surgical
exposure of the tissue or cells, to eliminate any intervening
tissue between the gun andthe target organ. DNA encoding
a GST-x construct may be delivered via this method.
In a preferred embodimentof the invention, the antisense
oligo- or polynucleotides and expression vectors may be
entrapped in a liposome. Liposomesare vesicular structures
characterized by a phospholipid bilayer membrane and an
inner aqueous medium. Multilamellar liposomes have mul-
tiple lipid layers separated by aqueous medium. They form
spontaneously when phospholipids are suspended in an
excess of aqueous solution. The lipid components undergo
self-rearrangement before the formation of closed structures
and entrap water and dissolved solutes between the lipid
bilayers (Ghosh and Bachhawat, 1991). Also contemplated
are lipofectamine-nucleic acid complexes.
Liposome-mediated polynucleotide delivery and expres-
sion of foreign DNAin vitro has been very successful. Wong
et al. (1980) demonstrated the feasibility of liposome-
mediated delivery and expression of foreign DNA in cul-
tured chick embryo, HeLa and hepatomacells. Nicolau etal.
(1987) accomplished successful liposome-mediated gene
transfer in rats after intravenous injection.
In certain embodiments of the invention, the liposome
may be complexed with a hemagglutinating virus (HVJ).
This has been shown to facilitate fusion with the cell
membraneand promotecell entry of liposome-encapsulated
DNA(Kaneda et al., 1989). In other embodiments, the
liposome may be complexed or employed in conjunction
with nuclear non-histone chromosomal proteins (HMG-1)
(Kato et al., 1991). In yet further embodiments,the liposome
may be complexed or employed in conjunction with both
HVJ and HMG-1.In that such expression vectors have been
successfully employed in transfer and expression of a poly-
nucleotide in vitro and in vivo, then they are applicable for
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the present invention. Where a bacterial promoter is
employed in the DNA construct, it also will be desirable to
include within the liposome an appropriate bacterial poly-
merase.
“Liposome” is a generic term encompassing a variety of
single and multilamellar lipid vehicles formed by the gen-
eration of enclosedlipid bilayers. Phospholipids are used for
preparing the liposomes according to the present invention
and can carry a net positive charge, a net negative charge or
are neutral. Dicetyl phosphate can be employed to confer a
negative charge on the liposomes, and stearylamine can be
used to confer a positive charge on the liposomes.
Lipids suitable for use according to the present invention
can be obtained from commercial sources. For example,
dimyristyl phosphatidylcholine (“DMPC”) can be obtained
from Sigma Chemical Co., dicetyl phosphate (“DCP”) is
obtained from K & K Laboratories (Plainview, N.Y.); cho-
lesterol (‘Chol’) is obtained from Calbiochem-Behring;
dimyristyl phosphatidylglycerol (“DMPG”) and other lipids
may be obtained from Avanti Polar Lipids, Inc.
(Birmingham,Ala.). Other lipids for liposomaltransfection,
include but are not limited to phosphatidylcholine (PC),
phosphatidylserine (PS), cholesterol (Chol), N-[1-(2,3-
dioleyloxy)propyl]-N,N-trimethylammonium chloride
(DOTMA), dioleoylphosphatidylethanolamine (DOPE),
and/or 3B[N-(N'N'-dimethylaminoethane)-carbarmoyl cho-
lesterol (DC-Chol), as well as other lipids knownto those of
skill in the art. Those of skill in the art will recognize that
there are a variety of liposomal transfection techniques
which will be useful in the present invention. Among these
techniques are those described in Nicolau et al., 1987, Nabel
et al., 1990, and Gaoet al., 1991. Stock solutions of lipids
in chloroform or chloroform/methanol canbe stored at about
-20° C. Preferably, chloroform is used as the only solvent
since it is more readily evaporated than methanol.
Phospholipids from natural sources, such as egg or soy-
bean phosphatidylcholine, brain phosphatidic acid, brain or
plant phosphatidylinositol, heart cardiolipin and plant or
bacterial phosphatidylethanolamine are preferably not used
as the primary phosphatide,i.e., constituting 50% or more of
the total phosphatide composition, because of the instability
and leakiness of the resulting liposomes.
Liposomesused according to the present invention can be
made by different methods. Thesize of the liposomes varies
depending on the method of synthesis. A liposome sus-
pended in an aqueoussolution is generally in the shape of a
spherical vesicle, having one or more concentric layers of
lipid bilayer molecules. Each layer consists of a parallel
array of molecules represented by the formula XY, wherein
X is a hydrophilic moiety and Y is a hydrophobic moiety. In
aqueous suspension, the concentric layers are arranged such
that the hydrophilic moieties tend to remain in contact with
an aqueous phase and the hydrophobic regions tend to
self-associate. For example, when aqueous phases are
present both within and without the liposome, the lipid
molecules will form a bilayer, known as a lamella, of the
arrangement XY-YX.
Liposomes within the scope of the present invention can
be prepared in accordance with known laboratory tech-
niques. In one preferred embodiment, liposomes are pre-
pared by mixing liposomallipids, in a solventin a container,
e.g., a glass, pear-shaped flask. The container should have a
volumeten-times greater than the volume of the expected
suspension of liposomes. Using a rotary evaporator, the
solvent is removed at approximately 40° C. under negative
pressure. The solvent normally is removed within about 5
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min. to 2 hours, depending on the desired volumeof the
liposomes. The composition can be dried further in a des-
iccator under vacuum. The dried lipids generally are dis-
carded after about 1 week because of a tendency to dete-
riorate with time.
Dried lipids can be hydrated at approximately 25-50 mM
phospholipid in sterile, pyrogen-free water by shaking until
all the lipid film is resuspended. The aqueous liposomes can
be then separated into aliquots, each placed in a vial,
lyophilized and sealed under vacuum.
In the alternative, liposomes can be prepared in accor-
dance with other knownlaboratory procedures: the method
of Bangham etal. (1965), the contents of which are incor-
porated herein by reference; the method of Gregoriadis, as
described in DRUG CARRIERS IN BIOLOGY AND
MEDICINE, G. Gregoriadis ed. (1979) pp. 287-341, the
contents of which are incorporated herein by reference; the
method of the contents of which are incorporated by refer-
ence; and the reverse-phase evaporation method. The afore-
mentioned methods differ in their respective abilities to
entrap aqueous material and their respective aqueous space-
to-lipid ratios.
The dried lipids or lyophilized liposomes prepared as
described above may be dehydrated and reconstituted in a
solution of inhibitory peptide and diluted to an appropriate
concentration with an suitable solvent, e.g., DPBS. The
mixture is then vigorously shaken in a vortex mixer. Unen-
capsulated nucleic acid is removed by centrifugation at
29,000xg and the liposomal pellets washed. The washed
liposomes are resuspended at an appropriate total phospho-
lipid concentration, e.g., about 50-200 mM. The amountof
nucleic acid encapsulated can be determined in accordance
with standard methods. After determination of the amountof
nucleic acid encapsulated in the liposome preparation, the
liposomes maybe diluted to appropriate concentrations and
stored at 4° C.until use.
In a preferred embodiment, the lipid dioleoylphosphati-
dylchoine is employed. Nuclease-resistant oligonucleotides
were mixed with lipids in the presence of excess t-butanol.
The mixture was vortexed before being frozen in an acetone/
dry ice bath. The frozen mixture was lyophilized and
hydrated with Hepes-buffered saline (1 mM Hepes, 10 mM
NaCl, pH 7.5) overnight, and then the liposomes were
sonicated in a bath type sonicator for 10 to 15 min. The size
of the liposomal-oligonucleotides typically ranged between
200-300 nm in diameter as determined by the submicron
particle sizer autodilute model 370 (Nicomp, Santa Barbara,
Calif.).
Liposomes may beintroduced into contact with cells to be
transfected by a variety of methods. In cell culture, the
liposomes can simply be dispersed in the cell culture solu-
tion. For application in vivo, liposomes are typically
injected. Intravenous injection allow liposome-mediated
transfer of DNA complex to the liposomesto, for example,
the liver and the spleen. In order to allow transfection of
DNAinto cells which are not accessible through intravenous
injection, it is possible to directly inject the liposome-DNA
complexes into a specific location in an animal’s body. For
example, Nabelet al. teach injection via a catheter into the
arterial wall. In another example, the inventors have used
intraperitoneal injection to allow for gene transfer into mice.
The present invention also contemplates compositions
comprising a liposomal complex. This liposomal complex
will comprise a lipid component and a DNA segment
encoding a GST-m gene or an antisense construct thereof.
The gene employed in the liposomal complex can be, for
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example, GSTP1*B, GSTP1*Cor any variant thereof. Lipo-
somal complexes comprising antisense constructs may have
distinct advantages as described herein. It is proposed that
one may employ any gene product outlined herein in lipo-
somal delivery, or alternatively two or more gene products
together may be used in the practice of the invention.
It is proposed that it will ultimately be preferable to
employ the smallest region needed to elicit the necessary
therapeutic effect so that one is not introducing unnecessary
DNAinto cells which receive a GST-m gene construct.
Techniques well knownto those of skill in the art, such as
the use of restriction enzymes, will allow for the generation
of small regions of GST-z for such purposes. The ability of
these regions to inhibit tumors can easily be determined by
the assays reported in the Examples.
Another mechanism for transferring expression vectors
into cells is receptor-mediated delivery. This approach takes
advantage of the selective uptake of macromolecules by
receptor-mediated endocytosis in almostall eukaryotic cells.
Because of the cell type-specific distribution of various
receptors, the delivery can be highly specific (Wu and Wu,
1993). Receptor-mediated gene targeting vehicles generally
consist of two components: a cell receptor-specific ligand
and a DNA-binding agent. Several ligands have been used
for receptor-mediated gene transfer. The most extensively
characterized ligands are asialoorosomucoid (ASOR) (Wu
and Wu, 1987) and transferrin (Wagner et al., 1993).
Recently, a synthetic neoglycoprotein, which recognizes the
same receptor as ASOR,has been used as a gene delivery
vehicle (Ferkol et al., 1993; Perales et al., 1994) and
epidermal growth factor (EGF) has also been usedto deliver
genes to squamous carcinomacells (Myers, EPO 0273085).
In other embodiments, the delivery vehicle may comprise
a ligand and a liposome. For example, Nicolau etal. (1987)
employed lactosyl-ceramide, a galactose-terminal
asialganglioside, incorporated into liposomes and observed
an increase in the uptake of the insulin gene by hepatocytes.
Thus,it is feasible that an adenoviral expression vector also
may be specifically delivered into a cell type such as lung,
epithelial or tumor cells, by any numberof receptor-ligand
systems, with or without liposomes. For example, epidermal
growth factor (EGF) may be used as the receptor for
mediated delivery of GST-a construct in many tumorcells
that exhibit upregulation of EGF receptor. Mannose can be
used to target the mannose receptor on liver cells. Also,
antibodies to CD5 (CLL), CD22 (lymphoma), CD25 (T-cell
leukemia) and MAA (melanoma) can similarly be used as
targeting moieties.
In certain embodiments, gene transfer may moreeasily be
performed under ex vivo conditions. Ex vivo gene therapy
refers to the isolation of cells from an animal, the delivery
of a polynucleotideinto the cells, in vitro, and then the return
of the modified cells back into an animal. This may involve
the surgical removal of tissue/organs from an animal or the
primary culture of cells and tissues. Anderson et al., U.S.
Pat. No. 5,399,346, and incorporated herein in its entirety,
disclose ex vivo therapeutic methods. During ex vivo
culture, the expression vector can express the GST-z con-
struct. Finally, the cells may be reintroducedinto the original
animal, or administered into a distinct animal, in a pharma-
ceutically acceptable form by any of the means described
below.
F. Antibodies
Antibodies to GST-z peptides or polypeptides may be
readily prepared through use of well-known techniques,
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such as those exemplified in U.S. Pat. No. 4,196,265.
Typically, this technique involves immunizing a suitable
animal with a selected immunogen composition, e.g., puri-
fied or partially purified protein, synthetic protein or frag-
ments thereof, as discussed in the section on polypeptides.
Animals to be immunized are mammals such as cats, dogs
and horses, althoughthere is no limitation other than that the
subject be capable of mounting an immuneresponse of some
kind. The immunizing composition is administered in a
manner effective to stimulate antibody producing cells.
Rodents such as mice and rats are preferred animals,
however, the use of rabbit, sheep or frog cells is possible.
The use of rats may provide certain advantages, but mice are
preferred, with the BALB/c mouse being most preferred as
the most routinely used animal and onethat generally gives
a higher percentage of stable fusions.
For generation of monoclonal antibodies (MAbs), follow-
ing immunization, somatic cells with the potential for pro-
ducing antibodies, specifically B lymphocytes (B cells), are
selected for use in the MAb generating protocol. Thesecells
may be obtained from biopsied spleens, tonsils or lymph
nodes, or from a peripheral blood sample. Spleen cells and
peripheral blood cells are preferred, the former because they
are a rich source of antibody-producing cells that are in the
dividing plasmablast stage, and the latter because peripheral
blood is easily accessible. Often, a panel of animals will
have been immunized and the spleen of the animal with the
highest antibody titer removed. Spleen lymphocytes are
obtained by homogenizing the spleen with a syringe.
Typically, a spleen from an immunized mouse contains
approximately 5x10’ to 2x10* lymphocytes.
The antibody-producing B cells from the immunized
animal are then fused with cells of an immortal myeloma
cell line, generally one of the same species as the animal that
was immunized. Myeloma cell lines suited for use in
hybridoma-producing fusion procedures preferably are non-
antibody-producing, have high fusion efficiency and enzyme
deficiencies that render them incapable of growing in certain
selective media which support the growth of only the desired
fused cells, called “hybridomas.”
Any one of a number of myelomacells may be used and
these are knownto those of skill in the art. For example,
where the immunized animal is a mouse, one may use
P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 41, Sp210-Ag14,
FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/
5XX0 Bul; for rats, one may use R210.RCY3, Y3-Ag 1.2.3,
IR983F and 4B210; and U-266, GM1500-GRG2, LICR-
LON-HMy?2and UC729-6 are all useful in connection with
humancell fusions.
One preferred murine myeloma cell line is the NS-1
myelomacell line (also termed P3-NS-1-Ag4-1), which is
readily available from the NIGMS Human Genetic Mutant
Cell Repository by requesting cell line repository number
GM3573. Another mouse myeloma cell line that may be
used is the 8-azaguanine-resistant mouse murine myeloma
SP2/0 non-producer cell line.
Methods for generating hybrids of antibody-producing
spleen or lymph node cells and myeloma cells usually
comprise mixing somatic cells with myelomacells in a 2:1
proportion, though the proportion may vary from about 20:1
to about 1:1, respectively, in the presence of an agent or
agents (chemicalor electrical) that promote the fusion ofcell
membranes. Fusion methods using Sendai virus have been
described by Kohler & Milstein (1975; 1976), and those
using polyethylene glycol (PEG), such as 37% (v/v) PEG,
by Gefteret al. (1977). The useofelectrically induced fusion
methods is also appropriate.
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Fusion procedures usually produce viable hybrids at low
frequencies, from about 1x10~° to 1x10-®. This does not
pose a problem, however, as the viable, fused hybrids are
differentiated from the parental, unfused cells (particularly
the unfused myelomacells that would normally continue to
divide indefinitely) by culture in a selective medium. The
selective medium generally is one that contains an agent that
blocks the de novo synthesis of nucleotides in the tissue
culture media. Exemplary and preferred agents are
aminopterin, methotrexate and azaserine. Aminopterin and
methotrexate block de novo synthesis of both purines and
pyrimidines, whereas azaserine blocks only purine synthe-
sis. Where aminopterin or methotrexate is used, the media is
supplemented with hypoxanthine and thymidine as a source
of nucleotides (HAT medium). Where azaserine is used, the
media is supplemented with hypoxanthine.
The preferred selection medium is HAT. Only cells
capable of operating nucleotide salvage pathwaysare able to
survive in HAT medium. The myelomacells are defective in
key enzymes of the salvage pathway, e.g., hypoxanthine
phosphoribosyl transferase (HPRT), and they cannot sur-
vive. The B cells can operate this pathway, but they have a
limited life span in culture and generally die within about
two weeks. Therefore, the only cells that can survive in the
selective media are those hybrids formed from myeloma and
B cells.
This culturing provides a population of hybridomas from
which specific hybridomasare selected. Typically, selection
of hybridomas is performed by single-clone dilution in
microtiter plates, followed by testing the individual clonal
supernatants (after about two to three weeks) for the desired
reactivity. The assay should be sensitive, simple and rapid,
such as radioimmunoassays, enzyme immunoassays, cyto-
toxicity assays, plaque assays, dot immunobinding assays,
and the like.
The selected hybridomas are then serially diluted and
cloned into individual antibody-producing cell lines, which
clones can then be propagated indefinitely to provide MAbs.
The cell lines may be exploited for MAb production in two
basic ways. A sample of the hybridoma can be injected,
usually in the peritoneal cavity, into a histocompatible
animalof the type that was used to provide the somatic and
myelomacells for the original fusion. The injected animal
develops tumors secreting the specific monoclonal antibody
produced by the fused cell hybrid. The body fluids of the
animal, such as serum orascites fluid, can then be tapped to
provide MAbs in high concentration. The individual cell
lines could also be cultured in vitro, where the MAbs are
naturally secreted into the culture medium from which they
can be readily obtained in high concentrations. MAbs pro-
duced by either means may be further purified, if desired,
using filtration, centrifugation and various chromatographic
methods such as HPLC oraffinity chromatography.
Monoclonal antibodies of the present invention also
includeanti-idiotypic antibodies produced by methods well-
known in the art. Monoclonal antibodies according to the
present invention also may be monoclonal heteroconjugates,
1e., hybrids of two or more antibody molecules. In another
embodiment, monoclonal antibodies according to the inven-
tion are chimeric monoclonal antibodies. In one approach,
the chimeric monoclonal antibody is engineered by cloning
recombinant DNA containing the promoter, leader, and
variable-region sequences from a mouse antibody producing
cell and the constant-region exons from a human antibody
gene. The antibody encoded by such a recombinant geneis
a mouse-human chimera. Its antibody specificity is deter-
mined by the variable region derived from mouse sequences.
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Its isotype, which is determined by the constant region, is
derived from human DNA.
In another embodiment, monoclonalantibodies according
to the present invention is a “humanized” monoclonal
antibody, produced by techniques well-known in the art.
That is, mouse complementary determining regions
(“CDRs”) are transferred from heavy and light V-chains of
the mouse Ig into a human V-domain, followed by the
replacement of some human residues in the framework
regions of their murine counterparts. “Humanized” mono-
clonal antibodies in accordance with this invention are
especially suitable for use in in vivo diagnostic and thera-
peutic methods for treating Moroxella infections.
As stated above, the monoclonal antibodies and fragments
thereof accordingto this invention can be multiplied accord-
ing to in vitro and in vivo methods well-knownin theart.
Multiplication in vitro is carried out in suitable culture
media such as Dulbecco’s modified Eagle medium or RPMI
1640 medium, optionally replenished by a mammalian
serum suchasfetal calf serum or trace elements and growth-
sustaining supplements, e.g., feeder cells, such as normal
mouse peritoneal exudate cells, spleen cells, bone marrow
macrophagesor the like. In vitro production providesrela-
tively pure antibody preparations and allowsscale-up to give
large amountsof the desired antibodies. Techniquesfor large
scale hybridoma cultivation undertissue culture conditions
are known in the art and include homogenous suspension
culture, e.g., in an airlift reactor or in a continuousstirrer
reactor or immobilized or entrapped cell culture.
Large amounts of the monoclonal antibody of the present
invention also may be obtained by multiplying hybridoma
cells in vivo. Cell clones are injected into mammals which
are histocompatible with the parent cells, e.g., syngeneic
mice, to cause growth of antibody-producing tumors.
Optionally, the animals are primed with a hydrocarbon,
especially oils such as Pristane (tetramethylpentadecane)
prior to injection.
In accordance with the present invention, fragments of the
monoclonal antibody of the invention can be obtained from
monoclonal antibodies produced as described above, by
methods which include digestion with enzymes such as
pepsin or papain and/or cleavage of disulfide bonds by
chemical reduction. Alternatively, monoclonal antibody
fragments encompassed by the present invention can be
synthesized using an automated peptide synthesizer, or they
may be produced manually using techniques well known in
the art.
The monoclonal conjugates of the present invention are
prepared by methods known in heart, e.g., by reacting a
monoclonal antibody prepared as described above with, for
instance, an enzymein the presence of a coupling agent such
as glutaraldehyde or periodate. Conjugates with fluorescein
markers are prepared in the presence of these coupling
agents, or by reaction with an isothiocyanate. Conjugates
with metal chelates are similarly produced. Other moieties
to which antibodies may be conjugated include radionu-
clides such as 7H, 17°1, *41°°P, #8, *4C, >4Cr, 3°C1, °7Co,
58Co, °°Fe, Se, ?Eu, and °°mTe, are other useful labels
which can be conjugated to antibodies. Radioactively
labeled monoclonal antibodies of the present invention are
produced according to well-known methods in the art. For
instance, monoclonal antibodies can be iodinated by contact
with sodium or potasstum iodide and a chemical oxidizing
agent such as sodium hypochlorite, or an enzymatic oxidiz-
ing agent, such as lactoperoxidase. Monoclonal antibodies
according to the invention may be labeled with technetium-
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°°m by ligand exchange process, for example, by reducing
pertechnate with stannous solution, chelating the reduced
technetium onto a Sephadex column and applying the anti-
body to this columnorby direct labeling techniques,e.g., by
incubating pertechnate, a reducing agent such as SNCI,, a
buffer solution such as sodium-potassium phthalate solution,
and the antibody.
G. Diagnostic Applications
The present invention provides for the diagnosis of can-
cers by virtue of determining the presence of particular
forms of GST-a. This can be done by examiningthe cellular
phenotype at the nucleic acid level orat the protein level. At
the nucleic acid level, several different formats are contem-
plated. First, one may perform arestriction fragment analy-
sis of the gene of interest. This may be accomplished by
isolating the gene and performing a restriction digest
thereof. Alternatively, this can be accomplished by digesting
genomic DNA and probing the cleaved DNA with an
appropriate labeled probe. In either case, the probing
experiments, called Southern blots, rely on the ability of a
labeled nucleic acid, complementary to the target sequence,
to hybridize thereto. Based on differences in restriction
patterns, different sized nucleic acids will be produced.
Generally, size fractionation is performed by
electrophoresis, prior to probing. The nucleic acids are
transferred or “blotted” on to a suitable support (e.g.
nitrocellulose), which is then probed with the labeled
nucleic acid.
Second, one may perform a nucleic acid sequence analy-
sis. Again, one mayfirst clone the gene of interest but, more
typically, one will sequence the genomic DNA prior to
cloning, often employing a PCR approach with labeled
primers. The primers are located upstream of the sequence
of interest and are extended by a polymerase, e.g., Seque-
nase™, Using a series of naturation-denaturation steps,
amplification of templates is achieved. Use of dideoxy
nucleotides permits implementation of the Sanger dideoxy-
chain termination sequencing protocol.
Atthe protein level, the examination will performed from
an immunologic standpoint, employing GST--specific anti-
bodies as described above. Thus, it is proposed that the
monoclonal antibodies of the present invention will find
useful diagnostic application in standard immunochemical
procedures, such as ELISA and western blot methods, as
well as other procedures which may utilize antibodies spe-
cific to GST-z epitopes. While ELISAs are preferred forms
of immunoassays, it will be readily appreciated that assays
also include RIAs and other non-enzyme linked antibody
binding assays or procedures. Additionally, it is proposed
that monoclonal antibodies specific to the particular GST-1
epitope may be utilized in other useful applications. For
example, their use in immunoabsorbent protocols may be
useful in purifying native or recombinant GST-z species or
variants thereof.
It also is proposed that the disclosed GST-x peptides and
polypeptides will find use as antigens for raising antibodies
and in immunoassays for the detection of anti-GST-2
antigen-reactive antibodies and GST-z antigens
(competitive assays). Alternatively, immunoassays may be
exploited to determine the structural-antigenic relationship
between certain GST-a mutant peptides. Such screening
assays may involve (i) the generation of antisera or anti-
bodies against peptides or (ii) the testing of mutant peptide
reactivity with a battery of immunoreagents developed
against GST-z antigens. In this way, a mutational analysis of
various epitopes may be performed.
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Immunoassays encompassed by the present invention
include, but are not limited to those described in U.S. Pat.
No. 4,367,110 (double monoclonal antibody sandwich
assay) and U.S. Pat. No. 4,452,901 (western blot). Other
assays include immunoprecipitation of labeled ligands and
immunocytochemistry, both in vitro and in vivo.
Immunoassays, in their most simple and direct sense, are
binding assays. Certain preferred immunoassays are the
various types of enzyme linked immunosorbent assays
(ELISAs) and radioimmunoassays (RIAs) knownin theart.
Immunohistochemical detection using tissue sections is also
particularly useful. However, it will be readily appreciated
that detection is not limited to such techniques, and western
blotting, dot blotting, FACS analyses, and the like may also
be used.
In one exemplary ELISA, the anti-GST- antibodies of
the invention are immobilized onto a selected surface exhib-
iting protein affinity, such as a well in a polystyrene micro-
titer plate. Then, a test composition suspected of containing
the desired antigen, such as a clinical sample, is added to the
wells. After binding and washing to remove non-specifically
bound immune complexes, the bound antigen may be
detected. Detection is generally achieved by the addition of
another antibody, specific for the desired antigen, that is
linked to a detectable label. This type of ELISA is a simple
“sandwich ELISA.” Detection also may be achieved by the
addition of a second antibody specific for the desired
antigen, followed by the addition of a third antibody that has
binding affinity for the second antibody, with the third
antibody being linked to a detectable label.
In another exemplary ELISA, the samples are immobi-
lized onto the well surface and then contacted with the
anti-GST-z antibodies. After binding and appropriate
washing, the bound immune complexesare detected. Where
the initial antigen specific antibodies are linked to a detect-
able label, the immune complexes maybe detected directly.
Again, the immune complexes may be detected using a
second antibody that has binding affinity for the first antigen
specific antibody, with the second antibody being linked to
a detectable label.
Competition ELISAs are also possible in which test
samples compete for binding with known amounts of
labeled antigens or antibodies. The amount of reactive
species in the unknown sample is determined by mixing the
sample with the known labeled species before or during
incubation with coated wells. Peptide antigen or antibodies
may also be linkedto a solid support, such as in the form of
beads, dipstick, membrane or column matrix, and the sample
to be analyzed applied to the immobilized peptide or anti-
body. The presence of reactive species in the sample acts to
reduce the amountof labeled species available for binding to
the well, and thus reduces the ultimate signal.
Irrespective of the format employed, ELISAs havecertain
features in common,such as coating, incubating or binding,
washing to remove non-specifically bound species, and
detecting the bound immune complexes. These are
described below.
In coating a plate with either antigen or antibody, one will
generally incubate the wells of the plate with a solution of
the antigen or antibody, either overnight or for a specified
period. The wells of the plate will then be washed to remove
incompletely adsorbed material. Any remaining available
surfaces of the wells are then “coated” with a nonspecific
protein that is antigenically neutral with regard to the test
antisera. These include bovine serum albumin (BSA), casein
and solutions of milk powder. The coating allows for block-
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ing of nonspecific adsorption sites on the immobilizing
surface and thus reduces the background caused by nonspe-
cific binding of antisera onto the surface.
After binding of material to the well, coating with a
non-reactive material to reduce background, and washing to
remove unbound material, the immobilizing surface is con-
tacted with the antisera or clinical or biological extract to be
tested in a manner conducive to immune complex (antigen/
antibody) formation. Such conditions preferably include
diluting the antisera with diluents such as BSA, bovine
gamma globulin (BGG) and phosphate buffered saline
(PBS)/Tween. These added agents also tend to assist in the
reduction of nonspecific background. The layered antisera is
then allowed to incubate for from 2 to 4 hours, at tempera-
tures preferably on the order of 25° to 27° C. Following
incubation, the antisera-contacted surface is washed so as to
remove non-immunocomplexed material. A preferred wash-
ing procedure includes washing with a solution such as
PBS/Tween,or borate buffer.
Following formation of specific immunocomplexes
between the test sample and the bound antigen or antibody,
followed by subsequent washing, the occurrence and even
amount of immunocomplex formation may be determined
by subjecting same to a second antibody having specificity
for the first or for a distinct epitope of the bound antigen. Of
course, in a test sample suspected of containing antibodies
of humanorigin, the second antibody will preferably be an
antibody having specificity in general for human IgG. To
provide a detecting means, the detecting antibody will
preferably have an associated enzyme that will generate a
color development upon incubating with an appropriate
chromogenic substrate. Thus, for example, one will desire to
contact and incubate the antisera-bound surface with a
urease or peroxidase-conjugated anti-human IgG for a
period of time and under conditions which favor the devel-
opment of immunocomplex formation (e.g., incubation for 2
hours at room temperature in a PBS-containing solution
such as PBS-Tween).
After incubation with the enzyme-tagged antibody, and
subsequent to washing to remove unbound material, the
amount of label is quantified by incubation with a chro-
mogenic substrate such as urea and bromocresol purple or
2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid
[ABTS] and H,0,, in the case of peroxidase as the enzyme
label. Quantification is then achieved by measuring the
degree of color generation, e.g., using a visible spectra
spectrophotometer. Alternatively, the label may be a chemi-
luminescent one. The use of such labels is described in US.
Pat. Nos. 5,310,687, 5,238,808 and 5,221,605.
In competitive formats, one may use labeled or unlabeled
peptide as a competitor for the antigen in a sample.
Alternatively, competing antibodies will require that the
binding of two different antibodies be distinguishable. This
can be accomplished by labeling species and not the other,
or by labeling both species with differential labels (e.g.,
rhodamine and fluorescein).
H. Small Molecule Inhibitors of GST-m Variant
Proteins
The present invention provides methodsfor screening and
identifying small molecule inhibitors of GST-a proteins and
identifies such inhibitors (see Tables 14-17). The rationale
behind the design of the small molecule GST-a protein
inhibitors is that the structural differences between GST-1
proteins, caused by the deviations in the interatomic dis-
tances of the amino acid residues in the active site of the
10
15
20
30
35
40
45
50
55
60
65
36
protein, will be exploited to design chemical ligands that
bindto the active site of the different variantproteins to yield
complexes with sufficient thermodynamic stability to effec-
tively inhibit the functional activity of the protein. The
inhibited GST-z protein is thus unable to protect the tumor
cell against the toxic action of the anticancer agent used to
treat it. To obtain appropriate ligands that bind to the active
sites of different GST-z variant proteins, the inventors utilize
the technique of forcefield docking of chemical fragments
from both commercially available chemical fragment
libraries, as well as in-house generated libraries, into the
active electrophile-binding (H-) site in the derived crystal
structure of each variant protein. The docked fragments will
be energy-minized and the binding energies computed and
used to select candidate ligands.
Generation of GST-x inhibitors. Generation of inhibitors
is accomplished by a rational drug development strategy
involving force field docking and energy-minimization of
chemical fragments and compoundsinto the active site of
the variant GST-a proteins. The compounds and chemical
fragments can be drawn from chemical fragment libraries,
such as that available in the Leapfrog database. Additional
chemicallibraries will be generated as necessary. The active
site and other structural components of the variant GST-7
proteins will be derived from the published crystal structure
of the GSTP1*A encoded protein. The protein encoded by
GSTP1*Bare obtained by substituting valine for isoleucine
at amino acid 104; the protein encoded by GSTP1*C by
substituting valine for isoleucine at amino acid 104, and
valine for alanine at amino acid 113. Based on the resultant
AAHvalues obtained after energy minimization of chemical
fragments/compounds,candidate inhibitors are selected and/
or newly constructed from chemical fragments for synthesis
and further analyses for their inhibitory or other action on
the variant GST-a proteins. Selection criteria for inhibitors
for synthesis and further analysis includes lipophilicity,
chemical stability and availability or ease of synthesis.
Candidate inhibitors of the present invention include such
molecules as substituted isoxazole for example the mol-
ecules shownin Table 14; heterocyclic aromatic compounds,
(Table 15); sugar-linked aromatic compounds(Table 16) and
other aromatic compounds (Table 17). The substituted isox-
azole compounds may have a generic structure such as that
given below:
oO
Ry Rgay 4 xif \,N.Ni R RsO 4
General Structure (Substituted Isoxazoles)
The substituted groups may vary between the different
compounds and result in significant changes in binding
energies of the compounds in the active site pocket of the
GST-a protein. For example, R, substitutions of either NH,
or OH, cause changes in binding energies of almost 10
kcals/mol. Other important substitutions are the alkyl or
aminoalkyl substitutions of R,, and the alkyl, phenyl or
2-pyridyl substitutions of R,, some of which result in
changes in binding energies of greater than 10 kcals/mol.
Howeverit is conceivable that any of the R groups of the
substituted isoxazoles may be a phenyl group, a benzyl
group, an aryl group, an alkyl group, an aryl group linked to
another aryl group through an ester linkage, an aryl group
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linked to an alkyl group with an ester linkage, an aryl group
linked to another aryl group through an ether linkage and
aryl group linked to an alkyl group with a thiolester linkage,
an alkyl group linked to another alkyl group through an ester
linkage, an alkyl group linkedto another alkyl group through
an ether linkage, an alkyl to alkyl linked through an amino
group, an aryl to alkyl linked through an amino group. an
alkyl alkyl group through a disulphide group, an aryl linked
to an alkyl group through a disulphide group, an aryl linked
to another aryl group through a disulphide group, an alkyl
linked to another alkyl group througha thioester linkage, an
aryl linked to an alkyl group through a polyester linkage, an
aryl group linked to anotheraryl through a polyester linkage,
an alkyl group linked to another alkyl group through a
polyamine linkage, an aryl linked to an alkyl group through
a polyamine linkage, an aryl group linked to another aryl
through a polyamine linkage, an alkyl group linked to
another alkyl group through a polythioester linkage, an aryl
linked to an alkyl group through a polythioester linkage, an
aryl group linked to another aryl through a polythioester
linkage.
An individual skilled in the art of organic synthesis in
light of the present disclosure is able to prepare or identify
a large variety of substituted isoxazoles which would be
expected to have GST-z inhibitory effects in the light of the
present disclosure and may be used in the for inhibiting
tumors and/or other diseases GST-a proteins play a promi-
nentrole.
Screening for modulators of GST-m. Within certain
embodiments of the invention, methods are provided for
screening for modulators of GST-a protein activity. Such
methods may use labeled GST-z proteins or analogs, anti-
GST- proteins or anti-GST-a antibodies and the like as
reagents to screen small molecule and peptide libraries to
identify modulators of GST-a protein activity. Within one
example, a modulator screening assay is performed in which
cells expressing GST-z proteins are exposed to a test sub-
stance under suitable conditions and for a time sufficient to
permit the agent to effect activity of GST-m proteins. The
GST-a activity is then detected by incubating the reaction
mixture with a GST-z protein-specific antibody, which anti-
body may be labeled directly or may be detected
secondarily, e.g. using a labeled idiotypic or species specific
antibody) under conditions that permit the formation of
immune complexes between GST-z protein and its specific
antibody. The test reaction is compared to a control reaction
which lacks the test sample. To complete the modulator
screening assay, the presence and/or amount of complexes
formed between GST-z protein and the anti-GST-z antibody
is detected in the test sample (e.g. by determining the
presence or amount of label bound directly to the antibody
or to a secondary antibody directed against the primary
antibody). Within this exemplary assay, agents that inhibit
activity of GST-z protein will demonstrate a reduced bind-
ing with GST-a protein-specific antibodies relative to the
control sample and agents that induce activity of GST-7
protein will demonstrate an increased binding with GST-2
protein specific antibodies relative to the control sample.
Generally the test substance is added in the form of a
purified agent, however it is also contemplated that test
substances useful within the invention may include sub-
stances present throughout the handling of test sample
components, for example host cell factors that are present in
a cell lysate used for generating the test sample. Such
endogenous factors may be segregated between the test and
control samples for example by using different cell types for
preparing lysates, where the cell type used for preparing the
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test sample expresses a putative test substance that is not
expressed by the cell type used in preparing the control
sample.
Useful compounds in this regard will not be limited to
those mentioned in Tables 14-17. The active compounds
may include fragments or parts of naturally-occurring com-
pounds or may be only found as active combinations of
known compounds whichare otherwise inactive. However,
prior to testing of such compounds in humans or animal
models, it may be necessary to test a variety of candidates
to determine which have potential.
Accordingly, in screening assays to identify agents which
alter the activity of GST-x proteins in for example cancer
cells, it is proposed that compoundsisolated from natural
sources, such as animals, bacteria, fungi, plant sources,
including leaves and bark, and marine samples may be
assayed as candidates for the presence of potentially useful
pharmaceutical agents. It will be understood that the phar-
maceutical agents to be screened could also be derived or
synthesized from chemical compositions or man-made com-
pounds.
In these embodiments, the present invention is directed to
a method for determining the ability of a candidate sub-
stance to decrease the GST-a activity of cancer cells, the
method including generally the steps of:
(a) obtaining a cell with GST-z activity;
(b) admixing a candidate substance with the cell; and
(c) determining the ability of the candidate substance to
inhibit the GST-x activity of the cell.
To identify a candidate substance as being capable of
decreasing GST-z activity, one would measure or determine
the basal GST-z status of for example a cancercell prior to
any additions or manipulation. One would then add the
candidate substance to the cell and redetermine the GST-1
activity in the presence of the candidate substance. A can-
didate substance which decreases the GST-z activity relative
to the composition in its absenceis indicative of a candidate
substance being an inhibitor of GST-a
The candidate screening assay is quite simple to set up
and perform, and is related in many ways to the assay
discussed above for determining GST-a content.
“Fffective amounts”, in certain circumstances, are those
amounts effective at reproducibly decrease GST-a activity in
an assay in comparison to their normal levels. Compounds
that achieve significant appropriate changesin activity will
be used. If desired, a battery of compounds maybe screened
in vitro to identify other agents for use in the present
invention.
A significant decreases in GST-m activity, are represented
by a decrease in GST-z protein activity levels of at least
about 30%—40%, and most preferably, by decreases of at
least about 50%, with higher values of course being pos-
sible. Assays that measure GST-z activity in cells are well
knownin the art and may be conducted in vitro or in vivo,
and have been described elsewhere in the specification.
Alternatively, it may be desirable simply to measure
inhibition of growth of cancer cells, for example, by mea-
suring growth according to the MTT assay. A significant
inhibition in growth is represented by decreasesof at least
about 30%—40% as compared to uninhibited, and most
preferably, of at least about 50%, with more significant
decreases also being possible. Growth assays as measured
by the MTT assay are well knownin the art. Assays may be
conducted as described by Mosmannet al., 1983; Rubinstein
et al., 1990 (incorporated herein by reference). Therefore, if
a candidate substance exhibited inhibition of growth of
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cancercells in this type of study, it would likely be a suitable
compound for use in the present invention.
Quantitative in vitro testing of the GST-x inhibitors is not
a requirement of the invention as it is generally envisioned
that the agents will often be selected on the basis of their
known properties or by structural and/or functional com-
parison to those agents already demonstrated to be effective.
Therefore, the effective amounts will often be those amounts
proposedto be safe for administration to animals in another
context.
I. Therapeutic Methods
In the practice of the invention described in this
application, several aspects are unique. For therapy, the
invention will be used to modulate the response of the tumor
to subsequent therapy. This approach will be to administer
the small molecule inhibitor and/or antisense oligonucle-
otide or ribozyme, based on the GST-x variant present in the
tumor and/or patient’s cells. This treatment will reduce the
tumors’ ability to block the toxic action of any subsequent
therapy. The initial treatment with the AS-ON or ribozyme
will be followed some time later with the anticancer agent.
Anticancer agents will include but not be limited to alky-
lating agents and cisplatin and other platinum analogs.
Tumors against which this modulation will be used will
include those tumors that have been shownto be associated
with altered GST-z levels, including melanoma, leukemias
and lymphomas, melanoma,as well as tumorsof the brain,
head and neck, stomach,liver, lung, ovary, breast, colon and
bladder. Additionally in those tumors with elevated GST-a,
the small molecule inhibitor and/or antisense oligonucle-
otide or ribozymes will be given with the goal of decreasing
the malignant phenotype, reducing or inhibiting the growth,
or killing the tumors. It is expected that the latter will
involve longer term administration of these agents alone or
in combination with other therapeutic agents.
A wide variety of chemotherapeutic agents may be used
in combination with the therapeutic genes of the present
invention. These can be, for example, agents that directly
cross-link DNA, agents that intercalate into DNA, and
agents that lead to chromosomal and mitotic aberrations by
affecting nucleic acid synthesis.
Agents that directly cross-link nucleic acids, specifically
DNA,are envisaged and are shown herein, to eventuate
DNA damage leading to a synergistic antineoplastic com-
bination. Agents such as cisplatin, and other DNAalkylating
agents may be used.
Agents that damage DNAalso include compoundsthat
interfere with DNAreplication, mitosis, and chromosomal
segregation. Examples of these compounds include adria-
mycin (also known as doxorubicin), VP-16 (also known as
etoposide), verapamil, podophyllotoxin, and the like.
Widely used in clinical setting for the treatment of neo-
plasms these compounds are administered through bolus
injectionsintravenously at doses ranging from 25-75 mg/m*
at 21 day intervals for adriamycin, to 35-100 mg/m* for
etoposide intravenously ororally.
It is contemplated that antibiotics such as Doxorubicin,
Daunorubicin Mitomycin Actinomycin D Bleomycin Plant
Alkaloids such as Taxol, Vincristine Vinblastine, Alkylating
Agents such as Carmustine, Melphalan , Chlorambucil,
Busulfan, Lomustine and miscellaneous agents such as
Cisplatin, VP16 (etoposide), and Tumor Necrosis Factorwill
be useful in conjunction with the present invention. These
are examples of some routinely used chemotherapeutic
agents, these are only exemplary agents andthelist is by no
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means exhaustive and the skilled artisan is referred to
“Remington’s Pharmaceutical Sciences” 15th Edition, chap-
ter 61 regarding further information about these and other
chemotherapeutic agents. The person responsible for admin-
istration of chemotherapeutic agent will, determine the
appropriate doses for the individual subject.
In certain aspects the present invention provides antisense
and other genetic constructs for delivery into tumorcells.
The compositions of the present invention may thus be
applied advantageously in the treatmentof a cancer cell. The
compositions may comprise a liposome in which apoly-
nucleotide is encapsulated. Such a composition may advan-
tageously be delivered to a subject in a volumeof 0.50-10.0
ml per dose. It is envisioned that the dose of gene construct
may be delivered in an amount of between about 5 to about
30 mg polynucleotide per m?. Alternatively the dose may be
between about 6 and 25 mg polynucleotide per m*, between
about 7 and about 20 mg polynucleotide per m*, between
about 10 to about 15 mg polynucleotide per m?.
J. Pharmaceutical Compositions and Routes of
Administration
The present invention provides pharmaceutical composi-
tions for the generation of antibodies against GST-a and the
prevention or treatment of cancers in which a GST-z is
involved. Administration of antigens and generation of
antibodies is discussed above. Administration of nucleic
acids, including expression constructs, to cells in vivo may
be adapted from currently available information. Those of
skill in the art are well-versed in the treatment of tumors
generally and, given the information provided here, the
present invention may be exploited using various specific
pharmaceuticals, doses and routes of administration for
therapies.
Aqueous compositions of the present invention will have
an effective amountof an antigen or therapeutic agent. Such
compositions will generally be dissolved or dispersed in a
pharmaceutically acceptable carrier or aqueous medium.
The phrases “pharmaceutically or pharmacologically
acceptable” refer to molecular entities and compositions that
do not produce an adverse, allergic or other untoward
reaction when administered to an animal, or human, as
appropriate. As used herein, “pharmaceutically acceptable
carrier” includes any and all solvents, dispersion media,
coatings, antibacterial and antifungal agents, isotonic and
absorption delaying agents and the like. The use of such
media and agents for pharmaceutical active substances is
well known in the art. Except insofar as any conventional
media or agent is incompatible with the active ingredients,
its use in the therapeutic compositions is contemplated.
Supplementary active ingredients, such as analgesics and
anti-inflammatory agents, can also be incorporated into the
compositions.
In addition to the compounds formulated for parenteral
administration, such as those for intravenous or intramus-
cular injection, other pharmaceutically acceptable forms
include, e.g., tablets or other solids for oral administration;
time release capsules; and any other form currently used,
including cremes, lotions, mouthwashes, inhalants and the
like.
The active compoundsof the present invention may be
formulated for parenteral administration, e.g., formulated
for injection via the intravenous, intramuscular, sub-
cutaneous, or even intraperitoneal routes. The preparation of
an aqueous composition that contains active compounds of
the present invention ingredients will be knownto those of
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skill in the art in light of the present disclosure. Typically,
such compositions can be prepared as injectables, either as
liquid solutions or suspensions; solid forms suitable for
using to prepare solutions or suspensions upon the addition
of a liquid prior to injection can also be prepared; and the
preparations can also be emulsified.
Solutions of the active compounds as free base or phar-
macologically acceptable salts can be prepared in water
suitably mixed with a surfactant, such as hydroxypropylcel-
lulose. Dispersions can also be prepared in glycerol, liquid
polyethylene glycols, and mixtures thereof and in oils.
Under ordinary conditions of storage and use, these prepa-
rations contain a preservative to prevent the growth of
microorganisms. Direct intratumoral injection or continuous
perfusion of the resected tumor bed is a method of admin-
istration envisioned by the present invention.
The pharmaceutical forms suitable for injectable use
include sterile aqueous solutions or dispersions; formula-
tions including sesameoil, peanut oil or aqueous propylene
glycol; and sterile powders for the extemporaneous prepa-
ration of sterile injectable solutions or dispersions. In all
cases the form must besterile and mustbefluid to the extent
that easy syringability exists. It must be stable under the
conditions of manufacture and storage and must be pre-
served against the contaminating action of microorganisms,
such as bacteria and fungi.
The active compounds may be formulated into a compo-
sition in a neutral or salt form. Pharmaceutically acceptable
salts, include the acid addition salts (formed with the free
amino groups of the protein) and which are formed with
inorganic acids such as, for example, hydrochloric or phos-
phoric acids, or such organic acids as acetic, oxalic, tartaric,
mandelic, and the like. Salts formed with the free carboxyl
groups can also be derived from inorganic bases such as, for
example, sodium, potassium, ammonium, calcium,or ferric
hydroxides, and such organic bases as isopropylamine,
trimethylamine, histidine, procaine and the like.
The carrier can also be a solvent or dispersion medium
containing, for example, water, ethanol, polyol (for example,
glycerol, propylene glycol, and liquid polyethylene glycol,
and the like), suitable mixtures thereof, and vegetable oils.
The proper fluidity can be maintained, for example, by the
use of a coating, such as lecithin, by the maintenance of the
required particle size in the case of dispersion and by the use
of surfactants. The prevention of the action of microorgan-
isms can be brought about by various antibacterial and
antifungal agents, for example, parabens, chlorobutanol,
phenol, sorbic acid, thimerosal, and the like. In many cases,
it will be preferable to include isotonic agents, for example,
sugars or sodium chloride. Prolonged absorption of the
injectable compositions can be brought about by the use in
the compositions of agents delaying absorption, for
example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating
the active compoundsin the required amountin the appro-
priate solvent with various of the other ingredients enumer-
ated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium and the
required other ingredients from those enumerated above.In
the case of sterile powders for the preparation of sterile
injectable solutions, the preferred methods of preparation
are vacuum-drying and freeze-drying techniques which
yield a powderof the active ingredient plus any additional
desired ingredient from a previously sterile-filtered solution
thereof.
10
15
20
25
30
35
40
45
50
55
60
65
42
In certain cases, the therapeutic formulations of the inven-
tion could also be prepared in forms suitable for topical
administration, such as in cremes and lotions. These forms
may be used for treating skin-associated diseases, such as
various sarcomas.
Upon formulation, solutions will be administered in a
manner compatible with the dosage formulation and in such
amountas is therapeutically effective. The formulations are
easily administered in a variety of dosage forms, such as the
type of injectable solutions described above, with even drug
release capsules and the like being employable.
For parenteral administration in an aqueoussolution, for
example, the solution should be suitably buffered if neces-
sary and the liquid diluent first rendered isotonic with
sufficient saline or glucose. These particular aqueous solu-
tions are especially suitable for intravenous, intramuscular,
subcutaneous and intraperitoneal administration. In this
connection, sterile aqueous media which can be employed
will be known to those of skill in the art in light of the
present disclosure. For example, one dosage could be dis-
solved in 1 mL of isotonic NaCl solution and either added
to 1000 mL of hypodermoclysis fluid or injected at the
proposed site of infusion, (see for example, “Remington’s
Pharmaceutical Sciences” 15th Edition, pages 1035-1038
and 1570-1580). Some variation in dosage will necessarily
occur depending on the condition of the subject being
treated. The person responsible for administration will, in
any event, determine the appropriate dose for the individual
subject.
K.Kits
All the essential materials and reagents required for
practice of various embodiments of the present invention
may be assembled together in a kit. When the components
of the kit are provided in one or more liquid solutions, the
liquid solution preferably is an aqueous solution, with a
sterile aqueous solution being particularly preferred.
For in vivo use, an antigen or therapeutic agent, the
reagents may be formulated into a single or separate phar-
maceutically acceptable syringeable composition. In this
case, the container means mayitself be an inhalant, syringe,
pipette, eye dropper, or other such like apparatus, from
which the formulation may be applied to an infected area of
the body, injected into an animal, or even applied to and
mixed with the other components of the kit.
The components of these kits may also be provided in
dried or lyophilized forms. When reagents or components
are provided as a dried form, reconstitution generally is by
the addition of a suitable solvent. It is envisioned that the
solvent also may be provided in another container means.
The kits of the invention may also include an instruction
sheet defining administration of the active compound, or
explaining the assays for determining sebum formation in
samples.
The kits of the present invention also will typically
include a means for containing the vials in close confine-
ment for commercial sale such as, e.g., injection or blow-
molded plastic containers into which the desired vials are
retained. Irrespective of the number or type of containers,
the kits of the invention also may comprise, or be packaged
with, an instrument for assisting with the injection/
administration or placement of the ultimate complex com-
position within the body of an animal. Such an instrument
may be an inhalant, syringe, pipette, forceps, measured
spoon, eye dropperor any such medically approved delivery
vehicle. Other instrumentation includes devices that permit
the reading or monitoring of reactions in vitro.
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L. Examples
The following examples are included to demonstrate
preferred embodiments of the invention. It should be appre-
ciated by those of skill in the art that the techniques
disclosed in the examples that follow represent techniques
discovered by the inventors to function well in the practice
of the invention, and thus can be considered to constitute
preferred modesfor its practice. However, those of skill in
the art should, in light of the present disclosure, appreciate
that many changes can be madein the specific embodiments
that are disclosed and still obtain a like or similar result
without departing from the spirit and scope of the invention.
Example 1
Cloning and Characterization of Three Human GST Genes
1. Materials and Methods
Materials. Restriction endonucleases, Klenow enzyme
and T4 DNA ligase were purchased from Boehringer
Maniihein, Indianapolis, Ind. Proteinase K, RNAse A, and
all-trans retinoic acid (RA) were purchased from Sigma
Chemical Co., St. Louis, Mo. SuperCos I cosmid vector,
Bluescript phagemid 11, Gigapack 11 packaging System,
calf intestinal alkaline phosphatase (CIAP), pBK-CMV
expression vector, and the MSB mammalian transfection kit
were purchased from Strategene, La Jolla, Calif. [>°S]dATP
and [(a-*?P]dCTP were purchased from Amersham,Arling-
ton Heights,Ill. Taq DNA polymerase was purchased from
Perkin Elmer Cetus, Norwalk, Conn. Dulbecco’s modified
Eagle’s medium (DMEM)andfetal calf serum (FCS) were
purchased from Life Technology, Gaithersberg, Md. T7
DNA Sequenase 2.0 Dideoxy DNA Sequencing Kit was
purchased from US Biochemicals, Cleveland, Ohio.
Tumor Cells. The MGR-3 human glioblastoma multi-
forme cell line was established in the laboratory of the
inventors from a primary specimen,as previously described
(Ali-Osman, 1996). It is glial fibrillary acidic protein posi-
tive by immunocytochemistry, and the cells show the typical
pleomorphic features of neoplastic glial cells. It is routinely
maintained in DMEM supplemented with 10% FCS, non-
essential amino acids, and had undergone 11 in vitro pas-
sages prior to being used in these studies.
Southern and Northern blotting. These were performed
using standard techniques (Sambrooket al., 1989). For the
Southern analysis, genomic DNA was extracted from
MGR-3 cells using the phenol/chloroform procedure, and
for the Northern blots, total RNA wasisolated with the acid
guanidinium thiocyanate/phenol/chloroform method
(Chomeznski and Saachi, 1987).
PCR. Where indicated, PCR was performed in a DNA
thermocycler (Perkin-Elmer, Norwalk, Conn.). The 100 wl
reaction mixture contained 50 ng SuperCos-GSTpior other
DNAtemplate, 500 ng each of forward and reverse primers,
10xPCR buffer, 100 nM each of dATP, dCTP, dGTP and
dTTP, 2.5 units Amplitagq polymerase overlaid with mineral
oil. After 1 cycle of denaturing (95° C. for 90 secs),
annealing (55° C. for 2 mins), and chain extension (72° C.
for min), 35 cycles of 95° C. (1 min), 55° C. (2 min), and 72°
C. (3 min) were performed.
Construction of cosmid genomic DNAlibrary, screening
and mapping. High molecular weight genomic DNA from
MGR-3cells was partially digested with Sau3A I and the
fragments were ligated into SuperCos I cosmid vector that
had been digested with BamH I and XbaI and dephospho-
rylated with calf intestinal alkaline phosphatase (CIAP). The
constructs were packaged into bacteriophage lambda par-
ticles using the Gigapack 11 packaging system, and the
resulting phage was used to infect the bacterial host strain
10
15
20
25
30
35
40
45
50
55
60
65
44
XL-I Blue MR, amplified and plated onto LB/ampicillin
plates at 50,000 cfus per 150 mm plate for a total of
approximately 1x10° colonies. Colonies were pooled,
titered, and the stock was stored at —80° C. in LB broth
containing 20% glycerol. Aliquots were replated, lifted onto
positively charged nylon filters and screened by hybridiza-
tion with a [(a-*?P] labeled full-length GST- cDNAprobe,
using standard techniques (Sambrooket al., 1989). Follow-
ing secondary and tertiary screenings, one positive clone,
designated SuperCosGSTpi, was selected for further char-
acterization. Restriction mapping of SuperCos-GSTpi was
performed using standard methods and subsequently veri-
fied by computer analysis.
Subcloning of SuperCos-GSTpi. One-half ug of
SuperCos-GSTpi DNAwasdigested with Not I and HinD III
alone and in combination and electrophoresed in 1.2%
agarose. GST-a positive fragments, confirmed by Southern-
blotting, were purified from the agarose gel, ligated into Not
I and HinDIIIsites of the pBluescript 11 phagemid vector
and transfected into competent XL-I Blue cells. After
plating, GST-1-positive clones were identified by Southern
hybridization and overlapping GST-a gene fragments were
amplified by PCR from the clones, using primers derived
from published GST-a sequences (Cowell et al., 1988;
Morrowetal., 1989) and from the cosmid sequence (Table
1). The PCR products were electrophoresed in 1.2% agarose
and fragments of appropriate sizes were excised, purified,
blunt-ended with 0.05 unit/pmol DNA Klenow enzymeand
ligated into EcoRV-digested and CIAP-treated pBluescript
phagemid 11. Competent XL-I Blue cells were transfected
with the vector constructs and GST-z positive clones iden-
tified by Southern hybridization and used for sequencing.
DNA sequencing and structural analysis. Nucleotide
sequencing was performed with the *°S-dideoxynucleotide
chain termination method (Sanger et al., 1977), using T7
DNA Sequenase™, according to the manufacturer’s
protocols, with slight modifications. Each gene fragment
was sequenced twice in both directions. Sequencing primers
were designed from published GST-m gene sequences and
from the sequence of the cosmid. To ensure that sequences
obtained from PCR products did not contain PCRartifacts,
PCR and sequencing of each fragment was repeated at least
once.
Computer-assisted analysis of the nucleotide sequence
and structural organization of the isolated GST-2 gene were
performed using a commercial DNA sequence analysis
package (Macmolly Tetra, Berlin, Germany). The sequence
was compared with those of the previously described GST-z
genes from the MCF-7 and the HPB-ALL cell lines
(GenBank Accession Nos. X08058 and X0894-6,
respectively). For further analysis of introns 5 and 6 of the
isolated GST-m gene, a 1 kB DNA fragment containing
intron 5 and a 450 bp fragment containing intron 6, as well
as the regions flanking these introns, were amplified using
the primerpairs listed in Table 1. Following electrophoresis
in 1.2% agarose gel, the PCR products were purified and
digested with Spe I and AvaII to determine the presence of
SpeI restriction sites in intron 5 and for AvaII sites in intron
6, both of which were predicted by the nucleotide sequence
analysis to be present in these regions of the GST-a gene.
Because of previous data indicating that the GST-w gene
could be regulated by retinoic acid (Xiaet al., 1993, 1996),
we analyzed the cloned GST-m gene for tile presence of
sequences homologous with knownretinoic acid response
element (RARE) consensus sequences (Glass et al., 1991).
GST-a vector construction and expression in COS-1cells.
The complete GST-a gene was obtained by ligating a 2.2 kB
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Not I/BamH I pBS-GST-z fragment to a0.9kB BamH I/Kpn
I pBS-GST-z fragment and subsequently ligating this into
the Not I/Kpn I site of the PBK-CMVexpression vector
(Strategene, La Jolla, Calif.), in which eukaryotic expression
is driven by the cytomegalovirus (CMV) immediate early
promoter. The resulting GST-2 expression construct, desig-
nated pGSTpi-CMV, contained the entire 3.1 kB GST-a
gene, consisting of 131 bp of 5' promoter region, 109 bp of
3'-untranslated region including the polyadenylation signal,
and 68 bp downstream of the polyadenylation signal.
pGSTpi-CMV vector was transfected into exponentially
growing COS-1 cells using the calcium phosphate method
(Sambrook et al., 1989) and, after 48 hrs, the cells were
harvested, washed twice in PBS, homogenized and centri-
fuged at 20,000xg for 20 min at 4° C. Protein concentrations
and total GST enzyme activity in the supernatants were
determined as previously described (Ali-Osmanetal., 1990;
Habig et al., 1974), the latter using 1-chloro-2,4-
dinitrobenzene as a substrate. Specific GST-z protein con-
tent was determined by Western blotting was performed, as
we previously described (Ali-Osmanet al., 1990).
DNAmobility shift assay forRA-RAR binding to RAREs
in GST-z gene. The binding of the RARE sequencesin the
GST-a gene to RA-RAR complexes was examined using a
gel mobility shift assay (Hupp et al., 1992) with nuclear
extracts from MGR-3 cells treated with 1 uM all-trans RA
for 48 hrs to induce retinoic acid receptor (RAR) expression,
and to generate RA-RAR complexes. Immunoprecipitation
with anti-RAR-B monoclonal antibodies (Santa Cruz, Santa
Cruz, Calif.) showed a significant induction of RAR-B in the
nuclear extracts of RA-treated MGR- cells used in the
RAREbinding studies. A 200 bp fragment was synthesized
by DNA-PCR(for primers, see Table 2) from the isolated
GST-a gene to cover the region in intron 5 containing the
RARE consensus half-sites. 2.5 ug of nuclear proteins
prepared from both control and RA-treated cells were incu-
bated with y°*P-dATP end-labeled RAREsin a buffer of 100
mM Tris-HCl (pH 7.4), 100 mM KCl, 5 mM MgCl, 10%
glycerol, 1 mM DDTand 2 wg poly(dI-dC). After 30 mins
at room temperature, the reaction mixture was electrophore-
sed in a 3% stacking and 10% separating non-denaturing
polyacrylamide gel, after which the gel was fixed in 10%
methanol/10% acetic acid, dried on Whatmanfilter paper
and exposed to x-ray films. Binding competition experi-
ments were performed by incubating the nuclear extracts
with a 200 molar excess of unlabeled RAREs for 30 mins
before addition of *?P-labeled RARES.
Retinoic acid effect on GST-a gene expression in tumor
cells. To further determine the functionality of the RAREsin
GST-a gene of MGR-3 cell line, we examined changes in
GST-a gene transcripts in MGR-3 cells after exposure to
RA.Forthis study, MGR-3cells in exponential growth were
treated with 1 uM all-trans RA. Anotherset cultures without
RA treatment served as controls. After 24 and 48 hrs
incubation at 37° C., total RNA was extracted and GST-1
gene transcript levels were determined by Northernblotting,
as described earlier. Alterations in GST-a protein content
was determinedin cells similarly treated with 1 #M all-trans
RA. Cultures were harvested after 0, 12, 24 and 48 hrs
post-RA exposure, cell extracts prepared from them, as
previously described, and subjected to Western blotting with
anti-GST-x antibodies.
2. Results
Construction and screening of a genomic library.
Approximately 10° colonies of the MGR-3 SuperCos I
genomic library were initially screened with the GST-a
cDNAprobe. Twenty positive colonies were subjected to
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secondary screening after which two were selected for
tertiary screening. Onepositive clone, designated SuperCos-
GSTpi containing the intact GST- gene was selected for
further analysis.
Restriction endonuclease mapping of SuperCos-GSTpi.
The results of Southern analysis of Not I and HinD III
digested SuperCos-GSTpi with a GST-2 cDNAprobe were
used to construct a simplified restriction map of the
SuperCos-GSTpi clone (FIG. 1). The map showsthe GST-z
gene to be located between two NotI sites of the SuperCos-
GSTpi clone, and to overlap two HinD III fragments. The
entire gene is contained within a 2.1 kB Not IJ-HinD III
fragment and an 11.5 kB HinD III fragment. This was
subsequently verified by computer analysis of the final DNA
sequence.
Nucleotide sequence and structural analysis. FIG. 2A
shows the subclones of SuperCos-GSTpi used to sequence
the complete GST-z gene, and FIG. 2B showsthe sequenc-
ing strategy used. The nucleotide sequence of the isolated
GST-a gene is shown as SEQ ID NO:1. The sequenced
region is 3116 bp in size and contains the entire GST-x gene,
consisting of 7 exons and 6 introns located within nucle-
otides +30 and +2762. Each of the exon-intron boundariesis
characterized by the AG and GTsplicing signals at the 5' and
3' ends, respectively. The coding region of the isolated
GST-a gene consists of 211 codons including the ATG
initiation and TGA termination codons. The 3' non-coding
region of the gene covers nucleotides +2763 to +2984 and
includes the polyadenylation signal, AATAAA,at +2818 to
+2823. The 5'-flanking region upstream ofthe first exon of
the gene, i.e., the promoter region, contains 5 regulatory
motifs, all of which have been previously reported (Cowell
et al., 1988; Morrowet al., 1989). Relative to the transcrip-
tion initiation site (Morrowet al., 1989), these were, a TATA
box located at -31 to -27, two Spl sites at -46 to -41 and
-57 to -51, and an AP1 site at -69 to -63. Embeddedin the
AP1site at -70 to -61 was an antioxidant response element
(ARE)core consensus sequence, GTGACTCAGC (SEQ ID
NO:33).
Comparison of isolated gene with previously described
GST-a gene. Table 2 summarizes the structural differences
between the GST-a gene isolated from the MGR-3cell line
and that of the previously reported GST-m gene from the
MCE-7 cell line (Morrowet al,. 1989). Twotransitions, an
A-to-G at +1404 and a C-to-T at +2294 changed codon 105
from ATC(Ile) to GTC (Val) and codon 114 from GCG (Ala)
to GTG (Val), respectively. These findings confirmed the
isolated gene to be hGSTP1*C,the full-length cDNA which
was recently isolated in the laboratory. A silent T-to-C
nucleotide transition, present at nucleotide +2684, did not
alter the amino acid, serine, encoded in the affected codon
185.
In addition to the three nucleotide transitions in exons 5,
6 and 7, several intronic differences were also observed
between the MGR-3 and the MCF-7 GST-a genes. A region
of high homology with the core sequence (CCCGCCTC)of
the insulin response element-A, IRE-A (Nasrin et al., 1990)
was observed at +45 to +52. This IRE differed from that
previously described at the same location in the GST-z gene
isolated from the MCF-7 (Morrowet al., 1989) by having a
guanine insertion at +50, thus creating a cleavage site
(CG'CG) for several restriction endonucleases, including
Acc II, Aci I, Bsp 501, Bst UI and Mvn I. Additionally,
nucleotide transitions in introns 5 and 6 created extra
endonuclease cleavage sites in the MGR-3 GST-x gene,that
are absent in the MCF-7 gene. A G-to-A transition at
nucleotides +1968 created a Spe I site, A'CTAGT,in intron
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5, which was confirmed by Spel digestion of a 1 kB PCR
product containing intron 5. Interestingly, only partial cleav-
age was observed upon Spel digestion of the same DNA
region from human lymphocytes and MCF-7 cells, indicat-
ing the existence of polymorphism of the GST-z geneatthis
position. Additionally, two transitions of A-to-G and C-to-T
at +2557 and +2559, respectively, created within intron 6,
new AvaII cleavage sites, G'GTCC,that are not present in
the MCF-7 gene. AvaII digestion of a 450 bp DNAfragment
amplified from MGR-3 cells to cover this region of intron 6
showed the expected 400 and 50 bp fragments. In contrast,
the same DNA fragment from normal human lymphocytes
and MCF-7cells yielded these two AvaII cleavage products,
and, in addition, uncleaved DNA in the case of MCF-7 and
multiple restriction fragments in the case of lymphocytes.
RAREsin isolated GST-m gene. Retinoic acid response
elements, RARES, are direct repeat regulatory motifs to
which RA-RA receptor (RAR) complexes bind and mediate
transcription of RA-responsive genes (Glasset al., 1991; de
Theet al., 1990; Duesteret al., 1991). We report, for thefirst
time, the presence of RARE sequencesin the GST-a gene.
These RARE motifs are located in intron 5 of the GST-1
gene, in a region spanning nucleotides +1521 to +1644 and
consisted of one palindromic and four direct repeats of
RAREconsensus half-sites arranged in tandem. FIG. 3
shows region of the RAREhalf-sites. Table 3 compares the
consensus RAREsin the isolated GST-a gene with known
RAREsin other selected genes.
Gel shift studies. The results of the gel shift studies to
examine RARE binding to RA-RAR are show significant
binding of RARE consensus sequences in the GST-a gene to
nuclear proteins from MGR-3 cells treated with all-trans
RA. The binding could be competed out with excess cold
RARES,thus showing them to be RARE-specific. Under the
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same conditions, no binding of serum albumin controls to
the RAREs wasobserved. Immunoprecipitation showedthat
after a 48-hr exposure to 1 uM all-trans RA, RAR-B levels
in RA-treated cells had increased by more than 3-fold,
compared to untreated controls, and that the RARE-nuclear
protein complex was immunoreactive with anti-RAR-B anti-
bodies (data not shown). Significantly less RARE binding
wasobserved with nuclear proteins from cells that had not
been treated with RA.
Effect of retinoic acid on GST-w gene expression in
MGR-3 cells. The results of these studies designed to
examine whether RA was capable of regulating the GST-7
gene in MGR-3cells are summarized in FIGS. 4A, 4B, 4C
and 4D. Northern analysis (FIG. 4C) showed a moderate but
significant increase in the level of GST-z genetranscripts
over 24 and 48 hrs, following exposure of MGR-3 cells to
1.0 uM all-trans retinoic acid, with a maximum of 3.4-fold
increase relative to control levels at 48 hr. The Western blot
analysis (FIG. 4D) show asimilar increase in GST-x protein
at 24 and 48 hrs after exposure to 1 4M all-trans-retinoic
acid. After 48 hrs, GST-x protein content of RA-treated cells
increased by 2.8-fold, relative to untreated controls.
Expression of cloned GST-m gene in COS-1 cells. The
structure of the pGSTpi-CMVexpression vector is shown in
FIG. 5. Western blot analysis for GST-z protein in control
COS-1 cells and in COS-1 cells 48hrs after transfection with
the pGSTpi-CMV showed a 2.9-fold increased GST-x pro-
tein content in the transfected COS-1 cells relative to
controls. Bulk GST enzyme activity was 51.9 and 22.0
nmol/min/mg protein in transfected and control cells,
respectively. The similar levels of increase in total GST
activity and specific GST-z content by both Western analysis
indicates that the increase in GST enzymeactivity was due,
primarily, to the overexpressed GST-a protein.
 
TABLE 1
Primers for PCR amplification of overlapping GST-a DNA
fragments from SuperCos-GST-aclone.
Amplified Region Fragment
of GST-a gene *Amplification Primers Size (bp)
Exon 2-Exon 3 P1:CGCAAGCTTCGCCACCATGCCGCCCTACACCG (SEQ ID NO:9) 430
P23: GGAGGCTTTGAGTGAGCCCTC (SEQ ID NO:10)
Exon 3-Exon 6 P1: AGATCAGGGCCAGAGCTGGAAG (SEQ ID NO:11) 1,700
P2:CTGGTTCTGGGACAGGGTCTC (SEQ ID NO:12)
Exon 7-Poly A Site P1:CTCTGGTCTAGAGGAAGCGA (SEQ ID NO:13) 440
P23: TCTTCCTCTTCTAGTTTGTGAGG (SEQ ID NO:14)
Exon 2-Exon 7 P1: TCTTTGTTCGGACCATGCCGCCC (SEQ ID NO:15) 2,700
P2 s CAGAGTCCCCCCAACCCTCACTGTTT (SEQ ID NO:16)
Intron 5 P1:CAGCCCTGGTGGACATGGTGAATGAC (SEQ ID NO:17) 1,000
P2:CTGGTTCTGGGACAGCAGCTC (SEQ ID NO:18)
Intron 6 P1: TGGCAGCTGAAGTGGACAGGATT (SEQ ID NO:19) 450
P2 : GATCAGCAGCAAGTCCAGCAG (SEQ ID NO:20)
RAREs in intron 5 P1:GTGAGCATCTGCACCAGG (SEQ ID NO:21) 123
P2 : GGCTGGTTGATGATGTCCCAGG (SEQ ID NO:22)
 
*Pl and P2 represent forward and reverse primers, respectively.
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Summary of structural differences between GST-a gene isolated
from MGR-3 glioblastoma multiforme cell line (Genbank Accession
No. U21689) and that previously reported for the MCF-7 cell line
(Genbank Accession No. X08058). Nucleotide alterations
and deletions are in bold face.
Intron/Exon Structural Change
Cell Line (Nucleotides) Sequence Modified Endonuclease Cleavage Site
MGR 3 Intron 1 CGCGTC Guanine insertion;
(+50)MCF 7 cece TC CG'CG: Acc II, Aci I, Bsp 50I, BstU I, Mvn I
MGR 3 Intron 2 Tec A-c transversion(+556)
MCF 7 TAC No known endonuclease site modification
MGR 3 Intron 5 ACTAG GA transition;(+1968)
MCF 7 ACTGG A'CTAG: Mae I, Rma I; C'TAG: Spe I
MGR 3 Intron 6 ccTGGTCC AG and CT transitions;
MCF 7 (+2557, CCTAGCCC 'CCWGG: Apy I, Asu I; CC'WGG: EcoR II
+2559)
G'GWCC: AvaI I, Bme 181
G'GW: Sin I; C'TAG: Mae I, Rma I
MGR 3 Exon 5 GTC A>G transition(+1404)
MCF 7 ATC ATC (Ile)—GTC (Val) at codon 105
MGR 3 Exon 6 GTG CT transition(+2294)
MCF 7 GCG GCC (Ala)-~GTC (Val) at codon 114
MGR 3 Exon 7 AGC Tc transition (silent polymorphism)(+2684)
MCF 7 AGT AGT (Ser)—-AGC (Ser) at codon 185
 
TABLE 3
Comparison of RARE consensus sequences in human GST-a gene with
RAREs in other genes. The RARE half-sites are in bold-face.
Spacer regions with greater than six nucleotides are designated
by_the number of nucleotides.
Gene RARE Consensus Half-Site Sequences
GST-a TGACCC CTTCTT GGGTCA 13N GGGTCA GCTCT GGGCCA 70N GGGTCA
RARGQ2 GGGTCA TTCAG AGTTCA
RARB2 GGTTCA CCGAA AGGTGA
RARy2 GGGTCA GGAGG AGGTGA
ApoAI GGGTCA AG GGTTCA
ApoCIII TGGGCA A AGGTCA
PEPCK CGGCCA A AGGTCA
oxytocin GGGTCA AGGTCA
CRBPI AGGTCA AA AAGTCA
CRBPIIT AGGTCA C AGGTCA C AGGTCA C AGTTCA
Laminin Bl AGGTCA GC TAGGTTA 14N GGGTCA
ADH3 GGGTCA TTCAG AGTTCA 11N GGGTCA
Oct-3/4 GGGCCA G AGGTCA AGGCTA
Oct-4 GGGCCA G AGGTCA 28N AGGTGA 10N AGGTGA
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Example 2
Cloning and Expression of Three Human GST cDNAs
1. Materials and Methods
Cells, tissues and reagents. PBLs wereisolated from the
peripheral blood of healthy donors using a single step
Ficol-Hypaque gradient centrifugation (Ali-Osman, 1996).
Full-term human placentas were obtained after normal vagi-
nal delivery. Primary malignant glioma specimens were
obtained incidental to surgery. All specimens were acquired
oninstitutionally approved protocols. Gliomacell lines were
established from primary specimens, as previously
described (Maureret al., 1977), and were of less than 40 in
vitro passages. Unless otherwise stated, all chemicals were
from SIGMA Chemical Co., St. Louis, Mo. Restriction
enzymes and biochemicals were from Boehringer
Mannheim,Indianapolis, Ind., and PCR reagents from Per-
kin Elmer Cetus, Norwalk, Conn. Polyclonal antibodies
against human GST-a, GST-u and GST-a were obtained
from Biotrin Inc., Dublin, Ireland.
cDNA library synthesis and screening. Polyadenylated
RNAwaspurified on oligo-dT cellulose columns from total
RNAisolated from malignant glioma cell lines, using the
standard acid guanidinium thiocyanate phenol-chloroform
method (Sambrooket al., 1989). Agt 11 cDNAlibraries were
synthesized from the poly-ARNA according to the modified
procedure of Gubler and Hoffman (1983) using the protocol
of Clontech, Palo Alto, Calif. After first and second strand
cDNAsynthesis, the cDNA pool was size-fractionated at a
500 bp cut-off to reduce the proportion of truncated GST-1
cDNAs. The double-stranded cDNAs were then blunt-ended
with T4 DNA polymerase, methylated with EcoR I methy-
lase and ligated to EcoR I linkers. Following EcoR I
digestion to remove excesslinkers, the cDNAs were ligated
into bacteriophage Agt 11 EcoR1 arms and packaged using
the Gigapack 11 Gold packaging extract (Stratagene, La
Jolla, Calif.). Serial dilutions of the resulting cDNAlibraries
were screened using a rapid PCR screening procedure
(Takumi and Lodish, 1994), which the inventors had previ-
ously modified (Ali-Osman and Akande, 1995) by the use of
the Expand™ PCR system (Boehringer Mannheim). Posi-
tive cDNA pools were plated on £. coli strain Y109
Or-screened with a **P-labeled GST-2 cDNA probe and
GST-a positive clones amplified, the DNAisolated, purified
and sequenced.
DNAsequencing. Nucleotide sequencing was performed
with the [°°S]-dideoxynucleotide chain termination method
(Sanger et al., 1977) using the circumvent thermal cycle
sequencing protocol (New England Biolabs, Mass.), either
directly or, after subcloning into Bluescript phagemid II.
Sequencing primers were designed to overlap internal
GST-a cDNAregions, as well as, to the vector. Each clone
was sequenced twice in both directions.
Restriction site mapping. Computer-assisted analysis
(Macmolley Tetra, Berlin, Germany) was used to generate
restriction endonuclease mapsof the variant GST- cDNAs,
and to identify REs, which had gained orlost restriction
motifs as a consequenceof the nucleotide transitions. Two of
these REs, Mae II and Xcm I, with relatively few restriction
sites in the GST-2 cDNA,wereselected for restriction site
mapping. A 484 bp cDNA fragment, spanning positions
+112 to +596 of the GST-t cDNA, was amplified by
RI-PCR from each specimen, using the primers:
5'-ACGTGGCAGGAGGGCTCACTC-3' (forward SEQ
ID NO:23) and
5'-TACTCAGGGGAGGCCAGCAA-3' (reverse SEQ ID
NO:24)
For RT-PCR,total RNA wasisolated from cells or tissues
as described earlier. First strand cDNA synthesis was per-
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formed in a 20 ul reaction mixture containing 100 ng reverse
primer, 1 wg total RNA, 250 uM dNTPs, 3.2 mM Na
pyrophosphate, and 0.4 U/ml each of placental RNAse
inhibitor and AMVreversetranscriptase. After 2 mins at 94°
C., followed by 1 hour at 42° C., the mixture was heated to
95° C. for 2 mins and rapidly cooled to 25° C. 500 ng of
forward and reverse GST-z primers, 200 uM dNTPs, 1.5 uM
MgCL,, 0.025 U/ml ofAmplitaq polymerase and PCR buffer
(to 100 wl) were then added and PCR amplification per-
formed for 34 cycles of 94° C. (1 min), 58° C. (2 mins) and
72° C. (3 mins). The cDNA product was purified and after
restriction with Mae II and Xcm I, was electrophoresed in
2% agarose, stained with 0.5 ug/ml ethidium bromide, and
the restriction pattern photographed under ultraviolet illu-
mination. Fragment sizes were determined relative to
marker DNA(pX174 DNA-HaeIIIdigest) and the structures
were confirmed, in representative cases, by nucleotide
sequencing.
Southern hybridization of GST-a gene variants. For these
studies, 32-mer oligonucleotide probes were designed to
contain the nucleotide changes specific to each of the GST-1t
cDNAs. The probes covered the region +312 to +342 of the
GST-a cDNAand had the following sequences:
5'-CATCTCCCTCATCTACACCAACTATGAGGCG-3'
(GSTP1*A; SEQ ID NO:25),
5'-CG*TCTCCCTCATCTACACCAACTATGAGGCG-
3' (GSTP1*B; SEQ ID NO:26)
5'-CG*TCTCCCTCATCTACACCAACTATGAGGT*G-
3' (GSTP1*C; SEQ ID NO:27)
The asterisks indicate the transition nucleotides. Using T4
polynucleotide kinase, each probe was end-labeled with
y-*°P-ATP to a specific activity of approximately 4x10°
epm/ml. Southern hybridization was performed using stan-
dard methods (Chomeznski and Saachi, 1987) but with more
stringent conditions. Briefly, full length GST-1 cDNAs were
amplified from representative specimens by RNA-PCR,the
DNAproducts were purified and electrophoresed in 2%
agarose, as described earlier. After denaturation in 0.5M
NaOH and 1.5M NaCl followed by neutralization with 1M
Tris HCl (pH 7.4) containing 1.5M NaCl, the DNA was
capillary transferred in 10x SSC on to nylon membranes and
pre-hybridized at 42° C. for 2 hrs in 50% formamide, 5x
SSC, 1% SDSand 100 ug/ml denatured herring sperm DNA.
Hybridization with the **P-labeled oligonucleotide probe
was allowed to proceed overnight at 50° C., after which the
membranes were washed in 2x SSC for 30 min at room
temperature followed by 1x SSC at 60° C., and autoradio-
graphed on Kodak XAR-5 X-ray film. Following
photography, the membraneswerestripped of the hybridized
probe and reprobed with the next.
GST-a genotype analysis. To determine the concordance
between the GST-a genotype and phenotype in a given
specimen, the inventors examined the nucleotide sequences
of exons 5 and 6, which contained the nucleotide transitions
observed in the GST-1 mRNA variants. For this, nine
representative samples were selected to represent each of the
three GST-2 mRNAvariants. Using genomic DNA,a 305 bp
DNAfragment spanning nucleotides +1219 to +1524 of the
GST-a gene and containing the entire exon 5 and its flanking
regions in introns 4 and 5, as well as, a 321 bp fragment
spanning nucleotides +2136 to +2467, including all of exon
6 and its flanking regions in introns 5 and 6 were amplified
by PCR. Primers for these amplifications were designed
from the inventors’ GST-~ gene sequence data (GenBank
Accession No. U21689) and were as follows:
5'-CCAGGCTGGGGCTCACAGACAGC-3' (forward
SEQ ID NO:28) and
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5'-GGTCAGCCCAAGCCACCTGAGG-3' (reverse SEQ
ID NO:29) for exon 5;
5'-TGGCAGCTGAAGTGGACAGGATT-3' (forward
SEQ ID NO:30) and
5'-ATGGCTCACACCTGTGTCCATCT-3' (reverse SEQ
ID NO:31) for exon 6.
Prokaryotic expression of variant GST-x proteins. The full-
length cDNAs of the GST-z gene variants were amplified by
PCRfrom the respective GST-z clonesisolated from the Agt
11 libraries. To facilitate directional subcloning into the
expression vector, the forward and reverse primers were
designed to contain an EcoR Irestriction site and an Xba I
site, respectively, at their 5'-termini. Bothrestriction sites are
absent in the GST-a cDNA.After nucleotide sequencing to
ensure the absence of PCR-induced mutations, the cDNA
products were ligated into the pBK-CMV phagemid vector
(Stratagene, La Jolla, Calif.), in which prokaryotic gene
expression is driven by the lac promoter and eukaryotic
expression by the inmmediate early CMV promoter. Strain
XL1 Blue bacteria were transformed with the resulting
cDNAconstructs, screened for positive clones and bacterial
cultures of these grown overnight in LB broth. Isopropyl-
6-thiogalactopyranoside was added to 1 mM inthelast hour
of culture. The bacteria were pelletted by centrifugation,
resuspended in 50 mM Tris-HCl(pH 7.4) containing 2 ug/ml
lysozyme for 1 hr at 37° C. and ultrasonicated. The crude
homogenates were centrifuged at 30,000xg for 20 mins and
the supernatants concentrated 10-fold by membranefiltra-
tion at a 10 kD molecular weight cut-off. Protein content of
the supernatants was determined (Lowryetal., 1951) and
GST enzymeactivity was assayed, as previously described
(Ali-Osman et al., 1990), using CDNB assubstrate. SDS-
PAGE and western blotting with polyclonal antibodies
against human GST-a, -u, and -m were performed, as pre-
viously described (Ali-Osmanet al., 1990).
Purification and enzymekinetic analysis of variant GST-1
proteins. Functional consequences of the structural differ-
ences in the GST-z variant proteins was determined by the
differential ability of the recombinant GST-2 proteins to
catalyze the conjugation of GSH with 1-chloro-2,4-
dinitrobenzene (CDNB), a universal GST substrate. After
expression in FE. coli, the three GST-a proteins were purified
by GSH-affinity chromatography on S-hexyl glutathione
linked to epoxy-activated sepharose 6B, as previously
described (Simons and Van der Jagt, 1981) and then used for
enzymekinetic analysis. Reaction mixtures (25° C.) in 100
mM potassium phosphate buffer, pH 8.3 contained 0.5-2.5
mM CDNB,2.5 mM GSHand 0.015 unit of purified GST-1
protein. The change in absorbance was monitored at 340 nm
over two minutes and used to compute reaction rates. The
rates of the spontaneous reactions of GSH with CDNB,
determined with reaction mixtures in which the GST-x
enzyme wasreplaced with buffer, were subtracted from the
rates of the enzyme catalyzed reactions. The resulting reac-
tion rates were used to generate double reciprocal plots from
which Vmax and Km values were determined, using stan-
dard methodology (Segel, 1976).
Computer structural modeling of variant GST-a proteins.
To determine possible effects of the amino acid changes on
the three-dimensional architecture of the three GST-2
proteins, the X-ray crystallographic co-ordinates (2.8 A°
resolution ) of the placental GST-m (GSTP1a)
co-crystallized with S-hexyl-glutathione (Reindeer et al.,
1992) were imported from the Brookhaven Protein Data-
bank into the SYBYL molecular modeling program (Version
6.2, 1995; Tripos Associates, St. Louis, Mo.) running on a
Silicon Graphics Indigo 2 workstation (IRIX 5.2, 64 MB).
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GSTP1b wascreated by substituting Ie for Val at amino acid
residue 104, and GSTP1c was obtained by substituting Val
for Ile at amino acid residue 104 and Val for Ala at 113,
using the SYBYL BIOPOLYMER module. Each mono-
meric sub-unit of 209 amino acids was energy minimized
using the amberall-atom force field in SYBYL. The energy
minimized structures were super-imposed using the match
function of SYBYL. Changes in atomic co-ordinates and in
inter-side chain distances of amino acid residues lining the
putative electrophile-(H)-site were examined to determine
how these structural changes might predict differences in
functional activity.
Stability of variant GST-m gene transcripts. Transcrip-
tional block by actinomycin D has been shownin previous
studies to be a reliable method with which to determine
mRNAturnoverand stability in cells (Dani etal., 1984). The
inventors therefore applied this technique to investigate
differences in the intracellular stability of the transcripts of
the different GST-a genes. Three gliomacell lines, each
expressing one of the three GST-x variants, were grownto,
approximately, 70% confluency and then refed with fresh
culture medium containing 5 4/ml actinomycin D. Controls
were similarly set up but without actinomycin D treatment.
At 0, 6, 15 and 24 hrs after actinomycin D exposure,total
RNAwasisolated from each culture and electrophoresed, as
described earlier, at 7.5 ug RNA per lane. After
electrophoresis, the gels were stained with ethidium
bromide, viewed underultraviolet light to ensure equal RNA
loading of the lanes and transferred to nylon filters. Northern
hybridization for GST-x transcript levels was performed as
previously described. Hybridization bands were quantitated
by densitometry and plotted against time.
Thermostability of variant GST-z proteins. In a previous
study (Zimniak et al., 1994), it was shown that a recombi-
nant GST-a enzyme corresponding to GSTP1b-1b, created
by site-directed mutagenesis, was functionally more heat-
stable than the parent enzyme.In this study, therefore, the
inventors compared the thermal stabilities of the enzymatic
function of the three variant GST-z proteins. For this,
approximately 0.1 U/ml of each variant GST-z protein was
incubated at 45° C. in PBS (pH 7.2) in a water bath. Every
15 mins, over 1 hr, a 50 zal aliquot was removed from each
incubate and total GST activity was determined as previ-
ously described, using CDNB as substrate. Residual GST
activity was computed relative to the activity of controls
maintained at 25° C. and plotted against time. SDS-PAGE
and western blotting were performed,as described earlier, to
determineif degradation of the GST-a peptides had occurred
during the incubation.
2. Results
Isolation and sequencing of variant GST-~ cDNAclones.
The inventors analyzed approximately 3x10° plaque form-
ing units of each cDNAlibrary and several GST-z positive
clones were obtained, from which selected clones were
subjected to secondary and tertiary screening and subse-
quent sequencing. Several of the isolated clones contained
truncated GST-1 cDNAs, however, the inventors obtained
three clones, Pi 3A-7, Pi 3B-2 and Pi 3C-9, containing
full-length GST-7 cDNAs, corresponding to each of three
GST-c mRNA variants, which the inventors designated
hGSTP1*A, hGSTP1*B and hGSTP1*C, in accordance
with the proposed nomenclature for allelic GST gene vari-
ants (Mannervik et al., 1992).
The sequencing strategy is shown in FIGS.6A,6B, 6C,
6D, 6E, 6F, and 6G and the complete nucleotide and deduced
amino acid sequences of the cDNAs are shown in SEQ ID
NO:3 and SEQ ID NO:4 (GSTP1*A); SEQ ID NO:5 and
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SEQ ID NO:6 (GSTP1*B) and SEQ ID NO:7 and SEQ ID
NO:8 (GSTP1*C). Each cDNAcontained an open reading
frame of 630 nucleotides, encoding 210 amino acids, includ-
ing the initiating methionine. hGSTP1*A was completely
identical in nucleotide sequence to the previously reported
human GST-« cDNA (Kanoet al., 1987; Moscowet al.,
1988).It consisted of 712 nucleotides, of which 9 were in the
5' non-coding region. hGSTP1*B differed from hGSTP1*A
by having an A-G transition at nucleotide +313 thus
changing codon 104 from ATC (Ile)->GTC (Val). Of the 719
nucleotides 12 were in the 5' non-coding region. hGSTP1*C
was characterized by two active transitions, the AG tran-
sition at +313 observed in hGSTP1*B,and a C-+Ttransition
at +341, resulting in changes of ATC (Ile)GTC (Val)GCC
in codon 104 and of (Ala)=GTC (Val) in codon 113.
hGSTP1*C consisted of 723 nucleotides, 13 of which were
5' of the ATG start codon. The 3'-noncoding regionsof all
three cDNAs were similar and contained the AATAAA
polyadenylation signal at +689 to +696. In 8 cases
examined, there was complete concordance between the
nucleotide sequences of exons 5 and 6 in the genomic DNA
and that of the corresponding regions of the mRNA. In
addition to the transitions at nucleotide positions +313 and
+341, a silent CT transition at +555 was observed in
hGSTP1*B and hGSTP1*C.Thistransition, also previously
observed in the GST-a cDNAisolated by Moscow etal.
(1988), doesnot alter the encoded amino acid (serine) in the
affected codon 185.
Restriction endonuclease mapping. The partial restriction
endonuclease maps of the region containing the nucleotide
transitions in the three GST-2 cDNAs are shownin FIG.7.
The AGtransition at +313 created the MaeII recognition
sequence (A'CGT) in hGSTP1*B and hGSTP1*C. Thus
Mae II digestion of the 484 bp cDNA from specimens
expressing hGSTP1*B and hGSTP1*C yielded two
fragments, 199 bp and 285 bp in size. The gain of an Xcm
I recognition sequence (CCANNNNN'NNNNTGGSEQ ID
NO:34) in GSTP1*C,resulting from the C-*Ttransition at
+341, yielded 224 bp and 260 bp fragments upon Xcm I
digestion and allowed hGSTP1*C to be differentiated from
hGSTP1*A and hGSTP1*B. cDNAs from specimens that
expressed hGSTP1*A exclusively were not restricted by
either Mae II or Xcm I, since, as shown in FIG.7, the sites
for both REs are absent in this cDNA variant. Direct
sequencing of cDNAs obtained by RT-PCR from glioma
specimens expressing a mixture of GSTP1*A and GSTP1*B
and of GSTP1*A and GSTP1*C revealed the expected
sequence.
Detection of expressed GST genes by southern hybrid-
ization. The results of the southern hybridizations of the
cDNAs generated by RT-PCR from six specimens express-
ing different GST-z genes are as follows. Both hGSTP1*A
and hGSTP1*B specific probes hybridized strongly with
their respective DNA.As anticipated, the hGSTP1*C probe
did not hybridize with hGSTP1*A DNAand,conversely, the
hGSTP1*A probe hybridized only weakly with hGSTP1*C
DNA. The strongest hybridization signals were observed
when the hGSTP1*C probe was used to probe hGSTP1*C
DNAandtheleast specific hybridization was observed with
the hGSTP1*Bprobe, possibly, because only one nucleotide
difference exists between the probe for hGSTP1*B and
those hGSTP1*A and hGSTP1*C.
Expression, purification and functional analysis of variant
GST-a proteins. The GST-2 peptides encoded by the three
GST-m genes were designated GSTPla, GSTP1b and
GSTPic, as previously recommended (Mannervik et al.,
1992). The cDNAs were expressed in EF. coli and the
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expressed proteins purified by GSH-affinity chromatogra-
phy. The inventors achieved, approximately, a 200-fold
purification for all three GST-z proteins, with a yield of
78%, 63% and 72% for GSTPla-la, GSTP1b-1b and
GSTPic-1c, respectively. In each case, SDS-PAGE of the
isolated proteins showed a single band after Coumassie Blue
staining and positive immunoreactivity was observed by
western analysis with anti-GST-a antibody but not with
antibodies against GST-u or GST-a. Enzyme kinetic analy-
sis of the catalysis of the conjugation of GSH with CDNB
by the three GST-m proteins are summarized in the
Lineweaver-Burke plots in FIGS. 8A-C and in Table 4. K,,
(CDNB)andV,,,,. Values were 0.98 mM+0.06 and 4.7+0.03max“mol-min-*-mg~, respectively, for GSTPla-la, 2.7+0.023
mM and 1.7+0.087 «mol-min-?-mg~* for GSTP1b-1b, and
3.1+0.17 mM and 1.4+0.23 umol-min™’-mg™ for GSTP1-
le.
Structural analysis of variant GST-a proteins. Data from
the X-ray crystallographic structure of GSTP1a, previously
reported (Reindeer et al., 1992; Reinemer et al., 1993)
showed the key amino acid residues lining the putative
electrophile-binding (H-) site of human placental GST-a to
consist of Tyr5, Tyriog, Valio, Val,;, Phe, and Gly.s. The
inventors modeledthe effects of the amino acid substitutions
in the variant GST-z proteins on the structure of the resulting
peptides, particularly, the active (H-) site. The super-
imposed energy-minimizedstructures of the H-site region of
GSTPla and GSTP1b are shownin FIG.9A,and in FIG. 9B
for GSTP1a and GSTPic. The substitutions of Va,9,—Tle,,,
in GSTP1b and GSTP1c,and of Val,,,—~Ala,,3; in GSTP1c
caused significant deviations in the atomic co-ordinates of
side chains of the key H-site residues (Table 5). The devia-
tions caused by the Val,,, for Ile,,, substitution are mag-
nified in the samedirection, butto a lesser degree, than those
caused by the Ala,,, to Val,,, substitution. The highest
deviations involved the side chains of Tyr,,, and Tyr,,
which, relative to GSTPla, had shifted by 0.153 A®° and
0.116 A° in GSTP1b, and 0.242 A®° and 0.185 A° in GSTPIc.
Phe, was the least affected by the amino acid changes.
Overall, the deviations in atomic coordinates in the active
site residues were larger going from GSTPla to GSTP1c
than from GSTP1b to GSTPlc.
Changes in inter-side chain distances within the three-
dimensional structure of the variant peptides are summa-
rized in Table 6, and are also evident in FIG. 9A and FIG.
9B. The distances between the residues Tyr,and Val,, and
between Tyr,5, and Val,, decreased progressively going
from GSTP1a to GSTP1b and GSTPic. From the super-
imposed structures in FIG. 9A and FIG. 9B,it is apparent
that, in GSTP1b and GSTPic, the methyl group of Val,,,
proximal to Tyr,is closer to several of the putative active
site residues than is the secondary methyl group of Ie,,, in
GSTP1a. The orientation of the methyl group of Val,,,4 in
GSTP1b and GSTPic towards Tyr,,,, causes a decrease in
the distances between Val,), and both Val,, and Val,;, and
a restriction of the region of the active site bordered by
Tyriog, Val,o, and Val,;. The replacement of He,,, with the
less bulky Val,,, also opens up the region lined by Tyr,,
Tyri, Pheg. The distances between side-chains of the paired
residues, Tyr, and Val,, is shorter in GSTPla than in both
GSTP1b and GSTPic, whereas the distances between Tyr,
and Tyr,5, and between Tyr, and Phe, are longer.
Stability of variant GST-~7 mRNAs and protein. The
intracellular decay of the three variant GST-~ mRNAs in
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malignant glioma cell lines, each of which expressed a
different GST-7 mRNA, was determined following inhibi-
tion of de novo RNAsynthesis by exposure of the cells to
actinomycin D. The decay curves, FIGS. 10A—C, showed
only a modest difference in the intracellular stabilities of
transcripts of the three variant GST-m genes under these
conditions. The decay of the GST- messagein eachcell line
followed first order kinetics with half-lives of 9.4, 14.1 and
11.8 hrs, for GSTP1*A, GSTP1*B and GSTP 1*C, respec-
tively.
The time-dependentloss of enzymaticactivity ofthe three
variant recombinant GST-z proteins at 45° C. also followed
first order kinetics and was relatively rapid. The results,
summarized in FIGS. 11A-—C, demonstrated significant dif-
ferences between the three enzymes. The rates with which
GST enzymeactivity (CDNBassubstrate) waslost at 45° C.
were 1.81 hr’ for GSTPla-la, 1.01 hr? for GSTP1b-1b,
and 0.89 hr~? for GSTP1c-1c,with half lives of 23 mins, 47
mins and 51 mins, respectively. SDS-PAGE and western
blotting showed no detectable degradation in the GST-
peptides associated with the loss in enzyme activity under
these conditions.
Expression and distribution of variant GST-t mRNA in
normal cells, tissues and tumors. The frequencies with
which the three GST-a gene variants were observed in
malignant gliomas and normal specimens (lymphocytes and
placentas) are summarized in Table 7. The frequency of
GSTP1*A homozygosity was 0.22 (7 out of 32) for gliomas
compared to 0.51 (22 out of 43) for normal specimens. In
contrast, GSTPI*C homozygousity was at a frequency of
0.07 (3 out of 43) in normal specimens, and 0.0.25(8 out of
32) in gliomas. GSTP1*A/GSTP1*C heterozygosity was
observed at frequencies of 0.34 and 0.09 for gliomas and
normal specimens, respectively. Thus, overall, GSTP1*C
waspresent at a frequency of 0.59 in gliomas compared to
0.16 in normal specimens. Two of 43 normal specimens and
none of the gliomas were homozygous for GSTP1*B.
However, the frequency of GSTP1*A/GSTP1*B heterozy-
gosity was significantly higher, 0.19 in gliomas and 0.28 in
normal specimens, respectively. None of the 75 tumor and
normal specimens were lieterozygous for GSTP1*B and
GSTP1*C.
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TABLE 4
 
Enzyme kinetics of recombinant variant GST-a proteins. Each protein
was isolated by GSHaffinity chromatography and examined for its
ability to catalyze the conjugation of GSH with CDNB. Km and Vmax
were determined at 25° C. in 0.1M K-phosphate buffer (pH 8.3).
1-Chloro-2,4-dinitrobenzene eeeEeees
 
GST-a Protein Variant Vmax (umole/min/mg) Km (mM)
GSTPla—la 4.7 + 0.03 0.98 + 0.06
GSTP1b—1b 1.6 + 0.087 2.7 = 0.023
GSTP1c—1c 1.4 = 0.23 3.1 £0.17
TABLE 5
Deviations in atomic co-ordinates of key amino acid side chains in
H-site amino acid residues of variant GST-a peptides. GSTP1b was
created by substituting Val,,, for Ile,,4, and GSTP1c by substituting
both Ile,o4 and Ala,,3 with Val in the X-ray crystallographic structure
of the human placental GSTP1a, co-crystallized with
S-hexylglutathione (Reindeeret al., 1992; Reinemer, et al., 1993).
The resulting 3-dimensional structures were energy minimized. The
reference group of the amino acid side chain side chain is in
parenthesis and the reference atom is bold-faced and underlined. The
reference CH; for Val, is the one proximal to Pheg, and for Vals,
the one proximal to Val,, in FIGS. SA-C 
Reference Position in GST-a _Co-ordinate Deviation Relative to GSTPla 
 
Peptide GSTP1b GSTP1c
Tyt1og(QH) 0.153 0.242
Valio (CHs) 0.099 0.188Phe, (Ph-H4) 0.034 0.098
Tyr; (OH) 0.116 0.185
Val35 (CH3) 0.101 0.133
Pro,; (B-CH,) 0.108 0.126
TABLE 6
Changes in inter-side chain distances of amino acid residues lining the
H-site of variant GST-a peptides. GSTP1b and GSTPic were created
by amino acid substitutions in the X-ray crystallographic structure of
GSTPia, and energy minimized, as described in the text. The distances
are those between the closest atom pair (one in each side chain). 
Inter-side chain distance (A°)
Amino Acid Residue GSTPila GSTP1b GSTPic
Tyriog and Val, 4.358 4.211 4.156
Tytiog and Vals 8.883 8.683 8.638
Tyr; and Vali 2.489 2.613 2.660
Tyr, and Tyryo¢ 9.761 9.751 9.715
Tyr; and Pheg 2.958 2.936 2.935
 
TABLE 7
Distribution frequency of polymorphic GST-1 mRNAvariants among normal specimens
(peripheral blood lymphocytes, normal brain and placenta) and malignant gliomas. 
All Specimens Gliomas Normal Specimens
Gene Variant N= 75 N = 32 N=43 Tumor:Normal Ratio
GSTP1*A 0.38 (29/75) 0.22 (7/32) 0.51 (22/43) 0.43
GSTP1*B 0.03 (2/75 0 (0/32 ~=—-0.05 (2/43) 0)
GSTP1*C 0.15 (11/75) 0.25 (8/32) 0.07 (3/43) 3.57
GSTP1*A + GSTP1*B 0.24 (18/75) 0.19 (6/32) 0.28 (12/43)) 0.67
GSTP1*B + GSTP1*C 0 (0/75) 0 (0/32) 0 (0/43) 0)
GSTP1*A + GSTP1*C 0.20 (15/75) 0.34 (11/32) 0.09 (4/43) 3.78
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Example 3
Glutathione S-Transferase a Expression and Subcelllular
Localization in Gliomas
1. Materials and Methods
Antibodies, biochemical and other reagents. Rabbit poly-
clonal antibody against human placental GST-a was
obtained from Biotrin Inc., Dublin, Ireland, and was tested
at various dilutions to determine the optimum concentration
required for reproducible immunohistological staining with
minimum background staining Mouse anti-rabbit antibody
and non-immunized rabbit IgG were purchased from
Becton-Dickenson, Palo Alto, Calif. The same batch of
antibodies was used throughout the study. All other reagents,
unless otherwise stated, were purchased from Sigma Chemi-
cal Company, St. Louis, Mo.
Patients and Tumors. All patients in the study had surgery
at the M.D. Anderson Cancer Center (MDACC) and the
study had received prior approvalofthe Institutional Review
Board (IRB). Both surgery and diagnosis were made inde-
pendentof the study.
All specimens were processed by fixation for 6—24 hrs in
neutral 10% formalin and stained with hematoxylin-eosin.
After histological diagnosis and grading of the tumors by a
neuropathologist, 4 m-thick sections were cut from each
specimen for GST-m immunocytochemical analyses of
GST-a expression. Upon completion of the GST-2 immu-
nocytochemical analyses, the data were provided to a bio-
statistician who obtained, from patient hospital records, the
relevant clinical and histological information required for
the statistical correlations. Reference points for survival
were the date of surgery, date of last follow-up or date of
death. Forthis study, tumors were categorized into oneof the
following groups: glioblastoma multiforme, anaplastic
astrocytoma and other gliomas (consisting of astrocytomas,
aligo-astrocytomas and anaplastic oligo-astrocytomas) a cat-
egorization that has been shownto be prognostically rel-
evant (Nelson et al., 1983; Burgeret al., 1985).
Immunocytochemistry for GST-~ expression. Paraffin
sections were pre-warmed to 60° C., deparaffinized in two
exchanges of xylene, rinsed in decreasing concentrations
(100% to 70%) of ethanol and rehydrated in PBS. Endog-
enous peroxidase wasinactivated with 0.3% H,O, in metha-
nol and the slides were incubated overnight with a poly-
clonal rabbit anti-human GST-z antibodyat a 1:500 dilution.
After rinsing the slides with four exchanges of PBS, they
were incubated with a mouse anti-rabbit antibody for 30
mins at 4° C., followed with a solution of biotinylated
peroxidase (Vector Laboratories, Burlingame, Calif.). The
slides were developed with 0.05% diaminobenzidine and
0.01% H,O, in 50 mM Tris/HCl buffer, pH 7.5. Non-
immunized rabbit IgG wasused as a negative control for the
GST-a antibody, and the MGR 3 glioblastomacell line was
used as a positive control for GST-m staining.
Quantitation of the level of GST-m expression and evalu-
ation of its sub-cellular localization. Following immunocy-
tochemical staining as described above, the level of GST-1
expression in each specimen was determined by scoring the
staining intensity of a xxxfields, at 200x magnification.
GST-a staining intensity was assessed as low, moderate or
high, based on the staining characteristics of 70% or greater
of tumorcells. Since cytoplasmic GST-z immunoreactivity
wasalways positive in GST-a expressing cells, sub-cellular
GST-a expression was characterized as either the presence
or the absence of GST-m immunoreactivity in the nuclei of
tumor cells. The GST-m staining characteristics of other
non-tumorcells, e.g., reactive astrocytes, endothelial cells
and infiltrating lymphocytes were also determined but not
used in the evaluation of GST-1 expression in the tumors.
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Statistical analysis. The relationship between GST-1
expression and histology was determined using the Kruskal-
Wallis test (exact version). The presence of nuclear GST-a
in glioma cells as a function of age was determined by
probability estimates. The correlation of the level of GST-2
expression, and of the presence or absence of nuclear GST-1t
in gliomacells with patient survival was determined by both
univariate and multivariate analyses, using the Cox propor-
tional hazard regression model (Cox 1972). Survival esti-
mates were computed and plotted by the Kaplan-Meier
(1972) method. Covariates in the multivariate analyses were
age (continuous) and histology.
2. Results
Tumor and Patient Characteristics. Tumors from 61
patients were examined in this study. The distribution of
these specimens according to histopathology is shown in
Table 8. Fifty-four percent of the specimens wereflioblas-
toma multiforme, 21% anaplastic astrocytomas, and 25%
other gliomas. Of the 61 patients, 59 were newly diagnosed
and had received no prior therapy prior to the analysis for
GST-a expression. The remaining two were recurrent glio-
blastomas.
Pattern and heterogeneity of GST-a staining. The degree
of GST-a immunoreactivity in the tumors ranged from low
or absent, to intermediate and strong. Each tumor was thus
easily categorized semi-quantitatively into one of three
groups, namely, low, moderate and high, with respect to the
degree of GST-a expression. Such a categorization of GST-1
immunoreactivity has been shown to be prognostically rel-
evant (Gilbert et al., 1993; Tidefelt et al., 1992). In GST-x
positive tumors, regardless of the intensity, immunoreactiv-
ity was always exclusively in glioma cells and, in some
cases, also in reactive astrocytes. While the cytoplasm of
GST-a positive tumors was alwayspositive,cell nuclei were
either positive or negative for GST-a. One example showed
a glioblastoma multiforme in which both the nuclei and
cytoplasm of gliomacells are strongly positive for GST-z,
and another showed a glioblastoma in which the cytoplasm
of the tumor cells had strong GST-a staining and the cell
nuclei were GST-a negative. When both nuclear and cyto-
plasmic GST-z staining were present in a given tumor, the
pattern and intensity were generally similar, and the two
sub-cellular compartments were often indistinguishable with
respect to GST-2 staining. In the majority of tumors, the
overall level of GST-a immunoreactivity was uniform
within different regions of a given tumor section, however,
in a numberof cases, a significant degree of inter-cellular
heterogeneity was observed in GST-a staining. Cells with
strong nuclear and cytoplasmic GST-m expression can be
observed adjacent to cells negative for GST-a or to cells
which express only cytoplasmic GST-a. Nuclear GST-z was
always absent in reactive astrocytes, even when the cyto-
plasm wasstrongly positive. Normal non-reactive astrocytes
were generally negative, as were endothelial cells, and
tumor-infiltrating lymphocytes, present either as perivascu-
lar cuffs or diffuse within the tumor. Necrotic areas in the
tumor were negative for GST-x.
Relationship between the level of GST-a expression,
histology and patient age. The distribution of the histological
categories of gliomas according to their level of GST-a
expression is summarized in Table 8. Although, a trend
indicating an association of increased levels of GST-a
staining with increased grade of gliomas was observed, the
correlation was not statistically significant (p-value 0.16).
Within each histological category, however, a strong asso-
ciation existed between the proportions of tumors expressing
high or low GST-x and histological grade of that category.
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Thus, of the glioblastomas, 45% had high and 27% low
GST-z expression, compared to 31% and 15% of anaplastic
astrocytoma, and 27% and 47%, respectively, of other,
primarily lower grade gliomas.
Thestatistical analyses of the correlation of GST-z stain-
ing with age are shown in Table 9. The median ages for
patients with high, moderate and low GST-m expressing
tumors was 58, 46 and 48 yrs, respectively. There was a
modest trend towards higher GST-a levels in gliomas of
older patients, however, the correlation was modest and not
statistically significant; p-values=0.27 for all glioma
patients, 0.16 for patients with glioblastoma multiforme and
0.23 for anaplastic astrocytomapatients. No association was
observed between the level of GST-a expression and age in
the group of other gliomas (p-value=0.78).
Relationship between nuclear GST-z, histology and
patient age. Based on the nuclear GST-z staining
characteristics, gliomas were dichotomized into two
categories, one in which GST-x waspresentin the nuclei of
tumorcells and the other in which it was absent. The results
(Table 10) show a strong correlation (p-value of 0.0003)
between the level of GST-a expression and the presence/
absence of nuclear GST-1. 74% of gliomas with high GST-x
expression also had GST-a presentin the nucleus, compared
to 55% of tumors with moderate and 11% with low GST-x
levels. In contrast to the level of GST-m expression, the
correlation between patient age and nuclear GST-a presence
washighly significant, with a p-value of 0.0024 by Kruskal-
Wallis analysis. Seventy-nine percent of the tumors of
patients aged 60-75 yrs. had nuclear GST-x, compared to
22% of the tumorsofpatients between 15 and 39 yrs.of age.
The median age of glioblastoma patients with no nuclear
GST-a was 50 yrs. (range 49-75 yrs.) compared to 65 yrs.
(range 30-69) for those with nuclear GST-z. As shown in
Table 10, no statistically significant correlation was
observed between histology and the presence of nuclear
GST-a in glioma cells (p-value=0.63 by exact chi-squared
analysis).
Correlation of the level and subcellular pattern of GST-a
expression with patient survival. Univeriate and multivariate
Cox proportional hazard regression models were used to
examinethe relationship between the level of GST-z expres-
sion and patient survival. The multivariate analysis were
performed adjusting for histological grade of the tumor and
patient age. The results of these analyses, summarized in
Table 11, show that patients with tumors with high (or
moderate) GST-z levels were at a significantly higherrisk
than those with low GST-x expressing tumors. The relative
risk of high, compared to low GST-z, was 3.2 (95% CLL. 1.4,
7.5), with a p-value of 0.0069 by univariate analysis, and 2.6
(95% CI. 1.1, 6.2), p-value of 0.036 by multivariate analy-
sis. Similar values were observed when patients with mod-
erate and low GST-z expressing tumors were compared.
When contrasted with its absence, the relative risk of the
presence of nuclear GST-z was 1.98 (95% CLI. 1.43, 2.75),
p-value=0.0010 by univariate analysis, and increased to 4.4
(95% CI. 2.1, 9.2), p-value 0.0001, by multivariate analysis.
The Kaplan-Meier survival plots forall 61 patients, FIG.
12A, show a strong inverse relationship between the level of
GST-a expression and patient survival over the first 52
monthsof follow-up, with a p-value of 0.017. The difference
in survival of patients whose tumors exhibited high or
moderate GST-2 expression became progressively smaller
with longer follow-up time. Because glioblastoma multi-
forme has the worst prognosis of malignant gliomas, we
analyzed the sub-group of glioblastoma patients for the
correlation of GST-z expression and survival. The results,
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FIG. 12B, demonstrate a significantly lower survival rate for
glioblastoma patients with high GST-a expressing tumors
comparedto those whose tumors expressed low or no GST-1t
in the tumorcells (p-value=0.026). Similar to the data forall
patients, the differences in patient survival between the
different levels of GST-m expression was highest at the
earlier stages of follow-up.
FIG. 13A and FIG. 13B show Kaplan-Meiersurvival plots
for the presence or absence of nuclear GST-z in tumors of
all glioma patients (FIG. 13A) and of glioblastoma patients
(FIG. 13B). Patients with GST-a present in the nuclei of
their tumorcells had a significantly lower survival rate than
patients whose tumorcells were negative for nuclear GST-a.
For glioblastoma patients, the difference in survival was
particularly strong early in follow-up. At 15 months of
follow-up, approximately 92% of patients with negative
nuclear GST-x tumors were alive, compared with only 3%
of patients whose tumors were positive for nuclear GST-z.
TABLE 8
 
Distribution of gliomas according to histological category and level of
GST-x expression. GST-a expression was based on the intensity of
the immunoreactivity of 70% of the cells
Level of GST-a Expression
 
Histology n High Moderate Low
Glioblastoma multiforme 33 (54%) 15 (45%) 9 (27%) ~—-9 (27%)
Anaplastic astrocytoma 13 (21%) 4 (31%) 7 (54%) 2 (15%)
Other gliomas 15 (25%) 4 (27%) 4(27%) 7 (47%)
All Gliomas 61 23 (38%) 20 (33%) 18 (29%)
The p-value = 0.16 by exact chi-squared test.
TABLE 9
 
Relationship between level of GST-a expression in gliomas and patient
age and histology
Age (Years p-value
Mini- (Kruskal-
GST-ax Expression mum Median Maximum  n Wallis)
All gliomas
Low 24 48 75 18 0.27
Moderate 15 46 69 20
High 24 58 7 23
Glioblastoma multiforme
Low 30 50 75 9 0.16
Moderate 34 57 69 9
High 49 60 7 15
Anaplastic Astrocytoma
Low 24 26 27 2 0.23
Moderate 15 42 66 7
High 24 36 52 4
Other gliomas
Low 28 AT 68 7 0.78
Moderate 38 40 40 4
High 29 41 46 4
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TABLE 11-continued
 
Distribution of gliomas according to nuclear GST-a expression Panel a - univariate, and Panel b - multivariate Cox proportional hazard
regression analysis of the relationship between the level of tumor
 
 
 
Number (%) 5 GST-a expression, the presence/absence of nuclear GST-a in glioma
of Tumors cells, histology and patient age
with Nuclear
Variable n GST-x p-value Variable RR 95 % CI p-value
a) Level ofGST-a Expression Moderate vs Low 2.4 (4.0, 5.9) 0.05110 ii) Nuclear GST-x 4.4 (2.1, 9.2) 0.0001
Low 18 2 (11%) 0.0003 Present vs Absent
Moderate 20 11 (55%) (chi-squared)High 23 17 (74%)
b) Histology The multivariate models for the level of GST-a expression
. . and for presence/absence of nuclear GST-a were adjustedGlioblastoma multiforme 33 18 (55%) 0.63 1S £, ti d histol Th del I
Anaplastic astrocytoma 13 6 (46%) (exact chi-squared test) or age (con inuous) an . Isto Osy. 7 models a ‘SOOther gliomas 15 6 (40%) accounted for 51% of variation in survival time. Abbrevia-
c) Age (Years) tions: RR, relative risk; CI, confidence interval.
15-39 18 4 (22%) 0.0024 E le 440-49 12 6 (50%) (Kruskal-Wallis) 4) . xamnple50-59 12-5 (42%) Antisense Inhibitors of GST Variants
60-75 19 15 (79%) 1. Materials and Methods
Oligonucleotide synthesis. All anti-sense olideoxyribo-
nucleotides (AS-ONs) and control ONs were designed as
TABLE 11 95 15-mers and were purified by chromatography on NAP-10
Sephadex column. AS-ONsdirected at the initiation region
Panel a - univariate, and Panel b - multivariate Cox proportional hazard of hGSTP1*C, INIT-AS-ON,covered sequences +1 to +15
regression analysis of the relationship between the level of tumor of the mRNA. Jumbled ON controls contained the same base
GST-x expression, the presence/absence of nuclear GST-x in glioma oye . he AS-ONs b ith domizati f thcells. histology and patient age composition as the AS-ONs but wit a randomization of the
39 bases to avoid G quadruplets. Mismatch ON had the same
Variable RR 95 % CI p-value structure as the AS-ONwith the exception of two nucleotide
on mismatches at the 6th and 7th nucleotides. Partial phospho-a) Univariate Analyses . . le .eT rothioate ONs had thioate substitutions in the first three 3'
i) GST-a level and last three 5' nucleotides. Fully modified ONs contained
; 35 Substitutions of thioates for all phosphates in the phosphodi-
HighvsLOWiy 5. tor oy cose. ester bonds of the ON. Unmodified ONs contained phos-
ii) Nuclear GST-x 1.98 (1.43, 2.75) 0.0010 phodiester bonds with no substitutions. The primary struc-
Present vs Absent tures of the AS-ONsand control ONsare shownin Table 12.
b) Multivariate Analyses Transition-specific AS-ONs (TS-ONs) were designed to
. contain theAG and C-+Ttransitions at +313 and at +341,i) GST-at level 40 . . .—— respectively, that differentiate hGSTP1*C from the two
High vs Low 2.6 (1.1, 6.2) 0.036 other GST-z genes, hGSTP1*A and hGSTP1*B (Ali-Osman
et al., 1996). All TS-ONs were partial phosphorothioates.
TABLE 12
 
Structure of Oligodeoxyribonucleotides used in translational
inhibition of hGSTP1*C mRNA.
Oligodeoxynucleotide Designation Sequence
AS-ON targeted to translation initiation site of hGSTP1*C mRNA
i) Antisense-ON
ii) Controls
5'-GGIGTAGGGCGGCAT-3' (SEQ ID NO:35)
Sense-ON 5'-ATGCCGCCCTACACC-3' (SEQ ID NO:36)
Jumb led-ON 5'-CACGCTCCATCGCCA-3' (SEQ ID NO:37)
Partial mismatch-ON 5'-GGIGTGAGGCGGCAT-3' (SEQ ID NO:38)
AS-ONs:targeted to transition site of hGSTP1*C mRNA 
313-Antisense-ON 5'-GGGAGATGTATTTGC-3' (SEQ ID NO:39)
313-Transition-AS-ON 5'-GGGAGACGTATTTGC-3' (SEQ ID NO:40)
341-Antisense-ON 5'-TIGCCCGCCTCATAG-3' (SEQ ID NO:41)
341-Transition-AS-ON 5'-TTIGCCCACCTCATAG-3' (SEQ ID NO:42)
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Construction of GST-a expression vector. The GST-2
expression vector, pT’7B-Pi, used in these studies, was con-
structed from the plasmid pT7(, kindly made available by
Dr. Austin Cooney, Baylor College of Medicine, Houston,
Tex. pI7B is derived from pGEM2 (Genbank accession
number X65301) by inserting 44 nucleotides from the
upstream non-coding region of the human beta globin gene
into a region between a 5' HinD III site and a 3' T7 RNA
polymerase promoter. The pT7(-Pi was created by ligating
hGSTP1*C cDNAinto the multiple cloning site in pT7B,
suchthat the insert is 5' of an NcoI and 3' of an Xbalsite and
upstream of the non-coding beta globin sequence.
In Vitro Transcription of pT7$-Pi. 100 ug of the pT7B-Pi
vector was linearized by digestion with 80 units of Xbal for
1 hr, the linearized plasmid extracted with phenol/
chloroform, ethanol-precipitated, washed in 70% ethanol,
and redissolved in 400 yl of nuclease-free water. A 1 ml
transcription reaction mixture was set up containing 400 yd
linearized DNA, 100 mM dithiothreitol, 600 nM each of
ATP, UTP, CTP and GTP, 1000 U/ml of RNAsin ribonu-
clease inhibitor, and 400 units/ml of bacteriophage T7 RNA
polymerase. The mixture was incubated for 2 hrs at 38.5° C.
and additional 400 units of T7 RNApolymerase was added.
After a further 2 hrs, 78 units of RNAse-free DNAse were
added to digest the DNA template. Following a 15 min
incubation at 37° C., the RNA product was extracted with
phenol/chloroform, precipitated twice with ethanol/
ammonium acetate, redissolved in nuclease-free water and
the integrity of the run-off transcripts was monitored by
electrophoresis in a 1.3% denaturing agarose-formaldehyde
gel and UV spectrometry. Radiolabeled mRNAs were
obtained by a ten-fold scaledown of the same protocol and
substituting cold CTP with 250 wCi of 5[alpha®*P]CTP in
the reaction.
In vitro Translation of GST-pi with 7°S-labelled Methion-
ine. Approximately, 360 ng of recombinant hGSTP1*C
mRNA (or an equimolar amount of control luciferase
mRNA) were heated at 67° C. and quenched on ice for 10
mins to remove RNA secondary structure. The reaction
mixtures (25 ul total volume) contained 14.5 ug/ml GST
P1*C mRNAoran equimolar amountof luciferase control
mRNA,16.5 ul reticulocyte lysate, 60 mM exogenous KCl,
20 uM amino acid mixture without methionine, 800 U/ml
RNASin ribonuclease inhibitor, and 0.4 mCi/ml L-[°°S]
Methionine. The reaction was allowed to proceed for 1 hr at
30° C.and the translated proteins were analyzed by discon-
tinuous SDS-polyacrylamide gel electrophosesis with a 4%
stacking and a 12% separating gel, using 15 wl of 6-fold
diluted samples per lane. The gels were fixed, incubated for
30 mins in EN*HANCEsolution (Dupont Corporation,
Boston, Mass.), dried and autoradiographed on Kodak
XOMAT-ARSfilm.
RNase H Effects on AS ON Translational Block of GST-pi
mRNA.In vitro translation reaction mixtures were set up as
described earlier containing unmodified, partially-modified,
and fully-modified phosphorothioate AS ONs.E. coli RNase
H was added to each sample to achieve 10 U/ml final
concentration. RNAs in ribonuclease inhibitor was omitted
from the reactions. After 1 hr incubation, the samples were
analyzed as described earlier.
Oligonucleotide backbonestructure andefficacy of trans-
lationalinhibition. These series of studies were performed to
examine the extent to which the structural modifications of
the AS ON backbone performed to increase nuclease resis-
tance and increased stability, affected the efficacy of the
AS-ONs in inhibiting the translation of the hGSTP1*C
mRNA.Forthis, unmodified, partially modified, and fully-
modified phosphorothioate AS ONs were added to the
°S-Mettranslation reaction mixtures to achieve concentra-
tions of 0 to 12.5 uM. The mixtures were incubated for 1 hr
and analyzed for translation product as described earlier.
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Translational inhibition by AS ONtargeted to transition
nucleotides in hGSTP1*C. These studies were designed to
examine the ability to specifically inhibit the hGSTP1*C
variant with an AS ONs (TS-AS ON)containing the nucle-
otide transitions in this mRNA variant. In vitro translation
systems containing *°S-L-methionine were set up as
described earlier, and the various AS ONs were added to
achieve concentrations of 0 to 12.5 uM. After a 1 hr
incubation (37° C.), the reaction products were analyzed, as
described earlier. Controls for specificity of the TS-AS ON
consisted of a sense ON with the basic structure but of a
different base composition than the TS-AS ON,a jumbled
ONwith the same base composition but with the nucleotide
sequence jumbled, and a partial mismatch ON with the same
base composition but with the sixth and seventh nucleotides
switched. All the TS-ONs were partially modified phospho-
rothioates.
2. Results
The results, summarized in Table 13, show that the
antisense construct decreases GST-t mRNA by 42% and
GST-z protein by 53%, when compared to untreated con-
trols. The effect observed with jumbled and sense oligos
were 5 and 4.7% (mRNA) and 7.2 and 8.9% (protein),
respectively, indicating that the effects seen with the anti-
sense construct were not as a result of non-specific interac-
tions. Furthermore, clonogenic survival was significantly
lower with the antisense treatment, whereas the controls
were not.
Studies were conducted to examine the effects of anti-
sense ON’s on translation of GSTP1*C. As shown in FIG.
14, 5 uM of ON designed around the mRNAtranslation
initation site gave 50% inhibition of transcription, whereas
this same concentration gave negligible inhibition of
luciferase expression. At 10 uM ON, GSTP1*C expression
was completely blocked, while luciferase was inhibited by
about 60%. Using sense, partially mismatched and jumbled
ON’s, the specificity of the antisense ON directed to the
GSTP1*C mRNAtranslational start site was examined. At
10 uM, the inhibition was 100% for antisense, 60% for
mismatched, 45% for jumbled and 35% for sense (FIG.15).
Studies were performed to determine the ability of ON’s
directed to the regions of GSTP1 at which variation occur.
Using ON’sthat discriminate between the A/G at nucleotide
313, RNAse H was used to treat the ON’s bound to
GSTP1*C mRNA. As expected, the mismatch in the “A
version” of the ON resulted in RNAse H degradation and
impaired inhibition of GSTP1*C as compared with the “G
version” (FIG. 16). A similar experiment was performed
focusing on the C/T at position 341. Again, as expected, the
inhibition of GSTP1*C expression by the “T version” was
higher following RNAse H treatment, though only slightly
so (FIG. 17). Interestingly, without RNAse H treatment, the
“C version” had considerably better inhibition, especially at
lower ON concentrations (FIG. 17).
 
TABLE 13
% GSTpi
mRNA % GSTpi Protein __Clonogenic Survival®
Treatment Inhibition* Decrease BCNU Cisplatin
Control 0 0 1.00 1.00
Antisense-ON 42 53 0.34 0.24
Jumbled-ON 5 72 0.93 0.91
Sense-ON 4.7 8.9 0.94 0.94
 
*Determined by northern analysis.
>Determined by western analysis.
“Determined by capillary clonogenic acid.
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Example 5
Small Molecule Inhibitors of GST Variants
1. Materials and Methods
Generation of GST-z inhibitors. Generation of inhibitors
is accomplished by a rational drug development strategy
involving force field docking and energy-minimization of
chemical fragments and compoundsinto the active site of
the variant GST-a proteins. The compounds and chemical
fragments can be drawn from chemical fragmentlibraries,
such as that available in the Leapfrog database. Additional
chemicallibraries will be generated as necessary. The active
site and other structural components of the variant GST-7
proteins will be derived from the published crystal structure
of the GSTP1*A encoded protein. The protein encoded by
GSTP1*Bare obtained by substituting valine for isoleucine
at amino acid 104; the protein encoded by GSTP1*C by
substituting valine for isoleucine at amino acid 104, and
valine for alanine at amino acid 113. Based on the resultant
AAHvalues obtained after energy minimization of chemical
fragments/compounds,candidate inhibitors are selected and/
or newly constructed from chemical fragments for synthesis
and further analyses for their inhibitory or other action on
the variant GST-a proteins. Selection criteria for inhibitors
for synthesis and further analysis includes lipophilicity,
chemical stability and availability or ease of synthesis.
Synthesis of GST-a Inhibitors. If the identified and/or
newly constructed potential inhibitors are not commercially
available, then they will be synthesized using standard
organic synthetic methodology, including heterocyclic ring
construction and functionalization, and electrophilic and
nucleophilic substitution reactions. Reaction mixtures will
be separated by thin layer, flash silica gel column and high
performanceliquid chromatography (TLC, CC and HPLC).
The compounds will be purified using standard techniques
modified as necessary. Characterization of synthetic prod-
ucts will be done by melting point determination, Fourier
transform infrared (FT-1R), ultraviolet (UV) and high reso-
lution nuclear magnetic resonance (NMR) spectroscopy and
mass spectrometry. Compoundsforbiological testing will be
purified by preparative HPLC.The purity of compounds will
be determined by elemental analysis and HPLC.
Source of variant GST-z proteins. To examine the ability
of the inhibitors selected from the rational design described
above to inhibit the variant GST-z proteins, we will utilize
recombinant GST-z proteins expressed in F. coli transfected
with expression vectors containing the corresponding
cDNAs. These vectors have been described elsewhere in this
application. The GST-a proteins will be purified by GSH-
affinity chromatography on S-hexyl glutathione linked to
epoxy-activated sepharose 6B. and then used for enzyme
kinetic analysis.
Analysis of inhibitors for GST inhibitory activity. These
studies will be performed using standard enzyme kinetic
methodologies. The purified variant GST-z proteins will be
mixed with increasing inhibitor concentrations and at dif-
ferent time points, residual GSTactivity will be determined
in reaction mixtures (25° C.) in 100 mM potassium phos-
phate buffer, pH 8.3 containing 0-5 mM _1-chloro-2,4-
dintrobenzene (CDNB) and 2.5 mM GSH.The change in
absorbance will be monitored at 340 nm over two minutes
and used to compute reaction rates. The rates of the spon-
taneous reactions of GSH with CDNB, determined with
reaction mixtures in which the GST-2a enzyme will be
replaced with buffer, will be subtracted from the rates of the
enzymecatalyzed reactions. The resulting reaction rates will
be used to generate appropriate enzyme kinetic plots, using
standard methodology. Inhibitory constants will be com-
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puted for the different inhibitors and used in selecting
candidates for further analyses of activity in tumorcells and
subsequently in vivo.
Synthesis of Isoxazoles. Using the techniques described
above, potential GST-z inhibitors such as isoxazoles have
been identified. In the synthetic strategy for obtaining isox-
azole GSTinhibitors, the ring system can be achieved by the
usual approach of cyclization between hyroxylamine and
three-carbon atom component such as 1,3diketone or an
a,B-unsaturated ketone or by a 1,3-dipolar cycloaddition
reaction involving nitrile oxides with alkenes or an alkyne
(Glichrist, T. L. (1992) Heterocyclic Chemistry, 2nd Edn,
John Wiley & Sons, New York, Chapter 8, pp.314-316).
2. Results
Based on predicted binding energies for seven essential
amino acids in GST-z peptides, a group of related
compounds, substituted isoxazoles, were tested for their
binding energies with GSTP1a, as shown in Table 14.
TABLE 14
 
The binding energies of substituted isoxazoles with GSTPla
oO
Ry Rg“y 4 x
2 \ 5NL | R3
Oo Ry
General Structure (Substituted Isoxazoles)
 
 
Binding
Energy
Compound R, xX R R; Ry (kcal/mol)
1 H N H H H -38
2 NH, N H H H -443 NH, N 4H CH, H -454 CH, CH H CH, H -385 OH CH H  NHGBH, CH, -536 OH CH 4H NHCH,NH, CH, -567 NH, N 4H CH, Phenyl -749 NH, N 4 CH, 2-Pyridyl -84
TABLE 15
The binding energies of fused aromatic compounds with GSTPla
Binding Energy
 
Compound Structure (kcal/mol)
9 -34Ss
y N
N
CH,ONH,
10 -41
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TABLE 15-continued
 
The binding energies of fused aromatic compounds with GSTP1a
Binding Energy
 
Compound Structure (kcal/mol)
cay -94SS
ZACH; N
~ N\/
oO
12 -86
13 -67
14 N -56
S
oO
N
ry
A
15 NH) -36
N.S
a
‘SS N
a
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TABLE 16
 
The binding energy for sugar-linked aromatic compounds with GSTPic
Ligand Structure
Binding
Energy at
H-Site
(kcal/mol)
-33
-26
cay
NH
-29
HoN
 
-21
-31
NH
 
TABLE 17
The binding energy for four compounds with GSTPic
Ligand Structure Binding Energy at H-Site (kcal/mol)
C
S NH
OH
-23
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TABLE 17-continued
 
The binding energy for four compounds with GSTPic
Ligand Structure Binding Energy at H-Site (kcal/mol)
J -33
s Ct
OH
y -21
| NHs ~CH;
OH
-22a |
SSN NH
 
Initial results of the force field docking of chemical
fragments and compoundsinto the active site of the variant
GST-a proteins have resulted in the identification of several
classes of compounds that are potential GST-a variant
protein inhibitors.
The first class of compoundsare substituted isoxazoles,
with the general structure shown in structures 1-3 (Table
14). The substituted groups in the different compoundsare
represented by R,, R,, R,, and R,. The substituted groups
vary between the different compounds andresult in signifi-
cant changes in binding energies of the compounds in the
active site pocket of the GST-z protein. For example, R,
substitutions of either NH. or OH,cause changes in binding
energies of almost 10 kcals/mol. Other important substitu-
tions are the alkyl or aminoalkyl substitutions of R;, and the
alkyl, phenyl or 2-pyridyl substitutions of R,, some of which
result in changes in binding energies of greater than 10
keals/mol.
Another group of potential variant GST-a protein inhibi-
tors identified by the strategy described in this invention are
the heterocyclic aromatic compounds, whosestructures are
shownin Table 15. The binding energies range from -34 to
-94 kcal/mol, depending upon the type of compound or
substitution.
The other groups of inhibitors are aromatic compounds
and mono- and disaccharide derivatives of aromatic com-
pounds with or without branched chains. The structures of
representative candidates of these GST- H-site ligands are
given in Tables 16 and 17.
The structures shown in Tables 14-17 are only represen-
tatives of the structures that will be obtained with the
rational design approach described in this application. The
binding energies all show that the ligands will bind stably to
the H-site of the GST-m protein. The inventors expect,
however, to identify additional compounds using the same
strategies and to perform additional structural modifications
to these and to the other compounds to be obtained. These
modifications will be performed to optimize the
effectiveness, increase or decrease the solubility and or
stability, and/or otherwise enhance the biological and or
therapeutic efficacy of the compounds.
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SEQUENCE LISTING
(1) GENERAL INFORMATION:
(iii) NUMBER OF SEQUENCES: 42
(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3117 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
GCGGCCGCCG GGGCTGGGGC CGGCGGGAGT CCGCGGGACC CTCCAGAAGA GcGecceece 60
CCGTGACTCA GCACTGGGGC GGAGCGGGGC GGGACCACCC TTATAAGGCT CGGAGGCCGEC 120
GAGGCCTTCG CTGGAGTTTC GCCGCCGCAG TCTTCGCCAC CAGTGAGTAC Gceceeccce 180
CGTCCCCGGG GATGGGGCTC AGAGCTCCCA GCATGGGGCC AACCCGCAGC ATCAGGCCCG 240
GGCTCCCGGC AGGGCTCCTC GCCCACCTCG AGACCCGGGA CGGGGGCCTA GGGGACCCAG 300
GACGTCCCCA GTGCCGTTAG CGGCTTTCAG GGGGCCCGGA GCGCCTCGGG GAGGGATGGG 360
ACCCCGGGGG CGGGGAGGGG GGGGCAGGCT GCGCTCACCG CGCCTTGGCA TecTcccccG 420
GGCTCCAGCA AACTTTTCTT TGTTCGCTGC AGTGCCGCCC TACACCGTGG TCTATTTCCC 480
AGTTCGAGGT AGGAGCATGT GTCTGGCAGG GAAGGGAGGC AGGGGCTGGG GCTGCAGccC 540
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ACAGCCCCTC GCCCACCCGG AGAGATCCGA ACCCCCTTAT CCCTCCGTCG TGTGGCTTTT 600
ACCCCGGGCC TCCTTCCTGT TCCCCGCCTC TCCCGCCATG CCTGCTCCCC GCCCCAGTGT 660
TGTGTGAAAT CTTCGGAGGA ACCTGTTTCC CTGTTCCCTC CCTGCACTCC TGACCCCTCC 720
CCGGGTTGCT GCGAGGCGGA GTCGGCCCGG TCCCCACATC TCGTACTTCT cccTccccec 780
AGGCCGCTGC GCGGCCCTGC GCATGCTGCT GGCAGATCAG GGCCAGAGCT GGAAGGAGGA 840
GGTGGTGACC GTGGAGACGT GGCAGGAGGG CTCACTCAAA GCCTCCTGCG TAAGTGACCA 900
TGCCCGGGCA AGGGGAGGGG GTGCTGGGCC TTAGGGGGCT GTGACTAGGA TCGGGGGACG 960
CCCAAGCTCA GTGCCCCTCC CTGAGCCATG CCTCCCCCAA CAGCTATACG GGCAGCTCCC 1020
CAAGTTCCAG GACGGAGACC TCACCCTGTA CCAGTCCAAT ACCATCCTGC GTCACCTGGG 1080
CCGCACCCTT GGTGAGTCTT GAACCTCCAA GTCCAGGGCA GGCATGGGCA AGCCTCTGCC 1140
CCCGGAGCCC TTTTGTTTAA ATCAGCTGCC CCGCAGCCCT CTGGAGTGGA GGAAACTGAG 1200
ACCCACTGAG GTTACGTAGT TTGCCCAAGG TCAAGCCTGG GTGCCTGCAA TCCTTGCCCT 1260
GTIGCCAGGCT GCCTCCCAGG TGTCAGGTGA GCTCTGAGCA CCTGCTGTGT GGCAGTCTCT 1320
CATCCTTCCA CGCACATCCT CTTCCCCTCC TCCCAGGCTG GGGCTCACAG ACAGCCCCCT 1380
GGTTGGCCCA TCCCCAGTGA CTGTGTGTTG ATCAGGCGCC CAGTCACGCG GccTEcTccc 1440
CTCCACCCAA CCCCAGGGCT CTATGGGAAG GACCAGCAGG AGGCAGCCCT GGTGGACATG 1500
GTGAATGACG GCGTGGAGGA CCTCCGCTGC AAATACGTCT CCCTCATCTA CACCAACTAT 1560
GTGAGCATCT GCACCAGGGT TGGGCACTGG GGGCTGAACA AAGAAAGGGG CTTCTTGTGC 1620
CCTCACCCCC CTTACCCCTC AGGTGGCTTG GGCTGACCCC TTCTTGGGTC AGGGTGCAGG 1680
GGCTGGGTCA GCTCTGGGCC AGGGGCCCAG GGGCCTGGGA CAAGACACAA CCTGCACCCT 1740
TATTGCCTGG GACATCAACC AGCCAAGTAA CGGGTCATGG GGGCGAGTGC AAGGACAGAG 1800
ACCTCCAGCA ACTGGTGGTT TCTGATCTCC TGGGGTGGCG AGGGCTTCCT GGAGTAGCCA 1860
GAGGTGGAGG AGGATTTGTC GCCAGTTTCT GGATGGAGGT GCTGGCACTT TTAGCTGAGG 1920
AAAATATGCA GACACAGAGC ACATTTGGGG ACCTGGGACC AGTTCAGCAG AGGCAGCGTG 1980
TGTGCGCGTG CGTGTGCGTG TGTGTGCGTG TGTGTGTGTA CGCTTGCATT TGTGTCGGGT 2040
GGGTAAGGAG ATAGAGATGG GCGGGCAGTA GGCCCAGGTC CCGAAGGCCT TGAACCCACT 2100
AGTTTGGAGT CTCCTAAGGG CAATGGGGGC CATTGAGAAG TCTGAACAGG GCTGTGTCTG 2160
AATGTGAGGT CTAGAAGGAT CCTCCAGAGA AGCCAGCTCT AAAGCTTTTG CAATCATCTG 2220
GTGAGAGAAC CCAGCAAGGA TGGACAGGCA GAATGGAATA GAGATGAGTT GGCAGCTGAA 2280
GTIGGACAGGA TTTGGTACTA GCCTGGTTGT GGGGAGCAAG CAGAGGAGAA TCTGGGACTC 2340
TGGTGTCTGG CCTGGGGCAG ACGGGGGTGT CTCAGGGGCT GGGAGGGATG AGAGTAGGAT 2400
GATACATGGT GGTGTCTGGC AGGAGGTGGG CAAGGATGAC TATGTGAAGG CACTGCCCGG 2460
GCAACTGAAG CCTTTTGAGA CCCTGCTGTC CCAGAACCAG GGAGGCAAGA CCTTCATTGT 2520
GGGAGACCAG GTGAGCATCT GGCCCCATGC TGTTCCTTCC TCGCCACCCT CTGCTTCCAG 2580
ATGGACACAG GTGTGAGCCA TTTGTTTAGC AAAGCAGAGC AGACCTAGGG GATGGGCTTA 2640
GGCCCTCTGC CCCCAATTCC TCCAGCCTGC TCCCGCTGGC TGAGTCCCTG GTcccccTGC 2700
CCTGCAGATC TCCTTCGCTG ACTACAACCT GCTGGACTTG CTGCTGATCC ATGAGGTCCT 2760
AGCCCCTGGC TGCCTGGATG CGTTCCCCCT GCTCTCAGCA TATGTGGGGC GCCTCAGCGC 2820
CCGGCCCAAG CTCAAGGCCT TCCTGGCCTC CCCTGAGTAC GTGAACCTCC CCATCAATGG 2880
CAACGGGAAA CAGTGAGGGT TGGGGGGACT CTGAGCGGGA GGCAGAGTTT GCCTTCCTTT 2940
79
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CTCCAGGACC AATAAAATTT CTAAGAGAGC TACTATGAGC ACTGTGTTTC CTGGGACGGG
GCTTAGGGGT TCTCAGCCTC GAGGTCGGTG GGAGGGCAGA GCAGAGGACT AGAAAACAGC
TCCTCCAGCA CAGTCAGTGG CTTCCTGGAG CCCTCAGCCT GGCTGTGTTT
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 210 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Pro Pro Tyr Thr Val Val Tyr Phe Pro Val
1 5 10
Ala Leu Arg Met Leu Leu Ala Asp Gln Gly Gln
20 25
Val Val Thr Val Glu Thr Trp Gln Glu Gly Ser
35 40
Leu Tyr Gly Gln Leu Pro Lys Phe Gln Asp Gly
50 55
Gln Ser Asp Thr Ile Leu Arg His Leu Gly Arg
65 70 75
Gly Lys Asp Gln Gln Glu Ala Ala Leu Val Asp
Val Glu Asp Leu Arg Cys Lys Tyr Ile Ser Leu
100 105
Glu Ala Gly Lys Asp Asp Tyr Val Lys Ala Leu
115 120
Pro Phe Glu Thr Leu Leu Ser Gln Asn Gln Gly
130 135
Val Gly Asp Gln Ile Ser Phe Ala Asp Tyr Asn
145 150 155
Leu Ile His Glu Val Leu Ala Pro Gly Cys Leu
165 170
Leu Ser Ala Tyr Val Gly Arg Leu Ser Ala Arg
180 185
Phe Leu Ala Ser Pro Glu Tyr Val Asn Leu Pro
195 200
Lys Gln
210
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 712 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
TTCGCCACCA TGCCGCCCTA CACCGTGGTC TATTTCCCAG
CTGCGCATGC TGCTGGCAGA TCAGGGCCAG AGCTGGAAGG
ACGTGGCAGG AGGGCTCACT CAAAGCCTCC TGCCTATACG
GACGGAGACC TCACCCTGTA CCAGTCCAAT ACCATCCTGC
GGGCTCTATG GGAAGGACCA GCAGGAGGCA GCCCTGGTGG
Arg
ser
Leu
Asp
60
Thr
Met
Ile
Pro
Gly
140
Leu
Asp
Pro
Ile
Gly
Trp
Lys
45
Leu
Leu
val
Tyr
Gly
125
Lys
Leu
Ala
Lys
Asn
205
Arg
Lys
30
Ala
Thr
Gly
Asn
Thr
110
Gln
Thr
Asp
Phe
Leu
190
Gly
TTCGAGGCCG
AGGAGGTGGT
GGCAGCTCCC
GTCACCTGGG
ACATGGTGAA
ACTGAAC
Cys Ala
15
Glu Glu
Ser Cys
Leu Tyr
Leu Tyr
80
Asp Gly
Asn Tyr
Leu Lys
Phe Ile
Leu Leu
160
Pro Leu
175
Lys Ala
Asn Gly
CTGCGCGGCC
GACCGTGGAG
CAAGTTCCAG
CCGCACCCTT
TGACGGCGTG
3000
3060
3117
60
120
180
240
300
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GAGGACCTCC GCTGCAAATA CATCTCCCTC ATCTACACCA ACTATGAGGC GGGCAAGGAT 360
GACTATGTGA AGGCACTGCC CGGGCAACTG AAGCCTTTTG AGACCCTGCT GTCCCAGAAC 420
CAGGGAGGCA AGACCTTCAT TGTGGGAGAC CAGATCTCCT TCGCTGACTA CAACCTGCTG 480
GACTTGCTGC TGATCCATGA GGTCCTAGCC CCTGGCTGCC TGGATGCGTT CCCCCTGCTC 540
TCAGCATATG TGGGGCGCCT CAGCGCCCGG CCCAAGCTCA AGGCCTTCCT GGCCTCCCCT 600
GAGTACGTGA ACCTCCCCAT CAATGGCAAC GGGAAACAGT GAGGGTTGGG GGGACTCTGA 660
GCGGGAGGCA GAGTTTGCCT TCCTTTCTCC AGGACCAATA AAATTTCTAA GA 712
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 210 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Met Pro Pro Tyr Thr Val Val Tyr Phe Pro Val Arg Gly Arg Cys Ala
1 5 10 15
Ala Leu Arg Met Leu Leu Ala Asp Gln Gly Gln Ser Trp Lys Glu Glu
20 25 30
Val Val Thr Val Glu Thr Trp Gln Glu Gly Ser Leu Lys Ala Ser Cys
35 40 45
Leu Tyr Gly Gln Leu Pro Lys Phe Gln Asp Gly Asp Leu Thr Leu Tyr
50 55 60
Gln Ser Asn Thr Ile Leu Arg His Leu Gly Arg Thr Leu Gly Leu Tyr
65 70 75 80
Gly Lys Asp Gln Gln Glu Ala Ala Leu Val Asp Met Val Asn Asp Gly
85 90 95
Val Glu Asp Leu Arg Cys Lys Tyr Ile Ser Leu Ile Tyr Thr Asn Tyr
100 105 110
Glu Ala Gly Lys Asp Asp Tyr Val Lys Ala Leu Pro Gly Gln Leu Lys
115 120 125
Pro Phe Glu Thr Leu Leu Ser Gln Asn Gln Gly Gly Lys Thr Phe Ile
130 135 140
Val Gly Asp Gln Ile Ser Phe Ala Asp Tyr Asn Leu Leu Asp Leu Leu
145 150 155 160
Leu Ile His Glu Val Leu Ala Pro Gly Cys Leu Asp Ala Phe Pro Leu
165 170 175
Leu Ser Ala Tyr Val Gly Arg Leu Ser Ala Arg Pro Lys Leu Lys Ala
180 185 190
Phe Leu Ala Ser Pro Glu Tyr Val Asn Leu Pro Ile Asn Gly Asn Gly
195 200 205
Lys Gln
210
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 718 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
GTCTTCGCCA CCATGCCGCC CTACACCGTG GTCTATTTCC CAGTTCGAGG CCGCTGCGCG 60
83
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GCCCTGCGCA
GAGACGTGGC
CAGGACGGAG
CTTGGGCTCT
GTGGAGGACC
GATGACTATG
AACCAGGGAG
CTGGACTTGC
CTCTCAGCAT
CCTGAGTACG
TGAGCGGGAG
TGCTGCTGGC
AGGAGGGCTC
ACCTCACCCT
ATGGGAAGGA
TCCGCTGCAA
TGAAGGCACT
GCAAGACCTT
TGCTGATCCA
ATGTGGGGCG
TGAACCTCCC
GCAGAGTTTG
AGATCAGGGC
ACTCAAAGCC
GTACCAGTCC
CCAGCAGGAG
ATACGTCTCC
GCCCGGGCAA
CATTGTGGGA
TGAGGTCCTA
CCTCAGTGCC
CATCAATGGC
CCTTCCTTTC
(2) INFORMATION FOR SEQ ID NO:6:
CAGAGCTGGA
TCCTGCCTAT
AATACCATCC
GCAGCCCTGG
CTCATCTACA
CTGAAGCCTT
GACCAGATCT
GCCCCTGGCT
CGGCCCAAGC
AACGGGAAAC
TCCAGGACCA
(i) SEQUENCE CHARACTERISTICS:
AGGAGGAGGT
ACGGGCAGCT
TGCGTCACCT
TGGACATGGT
CCAACTATGA
TTGAGACCCT
CCTTCGCTGA
GCCTGGATGC
TCAAGGCCTT
AGTGAGGGTT
ATAAAATTTC
GGTGACCGTG
CCCCAAGTTC
GGGCCGCACC
GAATGACGGC
GGCGGGCAAG
GCTGTCCCAG
CTACAACCTG
GTTCCCCCTG
CCTGGCCTCC
GGGGGGACTC
TAAGAAGC
Met
Ala
val
Leu
Gln
65
Gly
val
Glu
Pro
val
145
Leu
Leu
Phe
Lys
(2)
(A)
(B)(Cc)(D)
LENGTH:
TYPE:
STRANDEDNESS:
TOPOLOGY:
amino acid
linear
210 amino acids
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Pro Pro Tyr Thr Val Val Tyr Phe Pro Val
Leu
val
Tyr
50
ser
Lys
Glu
Ala
Phe
130
Gly
Ile
ser
Leu
Gln
210
INFORMATION FOR SEQ ID NO:7:
Arg
Thr
35
Gly
Asn
Asp
Asp
Gly
115
Glu
Asp
His
Ala
Ala
195
Met
20
val
Gln
Thr
Gln
Leu
100
Lys
Thr
Gln
Glu
Tyr
180
ser
5
Leu
Glu
Leu
Ile
Gln
85
Arg
Asp
Leu
Ile
val
165
val
Pro
Leu Ala
Thr Trp
Pro Lys
55
Leu Arg
70
Glu Ala
Cys Lys
Asp Tyr
Leu Ser
135
Ser Phe
150
Leu Ala
Gly Arg
Glu Tyr
Asp
Gln
40
Phe
His
Ala
Tyr
val
120
Gln
Ala
Pro
Leu
val
200
Gln
25
Glu
Gln
Leu
Leu
val
105
Lys
Asn
Asp
Gly
ser
185
Asn
(i) SEQUENCE CHARACTERISTICS:
10
Gly
Gly
Asp
Gly
val
90
ser
Ala
Gln
Tyr
cys
170
Ala
Leu
Gln
ser
Gly
Arg
75
Asp
Leu
Leu
Gly
Asn
155
Leu
Arg
Pro
Arg
ser
Leu
Asp
Thr
Met
Ile
Pro
Gly
140
Leu
Asp
Pro
Ile
Gly
Trp
Lys
45
Leu
Leu
val
Tyr
Gly
125
Lys
Leu
Ala
Lys
Asn
205
Arg
Lys
30
Ala
Thr
Gly
Asn
Thr
110
Gln
Thr
Asp
Phe
Leu
190
Gly
cys
15
Glu
ser
Leu
Leu
Asp
95
Asn
Leu
Phe
Leu
Pro
175
Lys
Asn
Ala
Glu
cys
Tyr
Tyr
80
Gly
Tyr
Lys
Ile
Leu
160
Leu
Ala
Gly
120
180
240
300
360
420
480
540
600
660
718
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(A) LENGTH: 722 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
AGTCTTCGCC ACCATGCCGC CCTACACCGT GGTCTATTTC CCAGTTCGAG GCCGCTGCGC 60
GGCCCTGCGC ATGCTGCTGG CAGATCAGGG CCAGAGCTGG AAGGAGGAGG TGGTGACCGT 120
GGAGACGTGG CAGGAGGGCT CACTCAAAGC CTCCTGCCTA TACGGGCAGC TCCCCAAGTT 180
CCAGGACGGA GACCTCACCC TGTACCAGTC CAATACCATC CTGCGTCACC TGGGCCGCAC 240
CCTTGGGCTC TATGGGAAGG ACCAGCAGGA GGCAGCCCTG GTGGACATGG TGAATGACGG 300
CGTGGAGGAC CTCCGCTGCA AATACGTCTC CCTCATCTAC ACCAACTATG AGGTGGGCAA 360
GGATGACTAT GTGAAGGCAC TGCCCGGGCA ACTGAAGCCT TTTGAGACCC TGCTGTCCCA 420
GAACCAGGGA GGCAAGACCT TCATTGTGGG AGACCAGATC TCCTTCGCTG ACTACAACCT 480
GCTGGACTTG CTGCTGATCC ATGAGGTCCT AGCCCCTGGC TGCCTGGATG CGTTCCCCCT 540
GCTCTCAGCA TATGTGGGGC GCCTCAGCGC CCGGCCCAAG CTCAAGGCCT TCCTGGCCTC 600
CCCTGAGTAC GTGAACCTCC CCATCAATGG CAACGGGAAA CAGTGAGGGT TGGGGGGACT 660
CTGAGCGGGA GGCAGAGTTT GCCTTCCTTT CTCCAGGACC AATAAAATTT CTAAGAAGCT 720
Ac 722
(2 INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
210 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(A) LENGTH:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Met Pro Pro
5
Tyr Thr Val Val Tyr
Ala Leu Arg Met Leu Leu Ala Asp
20
Val Val Thr Val Glu Thr Trp Gln
35 40
Leu Tyr Gly Gln Leu Pro Lys Phe
50 55
Gln Ser Asn Thr Ile Leu Arg His
Gly Lys Asp Gln Gln Gl
85
u Ala Ala
Phe Pro Val
10
Gln Gly Gln
25
Glu Gly Ser
Gln Asp Gly
Leu Gly Arg
Leu Val Asp
90
Val Glu Asp Leu Arg Cys Lys Tyr Val Ser Leu
100
Glu Val Gly Lys Asp As
115
p Tyr Val
120
105
Lys Ala Leu
Pro Phe Glu Thr Leu Leu Ser Gln Asn Gln Gly
130 135
Val Gly Asp Gln Ile Ser Phe Ala Asp Tyr Asn
145 15 0
Leu Ile His Glu Val Leu Ala Pro
165
Leu Ser Ala Tyr Val Gl
180
y Arg Leu
155
Gly Cys Leu
170
Ser Ala Arg
185
Arg Gly Arg
Ser Trp Lys
30
Leu Lys Ala
45
Asp Leu Thr
60
Cys Ala
15
Glu Glu
Ser Cys
Leu Tyr
Thr Leu Gly Leu Tyr
Met Val Asn
Ile Tyr Thr
110
Pro Gly Gln
125
Gly Lys Thr
140
Leu Leu Asp
Asp Ala Phe
Pro Lys Leu
190
80
Asp Gly
95
Asn Tyr
Leu Lys
Phe Ile
Leu Leu
160
Pro Leu
175
Lys Ala
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Phe Leu Ala Ser Pro Glu Tyr Val Asn Leu Pro Ile Asn Gly Asn Gly
195 200 205
Lys Gln
210
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
CGCAAGCTTC GCCACCATGC CGCCCTACAC CG 32
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
GGAGGCTTTG AGTGAGCCCT C 21
(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
AGATCAGGGC CAGAGCTGGA AG 22
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
CTGGTTCTGG GACAGGGTCT C 21
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
CTCTGGTCTA GAGGAAGCGA 20
(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
5,968,737
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(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
TCTTICCTCTT CTAGTTTGTG AGG 23
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
TCTTTGTTCG GACCATGCCG CCC 23
(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
CAGAGTCCCC CCAACCCTCA CTGTTT 26
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
CAGCCCTGGT GGACATGGTG AATGAC 26
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
CTGGTTCTGG GACAGCAGCT C 21
(2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
TGGCAGCTGA AGTGGACAGG ATT 23
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
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GATCAGCAGC AAGTCCAGCA G 21
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
GTGAGCATCT GCACCAGG 18
(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
GGCTGGTTGA TGATGTCCCA GG 22
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
ACGTGGCAGG AGGGCTCACT C 21
(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
TACTCAGGGG AGGCCAGCAA 20
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:
CATCTCCCTC ATCTACACCA ACTATGAGGC G 31
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 3
(D) OTHER INFORMATION: /mod_base= OTHER
93
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/note= “N= C, T, A or G"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:
CGNTCTCCCT CATCTACACC AACTATGAGG CG 32
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: modified_base(B) LOCATION: 3..32
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “N= C, T, A or G"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:
CGNTCTCCCT CATCTACACC AACTATGAGG TNG 33
(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
CCAGGCTGGG GCTCACAGAC AGC 23
(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
GGTCAGCCCA AGCCACCTGA GG 22
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
TGGCAGCTGA AGTGGACAGG ATT 23
(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
ATGGCTCACA CCTGTGTCCA TCT 23
(2) INFORMATION FOR SEQ ID NO:32:
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-continued
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
GTGACAAAGC 10
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
GTGACTCAGC 10
(2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 4..12
(D) OTHER INFORMATION: /mod_base= OTHER
/note= “N =A, T, C, or G"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
CCANNNNNNN NNTGG 15
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
GGTGTAGGGC GGCAT 15
(2) INFORMATION FOR SEQ ID NO:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
ATGCCGCCCT ACACC 15
(2) INFORMATION FOR SEQ ID NO:37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
CACGCTCCAT CGCCA 15
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(2) INFORMATION FOR SEQ ID NO:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:
GGTGTGAGGC GGCAT
(2) INFORMATION FOR SEQ ID NO:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
GGGAGATGTA TTTGC
(2) INFORMATION FOR SEQ ID NO:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
GGGAGACGTA TTTGC
(2) INFORMATION FOR SEQ ID NO:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
TTGCCCGCCT CATAG
(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
TTGCCCACCT CATAG
15
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Whatis claimedis:
1. A method for the identification of a candidate GST-a
antisense or ribozyme molecule that inhibits GST-a activity «0
comprising the steps of:
a) contacting a cell expressing a GST-z protein with the
antisense or ribozyme molecule; and
b) comparing the growth of said cell with the growth of 65
said cell in the absence of the antisense or ribozyme
molecule;
wherein a decrease in growth in the presence of said
antisense or ribozyme molecule is indicative of the molecule
being an inhibitor of GST-a activity.
2. The method of claim 1, wherein said GST-z protein
expressed is GSTP*B.
3. The method of claim 1, wherein said GST-z protein
expressed is GSTP*C.
4. The method of claim 1, wherein said GST-a protein
being expressed is not GSTP*A.
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5. The method of claim 1, wherein said GST-m antisense
or ribozyme molecule is an antisense molecule to an
hGSTP1*B or hGSTP1*C nucleic acid.
6. The method of claim 1, wherein said GST-m antisense
or ribozyme molecule is a ribozyme that cleaves an
hGSTP1*B or hGSTP1*C nucleic acid under intracellular
conditions.
7. Amethodfor the identification of a candidate inhibitor
substance that inhibits GST-m expression comprising the
steps of:
a) contacting a cell expressing a GST-m protein with a
candidate inhibitor substance; and
(b) comparing the expression of GST-z ofsaid cell with
the expression of GST-a of said cell in the absence of
said candidate inhibitor substance;
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wherein a decrease in the expression of GST- in the
presence of said candidate inhibitor substance is indicative
of the substance being an inhibitor of GST-a expression.
8. The methodof claim 7, wherein said candidate inhibitor
substance is an antisense molecule to an hGSTP1*B or
hGSTP1*C nucleic acid.
9. The method of claim 7, wherein said candidate inhibitor
substance is a ribozyme that cleaves an hGSTP1*B or
hGSTP1*C nucleic acid under intracellular conditions.
10. The method of claim 7, wherein said candidate
inhibitor substance is a small molecule inhibitor.
11. The method of claim 10, wherein the small molecule
inhibitor is a substituted isoxazole, heterocyclic aromatic
compound; or a sugar-linked aromatic compound.
* * * * *
  
UNITED STATES PATENT AND TRADEMARKOFFICE
CERTIFICATE OF CORRECTION
PATENT NO. —: 5,968,737 Page 1 of 2
DATED : October 19, 1999
INVENTOR(S): Ali-Osman etal.
It is certified that error appears in the above-identified patent and that said Letters Patentis
hereby corrected as shown below:
Column 2
Line 44, please delete “+313 or +341”and insert therefor -- +326 or +354 --.
Line 61, please delete “SEQ ID NO: 4”andinsert therefor -- SEQ ID NO:7--.
 
Column 3
Line 2, please delete “+313 or +341”andinsert therefor --+326 or +354 --, and please
delete “SEQ ID NO:4”andinsert therefor -- SEQ ID NO:7 --.
Lines 10 and 11, please delete “SEQ ID NO:3”andinsert therefor -- SEQ ID NO:8--.
Line 22, please delete “SEQ ID NO:1”andinsert therefor -- SEQ ID NO:6--.
Line 23, please delete “SEQ ID NO:3”andinsert therefor -- SEQ ID NO%8--.
Line 26, please delete “SEQ ID NO:1”and insert therefor -- SEQ ID NO:6--.
Line 27, please delete “SEQ ID NO:3”andinsert therefor -- SEQ ID NO:8 --.
Line 31, please delete “SEQ ID NO:2”andinsert therefor -- SEQ ID NO:5 --.
Line 53, please delete “SEQ ID NO:4”andinsert therefor -- SEQ ID NO:7--.
Line 36, please delete “SEQ ID NO:1” andinsert therefor -- SEQ ID NO+6 --.
Line 38, please delete “SEQ ID NO:3”andinsert therefor -- SEQ ID NO:8--.
Line 41, please delete “SEQ ID NO:1”and insert therefor -- SEQ ID NO‘6--.
Line 42, please delete “SEQ ID NO:2”andinsert therefor -- SEQ ID NO:5 --.
Line 44, please delete “SEQ ID NO:3”and insert therefor -- SEQ ID NO:8--.
Line 45, please delete “SEQ ID NO:4”andinsert therefor -- SEQ ID No:7 --.
Lines 52 and 53 please delete “SEQ ID NO:3”and insert therefor -- SEQ ID NO:8--.
Column 6
Line 16, after “313”please insert -- (326 of SEQ ID NO:7)--.
Line 19, after “341”please insert -- (341 of SEQ ID NO:7)--.
Line 45, please delete “cDNAs”andinsert therefor -- SEQ ID NO:3 (+326 and +341 of
SEQ ID NO7)--.
Column 7
Line 6, please delete “+313”andinsert therefor -- +326 --, and insert -- (SEQ ID NO:
7) -- after “hGSTPI * B”.
Line 64, after “+341” please insert -- (+326 and +341 of SEQ ID NO:7)--.  
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